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Abstract 
 
Cells try to counteract mitochondrial respiratory chain deficiencies via various 
kinds of largely unknown compensatory mechanisms, which play a central role in 
determining the extent of tissue-specific defects leading to disease phenotypes. In 
this study, we directly disrupted mitochondrial protein synthesis in mice by 
deleting the mitochondrial aspartyl-tRNA synthetase (Dars2) gene in a tissue-
specific manner. We generated DARS2 deficiency in three different tissues (heart, 
skeletal muscle and forebrain neurons) and followed the dynamics and extent of 
pathological changes that occurred.  
 
Deficiency of this essential protein leads to severe deregulation of mitochondrial 
protein synthesis in both heart and skeletal muscle. Yet, mitochondrial stress 
responses, like increased biogenesis, decreased autophagy, upregulation of 
mitochondrial unfolded protein response and mitokine FGF21, are only observed 
in DARS2-deficient cardiomyocytes. Surprisingly, the initiation of these stress 
responses is stemming from perturbed mitochondrial proteostasis, rather than the 
respiratory deficiency. Skeletal muscle, on the other hand, has intrinsic protective 
mechanisms that make it better equipped for folding and turnover of 
mitochondrial proteins, as well as slow turnover of mitochondrial transcripts that 
is coupled with possible upregulation of muscle regeneration. As a result, skeletal 
muscle is able to cope with increased levels of unassembled proteins better.  
 
  
 xiv 
Although DARS2 depletion leads to very strong, deleterious respiratory 
deficiency in heart and skeletal muscle, causing animals to die within 7-8 weeks, 
its deficiency in forebrain neurons seems to have a milder effect that takes much 
longer time to develop.  Defective mitochondrial translation in forebrain neurons 
caused abnormal behavior, and severe forebrain atrophy, which is caused by 
neuronal cell apoptosis and accompanied by activation of inflammatory responses 
such as microgliosis and reactive astrogliosis. Surprisingly, neurodegeneration 
occurred in an age-dependent manner and affected cortex and hippocampal 
regions differently.  
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Zusammenfassung 
 
Zellen kompensieren Defekte der mitochondrialen Atmungskette mit Hilfe 
verschiedener oftmals noch weitgehend unbekannter Mechanismen, welche eine 
zentrale Rolle dabei spielen, in welchem Ausmaß gewebe-spezifische Defekte zu 
einem Krankheitsphänotyp beitragen. 
 
In dieser Arbeit wurde mit Hilfe eines konditionalen Mausmodells gewebe-
spezifisch die mitochondriale Protein-Synthese durch die Deletion des 
mitochondrialen Asprtyl-tRNA-Synthase (Dars2) Gens zerstört. Die Dynamik und 
das Ausmaß der hierdurch verursachten pathologischen Veränderungen wurden 
dabei einerseits im Herz- und Skelettmuskel sowie den Neuronen des Vorderhirns 
untersucht.  
 
Der Verlust dieses essenziellen Proteins führt zu einer schweren Dysregulation 
der mitochondrialen Proteinsynthese sowohl im Herzen wie auch im 
Skelettmuskel. In DARS2-defizienten Kardiomyozyten konnten mitochondriale 
Stressreaktionen wie vermehrte Biogenese, verminderte Autophagie, die 
Hochregulierung der mitochondriale unfolded protein response und des Mitokins 
FGF21 nachgewiesen werden. Überraschenderweise werden diese 
Stressreaktionen jedoch weniger durch die auftretende respiratorische 
Fehlfunktion als vielmehr durch eine gestörte Protein-Homöostase hervorgerufen.  
 
Im Skelettmuskel wiederum scheinen intrinsisch protektive Mechanismen zu 
existieren, welche die Faltung und Stabilität mitochondrialer Proteine erhöhen. 
Darüberhinaus weist der Skelettmuskel eine geringere Abbaurate mitochondrialer 
Transkipte auf, was möglicherweise in Zusammenhang mit einer erhöhten 
Muskel-Regeneration steht.  
 
 xvi 
Im Gegensatz zu dem starken Phänotyp in Herz- und Skelettmuskel, bei dem die 
Mäuse innerhalb der ersten 7-8 Lebenswochen sterben, hat der Verlust von 
DARS2 spezifisch in Vorderhirn-Neuronen einen milderen Effekt, der deutlich 
länger für eine Entwicklung braucht. Defekte in der mitochondrialen Translation 
in diesem Gewebe verursacht abnormales Verhalten der Mäuse, eine schwere 
Atrophie des Vorderhirns, welche durch Apoptose der Neuronen hervorgerufen 
wird und die Aktivierung inflammatorischer Prozesse wie Mikrogliose and 
reaktive Astrogliose. Erstaunlicherweise tritt diese Neurodegeneration in alters-
abhängiger Weise auf und betrifft den Cortex und Hippocampus Regionen in 
unterschiedlicher Wiese.   
 
 
  
 
1  
1. Introduction 
 
Chinese philosophy explains the basis of nature through yin and yang, opposing 
forces, interdependent and able to exist only in relation to each other. The cell 
and the mitochondria have a very similar story. It is a tale of two enemies, who 
later became friends and allies. On this particular day, an ancient bacterium has 
invaded a single cell organism and instead of killing its host -as it happened many 
times before- it has found a safe haven and decided to stay within. Why not? The 
available nutrients were more than sufficient and the host offered shelter from the 
hostile environment of the ancient world. As for the single cell, beside the fact that 
it has survived the attack, benefits have also been great. Finally, it was granted a 
way to fight the poisonous oxygen in the surrounding and moreover, a new, more 
efficient energy form was suddenly available. This random encounter, which 
happened around 1-2 billion years ago to give rise to a synergically superior 
eukaryote, is described by the ‘endosymbiotic theory’ (Margulis, 1975). We now 
believe that the bacterium became integrated into the recipient cell and evolved 
into an organelle, the mitochondrion. Whether the random encounter was an 
invasion, infection or an unwilling indigestion event, the yin -the anaerobic cell- 
and the yang -the aerobic mitochondrion- left their differences behind and 
cooperated. The story, which started almost as a horror movie, turned into a 
romantic comedy in the end; or did it? Does the initial invasion of the bacteria 
continue even if it lost its ability to live independently? Is the mitochondrion 
abusing its powers in the cell and waiting a suitable time for revenge like a smart 
serial killer? A number of different disorders and diverse disease manifestations, 
as well as mitochondrial involvement in age-associated diseases, seem to prove 
this (Dogan and Trifunovic, 2011). 
 
 
 2 
1.1. Mitochondria 
 
Mitochondria are small organelles found in almost every eukaryotic cell. They 
form a very dynamic network, with constant fusion and fission, and occupy 
roughly one fifth of its total volume (McBride et al., 2006). The mitochondrion 
comprises of two membranes, the outer (OMM) of which is separated from the 
inner (IMM) one by the intermembrane space (IMS). The inner membrane 
exhibits a folded structure, named cristae, to maximize its surface. The innermost 
compartment of the mitochondria is called the mitochondrial matrix, and contains 
the mitochondrial genome, ribosomes, transfer RNAs (tRNAs), and various 
proteins and enzymes required for mitochondrial function. Mitochondria are 
unique because they are the only organelles in animal cells containing their own 
DNA, mitochondrial DNA (mtDNA). 
 
The main function of the mitochondria is to use oxygen to generate the cell’s 
major energy source, adenosine triphosphate (ATP). Thus, mitochondria are the 
powerhouses of the cell, generating ATP through the process of oxidative 
phosphorylation (OXPHOS). The proteins mediating electron transport and 
OXPHOS reside in the inner mitochondrial membrane. Moreover, mitochondria 
are very important for other cellular processes such as the first step of iron-sulfur 
(Fe-S) cluster biosynthesis, pyruvate decarboxylation and tricarboxylic acid cycle 
(TCA cycle), programmed cell death (apoptosis), steroid synthesis, calcium 
homeostasis and reactive oxygen species (ROS) formation. 
 
The redox reactions in the cell feed the electron transport chain (ETC), which 
couples the electron transfer between an electron donor (NADH and FADH2) and 
acceptor (oxygen) with the transfer of protons across the inner membrane. ETC 
has four macromolecular complexes: complex I (CO I - NADH:ubiquinone 
oxidoreductase, EC 1.6.5.3), complex II (CO II - Succinate dehydrogenase, EC 
  
 
3  
1.3.5.1), complex III (CO III - Ubiquinol cytochrome-c reductase, EC 1.10.2.2) 
and complex IV (CO IV or COX - cytochrome c oxidase, COX, EC 1.9.3.1). ETC 
catalyzes the electron transfer from reducing equivalents to molecular oxygen. 
Electrons are carried from CO I and CO II to CO III by coenzyme Q (CoQ or 
ubiquinone), linking TCA cycle to the process. Other sources of electrons, such as 
glycolysis, fatty acid oxidation, pyrimidine biosynthesis, choline and amino acid 
oxidation, exist that can donate electrons to CoQ (Vafai and Mootha, 2012). The 
electron transport from CO III to CO IV is mediated by soluble electron carrier 
cytochrome c. The synthesis of ATP from ADP and Pi in mitochondria is 
catalyzed by Complex V (or ATP synthase) (CO V, EC 3.6.3.14), which is 
powered by the proton gradient generated.  
 
The organization of the OXPHOS system is more intricate than separately 
assembled complexes that are arranged in sequence in the inner mitochondrial 
membrane. Two models have been proposed for the organization of the 
mitochondrial respiratory chain: (i) the “fluid-state” or “random collision” model, 
where all OXPHOS complexes diffuse individually in the membrane and electron 
transfer depends on the random collision of the complexes and electron carriers 
(Hackenbrock et al., 1986); (ii) the “solid-state” model, which was proposed over 
50 years ago, where the complexes together form large, rigid supramolecular 
structures termed respirasomes (Hatefi et al., 1962). The most plausible scenario, 
however, is a combination of these two models: the “plasticity” model. In this 
model, single complexes (“fluid-state” model) and different types of 
supercomplexes (“solid-state” model) coexist in the inner membrane. Complex I, 
for instance, is mainly found in association with complex III in various 
supercomplexes that additionally contain the electron carriers coenzyme Q and 
cytochrome c, complex IV, and sometimes complex II or V, and are able to 
respire. On the other hand, most of the complexes II and IV are present as 
individual entities. How the supercomplexes are assembled is currently not 
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known, but the significance of this arrangement for the stability of the different 
complexes is certain (Acin-Perez et al., 2008). 
 
1.2. Mitochondrial Diseases 
 
Mitochondrial diseases are one of the most common inborn errors of metabolism 
with a frequency of ~ 1 in 5000 (Schaefer et al., 2004). The term “mitochondrial 
encephalomyopathies” is often used since the affected organs/tissues are mostly 
brain and skeletal muscle (Shapira et al., 1977). Nowadays, the term 
“mitochondrial diseases” is almost exclusively used to describe diseases caused 
by defects in mitochondrial oxidative phosphorylation (OXPHOS) and not 
regarding the defects in numerous other cellular processes within mitochondria. 
Even within these boundaries, the classification of the mitochondrial diseases 
became quite complicated because mutations in either mtDNA or nuclear DNA 
(nDNA) genes coding for mitochondrial proteins lead to major and catastrophic 
diseases in humans. The first patient suffering from a mitochondrial disorder was 
identified in 1962 (Luft et al., 1962). Since then, thousands of patients have been 
diagnosed with different kinds of mitochondrial diseases. Due to the complexity 
of mitochondrial diseases, a new way of classification is embraced, one that is 
using the diseases’ genetic defect rather then clinical manifestation.  
 
1.2.1 Mitochondrial genetics 
 
Human mitochondrial DNA (mtDNA) is a small (16,569 basepair long), circular, 
double-stranded molecule (Figure 1.1). mtDNA only encodes 13 respiratory chain 
subunits, 22 tRNAs and 2 rRNAs, which are essential for mitochondrial 
translation (Larsson, 2010). During the course of evolution, mtDNA lost more 
than 99% of its original genes, thus now depends on nDNA for all its basic 
functions such as synthesis and assembly of most respiratory chain subunits, 
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synthesis of the phospholipids of the inner mitochondrial membrane and the 
necessary aids for its DNA’s replication, transcription, and translation (Vafai and 
Mootha, 2012).  
 
A couple of unique features of mtDNA genetics and inheritance make it very 
difficult to predict the course of the disease, prenatal diagnosis and/or genetic 
counseling in everyday clinical practice (Dogan and Trifunovic, 2011):  
 
• mtDNA does not follow the Mendelian rules of inheritance while it is 
maternally inherited. Therefore, a mother carrying an mtDNA mutation 
can transmit it to her children, but only her daughters can further transmit 
it to the next generation. As each cell contains ∼10,000 copies of mtDNA, 
a pathogenic mutation could be present in all of them or just few of copies 
of the molecule. Existence of two or more different populations of mtDNA 
in a single cell is called ‘heteroplasmy’, in contrast to ‘homoplasmy’ 
where all mtDNA molecules are identical.  
 
• Threshold effect represents the minimal critical level of a pathogenic 
mutation in mtDNA that should be present in the cell or tissue to have a 
deleterious effect. A certain proportion of mutant mtDNA must be present 
before reduction in OXPHOS activity is observed, and the threshold seems 
to be lower in tissues that are more dependent on oxidative metabolism.  It 
has been shown that there are different thresholds for different types of 
mtDNA mutations, 60% for large mtDNA deletions (Bourgeron et al., 
1993) to 90% for some tRNA mutations (Chomyn et al., 1992; Hanna et 
al., 1995). 
 
• The last but not least problem of mtDNA genetics is the mitotic 
segregation. Random distribution of mtDNA molecules during cell 
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division can lead to increased amounts of mutant mtDNA molecules in 
one of the daughter cells. This can lead to a cell carrying low levels of 
mutated molecules giving rise to one of relatively high levels, which in 
turn will affect OXPHOS in that cell.  
 
1.2.2 Mitochondrial diseases caused by mitochondrial DNA (mtDNA) 
mutations 
 
About 200 mtDNA point mutations and numerous single large-scale partial 
deletions have been associated with human diseases, most of which affect the 
nervous system (Wallace, 2005). Although genetically distinct, most mtDNA 
diseases share common features such as lactic acidosis, mosaic pattern of cells 
deficient in cytochrome c oxidase (COX) activity and massive mitochondrial 
proliferation in muscle resulting in ragged-red fibers (DiMauro et al., 1985). The 
more mtDNA-related diseases are identified, the more it became clear that 
mitochondrial diseases commonly have a delayed onset and progressive course.  
 
Mutations in mtDNA are divided into two groups: (i) mtDNA point mutations and 
(ii) mtDNA rearrangements. A depiction of human mitochondrial DNA and the 
most common diseases can be found in Figure 1.1 (DiMauro and Schon, 2008). 
Diseases and the genes, the mutations in which cause the disease, are labeled with 
the same color. 
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Figure 1.1 Human mitochondrial DNA and related diseases. 
Human mitochondrial DNA. Names of the common mitochondrial diseases -caused by 
point mutations and/or rearrangements- are indicated on the figure. The disease 
manifestations and the related mutations are color-coded (DiMauro and Schon, 2008). 
LS, Leigh syndrome; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, 
and stroke-like episodes; MERRF, myoclonic epilepsy and ragged red fibres; MILS, 
maternally inherited Leigh syndrome; NARP, neurogenic weakness, ataxia, and retinitis 
pigmentosa; PS, Pearson syndrome. 
 
 
(i) mtDNA point mutations: 
 
Most human mtDNA point mutations occur in tRNA genes, thus the most 
common mtDNA-related disorders are caused by mutations in those genes: 
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Figure 1
The human mitochondrial genome. The mtDNA-encoded gene products for the 12S and 16S ribosomal RNAs, the subunits of
NADH-coenzyme Q oxidoreductase (ND), cytochrome c oxidase (COX), cytochrome b (Cyt b), and ATP synthase (A), and 22 tRNAs
(1-letter amino acid nomenclature) are shown, as are the origins of heavy- and light-strand replication (OH and OL) and the promoters
of heavy- and light-strand trans riptio (HSP and LSP). Some pathogenic mu ations (for exp nd d versions of all the key terms in this
article, see Supplemental Term List; follow the Supplemental Material link from the Annual Reviews home page at
http://www.annualreviews.org) that affect the nervous system in particular are indicated (colors correspond to those of the affected genes).
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sion is strongly suggestive of an mtDNA
point mutation.
About 200 mtDNA point mutations and
innumerable single large-scale (kilobase-sized)
partial deletions have been associated with hu-
man diseases, most of which affect the central
and peripheral nervous system, especially ifmy-
opathies are considered—as they should—the
domain of peripheral neurology. This concept
94 DiMauro · Scho
Supplemental Material
An
nu
. R
ev
. N
eu
ros
ci.
 20
08
.31
:91
-12
3. 
Do
wn
loa
de
d f
rom
 w
ww
.an
nu
alr
ev
iew
s.o
rg
by
 W
IB
63
86
 - U
niv
ers
ita
t z
u K
oln
 - U
nd
 St
ad
bib
lio
the
k o
n 1
1/0
4/1
0. 
Fo
r p
ers
on
al 
us
e o
nly
.
 8 
Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes 
(MELAS) is a multisystem disorder that is often fatal in childhood or in young 
adulthood. The disease principally affects muscle, brain and the endocrine system. 
Stroke-like episodes are experienced before the patients are 40 years old. Most 
people with MELAS have a buildup of lactic acid in their bodies. Less commonly, 
people with MELAS may experience involuntary muscle spasms (myoclonus), 
impaired muscle coordination (ataxia), hearing loss, heart and kidney problems, 
diabetes, and hormonal imbalances (Kaufmann et al., 2011). Although the most 
common mutation is A3243G in tRNALeu(UUR), other mutations (in protein coding 
genes, as well as tRNAs) have been found to be associated with the disease.  
 
Myoclonus epilepsy and ragged red fibres (MERRF) is almost exclusively a 
result of mutations in tRNALys. MERRF is characterized by muscle twitches, 
myopathy, and spasticity. Affected individuals sometimes have short stature and 
heart abnormalities (cardiomyopathy) (Moraes et al., 1993). Gomorri Trichrome 
staining of the muscle cells reveals clumps of diseased mitochondria 
accumulation in the subsarcolemmal region of the muscle fiber, which appear as 
‘rough’ or so-called ‘Ragged Red Fibers’. As in MELAS, the disease affects 
translational efficiency via failure in tRNA modification with taurine (Suzuki et 
al., 2011).  
 
Additionally, missense mutations in mtDNA protein coding genes can also result 
in an array of clinical manifestations:  
 
A mutation in the mtDNA ATP6 gene is associated with neurogenic muscle 
weakness, ataxia, and retinitus pigmentosum (NARP) when present at lower 
percentages of mutant (~40%) (Holt et al., 1990) and lethal childhood Leigh 
syndrome when present at higher percentages (~95%) of mutant (Tatuch et al., 
1992).  
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Leber’s hereditary optic neuropathy (LHON), the most common mtDNA-related 
disease, causes severe visual loss in both eyes. LHON, mostly an early-onset 
disease, is usually caused by homoplasmic mutations in one of three genes 
encoding complex I subunits (G11778A in NADH dehydrogenase 4 (ND4), 
G3460A in ND1 and T14484C in ND6). A significant percentage of people with a 
mutation that causes LHON do not develop any features. Specifically, more than 
50 percent of males with a mutation and more than 85 percent of females with a 
mutation never experience vision loss or related medical problems (Man et al., 
2002). 
 
(ii) mtDNA rearrangements: 
 
Systemically distributed mtDNA rearrangement mutations, mostly deletions, can 
be either inherited or spontaneous. Deletions usually result in a spectrum of 
symptoms. The nature and severity of the symptoms from mtDNA deletion 
rearrangements is usually due to the tissue distribution of the rearranged mtDNAs 
(Wallace, 2005).  
 
Kearns–Sayre syndrome (KSS) is defined by the onset before age 20 of 
ophthalmoplegia (paralysis of the muscles that move the eyeballs), ptosis (droopy 
eyelids), pigmentary retinopathy (Kearns and Sayre, 1958). In this multisystemic 
disorder, partially deleted mtDNAs are present in all examined tissues. In chronic 
progressive external ophthalmoplegia (CPEO) deleted mtDNAs are found only in 
muscle (Moraes et al., 1989). In Pearson’s syndrome, which is characterized by 
sideroblastic anaemia and exocrine pancreas dysfunction, deleted mtDNAs are 
initially abundant in haematopoietic cells (Pearson et al., 1979).  
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1.2.3 Mitochondrial diseases caused by nuclear DNA (nDNA) mutations 
 
Mitochondrial diseases caused by a mutation in nuclear encoded genes are a very 
heterogeneous group. Not only are most of the ~80 structural proteins of the 
OXPHOS system encoded by nDNA, but all the proteins needed for their import 
from the cytoplasm and assembly in mitochondria are also encoded by the 
nucleus. Defects in any of these proteins could lead to functionally impaired 
OXPHOS and therefore to mitochondrial disease. Furthermore, defects in any 
protein affecting stability, expression and/or integrity of mtDNA could lead to the 
same deleterious effect.  
 
Mitochondrial diseases caused by mutations in nDNA can be divided into four 
categories (DiMauro and Schon, 2008):  
1) Mutations in genes encoding respiratory chain subunits 
2) Mutations in genes encoding ancillary proteins 
3) Mutations in genes affecting the lipid milieu of respiratory chain 
4) Mutations in genes encoding for mtDNA maintenance, replication, 
transcription and translation 
 
1) Mutations in genes encoding respiratory chain subunits: A severe autosomal-
recessive neurological disease, clinical features of which includes psychomotor 
retardation with extrapyramidal signs, restlessness, global dementia, severe 
defects in verbal communication, and mild axial hypotonia has been found in 
2008 (Barel et al., 2008). Mutations in nuclear-encoded UQCRQ, encoding 
ubiquinol-cytochrome c reductase, CO III subunit VII, are found to be the main 
reason for the observed phenotypes. In most of the cases, the mitochondrial-
encoded subunit of CO III (cytb) is the main cause of disease phenotypes (CO III 
is composed of ten nuclear-encoded subunits and one mitochondrial-encoded 
subunit). So far, one other nuclear mutation in protein coding genes of respiratory 
chain has been identified: the UQCRB gene (ubiquinol-cytochrome c reductase 
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binding protein), encoding subunit VI of CO III (De Meirleir et al., 2003). One 
patient with this mutation is shown to have CO III dysfunction with clinical 
hypoglycemia and lactic acidosis (Haut et al., 2003).  
 
2) Mutations in genes encoding ancillary proteins: Leigh syndrome (LS), or 
subacute necrotizing encephalomyelopathy, is a neurodegenerative disorder 
characterized by predominant involvement of the central nervous system (CNS) 
(Leigh, 1951). LS is an early-onset and progressive disease. This condition is 
characterized by progressive loss of mental and movement abilities (psychomotor 
regression) and typically results in death within a couple of years, usually due to 
respiratory failure (Finsterer, 2008). Mutations in both nuclear and mitochondrial 
genes have been identified in LS patients. However, mutations in the nuclear 
Surf1 gene, coding for a putative CO IV assembly factor are one of the main 
cause of LS. In these patients, SURF1p mutations or depletions cause a reduction 
in the fully assembled COX (Tiranti et al., 1999).  
 
3) Mutations in genes affecting the lipid milieu of respiratory chain: Cardiolipin 
is the major component of the inner mitochondrial membrane and it has been 
shown to participate in the formation of supercomplexes in yeast (Zhang et al., 
2005). This fact exemplifies the importance of cardiolipin in proper respiratory 
function. Barth syndrome, an X-linked recessive disease manifesting 
cardiomyopathy, causes underdeveloped skeletal musculature and muscle 
weakness, growth delay, 3-methylglutaconic aciduria, and and altered 
composition of cardiolipin. Mutations in the TAZ gene, encoding for tafazzin, is 
found to be responsible for the disease (Schlame and Ren, 2006). Tafazzin, a 
phospholipid acyltransferase, is involved in cardiolipin remodelling and mutations 
in the TAZ gene cause defects in mitochondrial architecture and function. 
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4) Mutations in genes encoding for mtDNA maintenance, replication, 
transcription and translation: The most common nuclear mutations associated 
with mitochondrial diseases are found in the gene encoding mitochondrial DNA 
polymerase ϒ. Around 70 disease manifestations related to the mutations in the 
gene coding for the polymerase have been reported: such as progressive external 
ophthalmoplegia (PEO) (Van Goethem et al., 2001), Alpers syndrome (Naviaux 
and Nguyen, 2004), mitochondrial neurogastrointestinal encephalomyopathy 
(MNGIE) (Van Goethem et al., 2003) or sensory ataxic neuropathy, dysarthria 
and ophthalmoparesis (SANDO) (Van Goethem et al., 2003). 
 
One class of housekeeping genes encoded by nuclear genome, namely 
mitochondrial aminoacyl-tRNA synthetases, has also been implicated in various 
diseases.  Before going deeper with the disease phenotypes caused by aminoacyl-
tRNA synthetases, we will have a closer look to these fascinating enzymes.  
 
1.3. (Mitochondrial) Aminoacyl-tRNA synthetases and -related 
diseases 
 
1.3.1 Aminoacyl-tRNA synthetases 
 
One of the first steps during translation is aminoacylation: the covalent ‘charging’ 
of a tRNA with its cognate amino acid, a two-step process that uses ATP 
(Delarue, 1995). tRNA charging is performed by a highly specialized subgroup of 
enzymes, the aminoacyl-tRNA synthetases (ARSs). ARSs are ubiquitiously 
expressed and highly conserved enzymes, which can be found in a range of 
species. In the first step, the amino acid and a molecule of ATP is bound via a 
specific ARS for that amino acid (Figure 1.2). Following the formation of an 
aminoacyl adenylate intermediate, a pyrophosphate molecule is released. The 
second step starts with the binding of the cognate tRNA molecule to the ARS. 
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After the binding of tRNA molecule, the amino acid is transferred to the tRNA 
and an adenosine monophosphate (AMP) molecule is released. After the releasing 
of the charged tRNA molecule and ARS is free for another aminoacylation 
reaction. Typically, ARSs have a catalytic domain and an anticodon-binding 
domain but some also have an editing domain for deacylating mischarged amino 
acids. The anticodon binding domain as well as the editing domain, which only 
some ARSs contain, is very important for specificity of the ARSs, as well as 
serves as a quality control mechanism of protein synthesis (Ling et al., 2009).  
 
 
Figure 1.2 Aminoacylation reaction. 
The two-step aminoacylation reaction catalyzed by aminoacyl-tRNA synthetases (ARSs) 
(Antonellis and Green, 2008). AA: aminoacid; PPi: pyrophosphate; ATP: adenosine 
triphosphate; AMP: adenosine monophosphate. 
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The two-step aminoacylation reaction. Each aminoacyl-tRNA synthetase
(ARS) charges a specific tRNA molecule with its cognate amino acid (AA) via a
two-step enzymatic reaction. In the first step, the ARS binds the AA and an
ATP molecule to form the aminoacyl adenylate (AA-AMP) intermediate, and a
pyrophosphate molecule (PPi) is released. In the second step, a tRNA molecule
binds the ARS via the anticodon binding domain (white space on ARS with three
extensions), and the AA is transferred to the tRNA. An AMP molecule is then
released, followed by the charged tRNA. The ARS is then free to charge
another tRNA molecule. The chemical equation for each step is provided in
the lower right in each case.
produce pr tein. The first essential step of pro-
tein translation involves covalently attaching an
amino acid to its cognate transfer RNA (tRNA).
This process (often referred to as tRNA charg-
ing) is performed by a highly specialized group
of enzymes, the aminoacyl-tRNA synthetases
(ARSs) (11) (Figure 1). There is at least one
ARS enzyme designated for each amino acid.
Reflecting their fundamental importance for
cellular life, ARSs are ubiquitously expressed
enzymes that are present in species ranging
from bacteria to humans.
In a typical human cell, tRNAs are charged
(or aminoacylated) in three locations. First, this
process takes place in the nucleus to ensure that
nuclear-encoded tRNAs become charged (30);
the resulting tRNA:amino acid complexes are
then exported to the cytoplasm. Second, tR-
NAs are charged by ARSs in the cytoplasm, and
the tRNA:amino acid complexes are then trans-
ported to the ribosome for nascent polypep-
tide elongation (29). The cytoplasmic ARSs are
then free to charge additional tRNAmolecules,
which allows the cycle to continue. Finally, be-
cause protein translation also occurs in the mi-
tochondria, ARS activity is required in these
organelles (7). To facilitate the latter process,
nuclear-encoded ARSs are imported into the
mitochondria; this step involves the use of spe-
cific localization signals within the ARS pro-
teins. Thus, each ARS can be categorized as
cytoplasm-specific, mitochondria-specific, or
bifunctional (i.e., involved in charging tRNA
molecules in both locations) (Table 1). ARSs
can also be categorized into two groups on
the basis of their protein structural characteris-
tics. Group I ARSs contain a Rossman (parallel
β-sheet nucleotide-binding) fold in their cat-
alytic domain, whereas Group II ARSs share
other homologous amino acid sequence motifs,
termed motif 1, 2, and 3 (3).
Thirty-six ARSs perform all the required
aminoacylation of tRNAs in humans: 16 act ex-
clusively in the cytoplasm, 17 act exclusively
in the mitochondria, and 3 are bifunctional
(Table 1). The reason for the discrepancy be-
tween the number of available cytoplasmic
ARSs (i.e., 19) and the total number of amino
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Different criteria can be used for categorizing the ARSs. First, they can be 
grouped according to their place of action: (i) cytoplasmic, (ii) mitochondrial, and 
(iii) bifunctional. If we consider humans, there are 36 aminoacyl-tRNA 
synthetases; 17 cytoplasmic, 17 mitochondrial and 2 bifunctional.  If we add up 
cytoplasmic/mitochondrial and bifunctional ones, we achieve the number 19, still 
one less than the total number of amino acids. This is due to the fact that one 
ARS, glutamyl-prolyl-tRNA synthetase, is responsible for charging tRNAGlu and 
tRNAPro in the cytoplasm (Berthonneau and Mirande, 2000). Mammalian 
mitochondria have no enzyme corresponding to glutaminyl-tRNA synthetase so 
glutamine (Gln)-tRNAGln is synthesized indirectly via misacylated glutamic acid 
(Glu)-tRNAGln through transamidation (Nagao et al., 2009). The nomenclature for 
ARSs also differs according to where they are active. Cytoplasmic ARSs use the 
single-letter amino acid code followed by ARS: the gene symbol for cytoplasmic 
aspartyl-tRNA synthetase is, therefore, DARS. In the case of mitochondrial 
specific ARSs, a ‘2’ is added to the end, thus, the symbol for mitochondrial 
aspartyl-tRNA synthetase is DARS2.  
 
Another method of categorizing ARSs is via their distinct structural motifs: Class 
I and II. Class I ARSs have a characteristic ATP binding region, a parallel β-sheet 
nucleotide-binding domain, namely Rossmann fold. Class II ARSs contain three 
structural motifs (motif 1, 2, and 3) (Ibba and Soll, 2000). Class I synthetases 
attach the charged amino acid at the 2’ OH and, class II synthetases at the 3’ OH, 
on the ribose of the acceptor end of the tRNA. 
 
Why do we have two different sets of ARSs? The co-existence of cytoplasmic and 
mitochondrial translation apparatus results also in two sets of distinct ARSs. 
Interestingly, it was shown that at least some mitochondrial ARSs can 
aminoacylate the corresponding cytoplasmic tRNAs but not vice versa (Buck and 
Nass, 1969). Of course, one of the reasons for that phenomenon can be explained 
with differences in the mitochondrial tRNA structures. The mammalian 
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mitochondrial genomes contain one gene for each tRNA, with the exceptions of 
tRNALeucine and tRNASerine for which two genes are present. Whereas the vast 
majority of eukaryotic cytosolic and prokaryotic tRNAs share a canonical 
structure, mt-tRNAs can be very different, or even be called ‘bizarre’ 
(Wolstenholme et al., 1987). Whereas most of these tRNAs have cloverleaf-like 
structures (except tRNASer(AGY), where the D-arm is completely absent), large 
variations in D-, and especially T-loop sizes are seen. Moreover, in mammalian 
mitochondria, the genetic code diverges from the universal one by the use of 
AUA for Methionine, UGA for Tryptophan, and AGA/AGG for a stop codon. 
 
Some ARSs have been shown to have secondary, non-canonical functions. In 
humans, these functions includes, but not limited to, promoting rRNA biogenesis 
(for MARS) (Ko et al., 2000), inhibition of apoptosis (for QARS) (Ko et al., 
2001), and promoting angiogenesis (for YARS and WARS) (Wakasugi et al., 
2002a; Wakasugi et al., 2002b). Moreover, nine of the cytoplasmic synthetases 
are shown to be tightly bound together in a large multisynthetase complex (MSC), 
which also include three ‘aminoacyl tRNA synthetase-interacting multifunctional 
proteins’ (AIMPs): 1, 2, and 3 (Robinson et al., 2000; Han et al., 2003). Although 
there is still some ambiguity about the stoichiometry and total number of 
components, the synthetases found in those MSC are: EP-ARS, IARS, LARS, 
MARS, QARS, RARS, KARS and DARS. It was proposed that formation of 
MSCs increases the efficiency of tRNA charging by “channeling” substrates to 
the ribosome or to regulate the secondary functions of ARSs (Park et al., 2005). 
One of the open questions is whether mitochondria also contain MSCs. So far, 
there is only one example: it has been proposed that human mitochondrial tyrosyl-
tRNA synthetase (YARS2) and bifunctional glycyl-tRNA synthetase (GARS) 
function as part of a high-molecular-weight complex (Sasarman et al., 2012). 
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1.3.2 Mitochondrial aminoacyl-tRNA synthetase-related diseases 
 
The first case, in which mutations in a mitochondrial aminoacyl-tRNA synthetase 
gene cause a human genetic disease, was reported in 2003 (van der Knaap et al., 
2003). Leukoencephalopathy with brain stem and spinal cord involvement and 
lactate elevation (LBSL) was first defined by characteristic magnetic resonance 
imaging (MRI) and spectroscopic findings. LBSL is a childhood or juvenile-onset 
disorder clinically characterized by slowly progressive cerebellar ataxia and 
spasticity with dorsal column dysfunction (decreased position and vibration 
sense). Among limbs, legs are affected more than the arms. Difficulty in 
articulation develops as the cognitive decline and learning problems occur. The 
disease causes the patients to be wheelchair dependent, usually during their 
teenager times. The MRI pattern shows differences from the other defined 
leukoencephalopathies, therefore giving a diagnostic tool for the disease. MRIs of 
the affected individuals show signal abnormalities in the cerebral white matter and 
specific brain stem and spinal cord tracts. Magnetic resonance spectroscopy 
(MRS) shows increased lactate in the abnormal white matter in almost all affected 
individuals (van der Knaap et al., 2003; Linnankivi et al., 2004).  Involvement of 
other organs than the nervous system has never been reported. 
 
Four years after the disease is characterized, the mutation responsible was 
discovered: LBSL is caused by mutations in the DARS2 gene, which encodes for 
the mitochondrial aspartyl-tRNA synthetase (Scheper et al., 2007). Most mapped 
mutations are predicted to affect splicing of exon 3, which causes a frameshift and 
truncation of the protein. These mutations are ‘leaky’, leading to an ablated, but 
not absent, expression of full-length DARS2 (van Berge et al., 2012). As being a 
rare disease, only 54 cases have been reported, and just 29 of these have been 
described clinically (Tzoulis et al., 2011). Majority (43/45) of the genetically 
confirmed cases were compound heterozygous for DARS2 mutations, which in 
most cases (41/43) included a frameshift-causing mutation in intron 2. Except the 
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‘common’ mutation, different types of mutations have been found in the other 
allele of DARS2, such as deletions, nonsense, splice site, and missense mutations 
(van Berge et al., 2013). 
 
Previous reports hypothesized that homozygous DARS2 mutations might not be 
compatible with life. However, two homozygous DARS2 mutations were 
observed (Miyake et al., 2011; Synofzik et al., 2011). The mechanisms how these 
homozygous mutations are compatible with life need further addressing. 
 
Since the initial discovery of an ARS2-mutation-leading-to-a-disease, last six 
years witnessed a number of ARS2 mutations as being the sole cause of some 
diseases. Mutations in cytoplasmic and bifunctional ARSs share phenotypic and 
genotypic features, whereas diseases phenotypes caused by mutations in the 
corresponding mitochondrial enzymes are clinically more variable. Table 1.1 
summarizes the diseases and the affected organs due to the mutations in different 
mitochondrial ARS2s. 
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Table 1.1 Diseases and affected organs due to the mutations in mitochondrial 
aminoacyl-tRNA synthetases. 
Gene Disease Affected 
organ 
References 
DARS2 Leukoencephalopathy with brain stem and spinal 
cord involvement and lactate elevation (LBSL) 
Brain Scheper et al., 2007 
RARS2 Pontocerebellar Hypoplasia type 6 (PCH6) Brain Edvardson et al., 2007 
YARS2 Myopathy, Lactic Acidosis, and Sideroblastic 
Anemia (MLASA) 
Muscle Riley et al., 2010 
SARS2 Hyperuricemia, Pulmonary hypertension, Renal 
failure in infancy, and Alkylosis (HUPRA) 
Kidney Belostotsky et al., 2011 
HARS2 Perrault syndrome with progressive sensorineural 
hearing loss and ovarian dysgenesis 
Cochlea, 
ovary 
Pierce et al., 2011 
AARS2 Infantile mitochondrial cardiomyopathy Heart Gotz et al., 2011 
MARS2 Autosomal Recessive Spastic Ataxia with 
Leukoencephalopathy (ARSAL) 
Brain Bayat et al., 2012 
FARS2 Fatal epileptic mitochondrial encephalopathy Brain, 
muscle 
Elo et al., 2012 
EARS2 Early-onset Leukoencephalopathy with Thalamus 
and Brainstem Involvement and High Lactate 
(LTBL) 
Brain Steenweg et al., 2012 
LARS2 Premature Ovarian Failure and Hearing Loss in 
Perrault Syndrome 
Cochlea, 
ovary 
Pierce et al., 2013 
GARS Charcot-Marie-Tooth (CMT) disease and distal 
spinal muscular atrophy type V 
Nerve Seburn et al., 2006 
KARS Intermediate Charcot-Marie-Tooth (CMT) disease Nerve Santos-Cortez et al., 2013 
 
In addition, synthetases for glycine (GARS) and lysine (KARS) have been 
associated with diseases of peripheral neuropathy. GARS mutations cause 
Charcot-Marie-Tooth (CMT) disease and distal spinal muscular atrophy type V 
(Seburn et al., 2006; Dubourg et al., 2006), whereas KARS mutations have been 
described in an unusual combination of intermediate CMT (Santos-Cortez et al., 
2013). In contrast to the recessive ARS2 diseases, GARS mutations are 
dominantly inherited and toxicity in peripheral neurons due to the mutant GARS 
has been experimentally observed (Motley et al., 2011). GARS and KARS are the 
bifunctional synthetases that are ‘charging’ their respective amino acids both in 
cytoplasm and mitochondria. Thus, the question whether these diseases are the 
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results of defective mitochondrial or cytoplasmic translation has to be 
investigated.  
 
Currently, the tissue specificity and diverse clinical presentations of the ARS2s 
are one of the most puzzling questions in the field. To exemplify, LBSL and 
PCH6 involve specific progressive central nervous system dysfunction, whereas 
MLASA causes sideroblastic anemia; HUPRA is a multisystemic disorder 
involving progressive renal failure. Interestingly, reduced synthetase activity 
and/or decreased mitochondrial translation leading to a lower activity of 
OXPHOS complexes harboring mtDNA encoded-subunits have been observed in 
some, but not all diseases. However, a general feature that is common for all 
diseases caused by mutations in ARS2 genes is still missing. To investigate those 
diseases in detail, mouse models mimicking the disease mutations should be 
generated and studied.   
 
1.4. Mitochondrial Stress Signaling 
 
What happens to the mitochondria during ‘dysfunctional/disease state’? Do they 
accept their fate and wait for the inevitable or do they strike back? You are not 
expecting the mitochondria to be the silent victims in a drama, are you? They 
behave as the last survivor in a teen slasher (like Sydney Prescott in the genre-
redefining Wes Craven movie ‘Scream’) who tries to find clever ways to defeat the 
evil serial killer, and to achieve that they use every possible way imaginable – 
even evoking responses from the local authorities.  
 
Many different stress responses have been described in mitochondria that involves 
diverse nuclear and mitochondrial signaling pathways. As mentioned before, 
mitochondria encode only 13 proteins that are components of mitochondrial 
respiratory complexes (MRC) and the rest of its protein pool (~1500 proteins) is 
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encoded by the nuclear genome. Therefore, responses to different stresses require 
coordination of those two genomes and in great need of cross talk between the 
nucleus and mitochondria. Mitochondria evokes those responses in order to (i) 
increase their biogenesis (their number or volume), (ii) enhancing the expression 
or activity of the OXPHOS subunits, (iii) send out signals to the nucleus and even 
to other organelles/organs to get more help, (iv) induce apoptosis, and (v) fight 
with oxidative damage. The well-defined signaling cascades include retrograde 
signaling leading to upregulation of mitochondrial biogenesis, anti-oxidative 
response and more recently, mitochondria specific unfolded protein response 
(UPRmt). Respiratory deficiency, causing a decreased production of ATP, is 
considered to be the primary activator of most of these adaptive responses in the 
course of mitochondrial diseases. However, we have very limited knowledge 
about signaling cascade involved in these responses, while the mechanisms that 
regulate tissue specificity are basically not known. 
 
1.4.1 Mitochondrial retrograde signaling 
 
Mitochondrial retrograde signaling is a pathway of communication from 
mitochondria to the nucleus that influences many cellular and organismal 
activities under both normal and pathophysiological conditions. In budding yeast, 
Saccharomyces cerevisiae, it is used as a sensor of mitochondrial dysfunction that 
initiates readjustments of carbohydrate and nitrogen metabolism (Butow and 
Avadhani, 2004). In higher organisms retrograde response is much less 
understood and is commonly linked to increased mitochondrial 
biogenesis/proliferation. 
 
Patients with mitochondrial dysfunction in muscle, show a phenotype called 
‘ragged-red fibers’. Those fibers can be seen when muscle is stained with Gomori 
Trichrome staining as a result of high subsarcolemmal accumulation of abnormal 
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mitochondria due to increased biogenesis. As discussed before, ragged-red fibers 
are seen in MERRF (myoclonic epilepsy associated with ragged-red fibers) 
syndrome patients, who have decreased mitochondrial translation and ETC 
defects (Zeviani et al., 1993). Those defects cause the retrograde signaling to the 
nucleus to increase mitochondrial mass (Wallace, 2005).  
 
Mitochondrial biogenesis is regulated by specific set of transcription factors 
including: nuclear respiratory factors 1 and 2 (NRF1 and NRF2, estrogen related 
receptor α (ERRα), the cAMP response element (CREB) and ying yang 1 
transcription factor (YY1) (Scarpulla et al., 2012). NRF1 and NRF2 also directly 
regulate mitochondrial transcription factor A (TFAM), which packages and 
maintains mtDNA, and is important for mitochondrial transcription and 
replication (Kukat and Larsson, 2013). Transcriptional control of nuclear genes 
encoding mitochondrial enzymes and proteins is also dependent on the members 
of the nuclear receptor superfamily, namely the peroxisome proliferator-activated 
receptor (PPAR) family that includes PPARα, PPARβ (also known as PPARδ) 
and PPARγ.  
 
How do these transcription factors control mitochondrial biogenesis? The clues 
led to the identification of peroxisome-proliferator-activated receptor coactivator-
1α (PGC-1α) as a master regulator of mitochondrial biogenesis (Puigserver et al., 
1998). PGC-1α is a member of a family of transcriptional coactivators that 
includes PGC-1β (Lin et al., 2002) and PRC (PGC-1 related coactivator) (Kelly 
and Scarpulla, 2004).  It was shown that the level of PGC-1α in cells is closely 
correlated with the number of mitochondria (Kelly and Scarpulla, 2004). Tissue-
specifity is a hallmark of PGC-1α. For example, cold exposure leads to the 
activation of PGC-1α in brown adipose tissue (Puigserver et al., 1998), whereas 
long-term exercise in skeletal muscle, leading to mitochondrial biogenesis (Zong 
et al., 2002). PGC-1α overexpression causes increases in mitochondrial content, in 
agreement with its role in mitochondrial biogenesis (Lehman et al., 2000). 
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However, loss of PGC-1α in mice causes disturbances only upon stress exposure, 
e.g. PGC-1α deficient mice are unable to maintain their body temperature upon 
cold exposure and they exhibit reduced exercise tolerance and abnormalities in the 
muscle fiber composition (Scarpulla, 2012). These results indicate that PGC-1α is 
indeed essential for mitochondrial-biogenesis on-demand, but seems not to be 
needed to maintain normal levels of mitochondria in the cell.  
 
1.4.2 Mitochondrial anti-oxidative response 
 
Mitochondrial respiratory chain is the main site of reactive oxygen species (ROS) 
production. Electrons can leak from the electron transport chain directly to 
oxygen, producing free radicals such as superoxide anion (O2 − ) (Droge, 2002). 
Superoxide anion is converted into hydrogen peroxide either spontaneously or via 
manganese superoxide dismutase (MnSOD or SOD2), a nuclear encoded primary 
antioxidant enzyme localized exclusively in the mitochondrial matrix (Weisiger 
and Fridovich, 1973). Membrane-permeable hydrogen peroxide can be diffused 
within the cell and can be scavenged via antioxidant systems such as catalase, 
glutathione peroxidase, and thioredoxin peroxidase (Nordberg and Arner, 2001). 
These are the sophisticated defense mechanisms evolved to limit the cellular 
damage that ROS can implement on lipids, proteins and nucleic acids, causing 
oxidative damage. One point that should not be neglected is the fact that ROS are 
also important signaling molecules in cell proliferation (Clement and Pervaiz, 
1999) or cell death (Burdon, 1996). 
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1.4.3 Mitochondrial unfolded protein response (UPRmt) 
 
Mitochondria have dedicated molecular chaperones and proteases that promote 
proper protein folding, complex assembly and quality control. All mitochondrial 
proteins that are translated in the cytoplasm should take a great journey to be 
functional in mitochondria. They have to pass through the double membrane of 
mitochondria, not to mention the unfolding, cleavage and refolding they have to 
go through. Mitochondrial dysfunction accumulates with increasing age and it is 
not surprising that increased levels of unfolded and/or misfolded proteins also 
escalate. Mitochondria respond to the accumulation of unfolded proteins by 
activating stress responses, which further upsurge the level of molecular 
chaperones and proteases, involved in protein quality control. Some of these stress 
responses are the well-documented ER unfolded protein response (UPRER) (Mori 
et al., 1993) and mitochondrial unfolded protein response (UPRmt) (Zhao et al., 
2002; Yoneda et al., 2004). The UPRmt activates the transcription of nuclear-
encoded mitochondrial chaperone genes to promote protein homeostasis within 
the organelle. Mitochondrial unfolded protein response is very specific and 
different from signaling cascades that are activated by heat-shock, endoplasmic 
reticulum stress or oxidative stress response (Haynes et al., 2013). 
 
Matrix-localized chaperones are required for protein import and facilitate protein 
folding, whereas proteases localized in the inner membrane and matrix degrade 
proteins that fail to fold or assemble correctly (Tatsuta and Langer, 2008). The 
targeting of many mitochondrial proteins synthesized in cytosol requires 
molecular chaperones such as cytosolic Hsp70 and Hsp90 (Young et al., 2003). 
Mitochondrial Hsp70 (mtHsp70) is required within the mitochondrial matrix for 
the import of unfolded protein across the inner membrane and with the help of 
chaperonins Hsp60/10, they fold the imported and mitochondrially-synthesized 
proteins (Ryan et al., 1997). MRC complexes are assembled and embedded into 
the inner mitochondrial membrane and possess their own quality control system: 
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two ATP-dependent metalloproteases (AAA protease). According to where their 
catalytic sides reside, they are named as the intermembrane space (i-AAA) or 
matrix side (m-AAA) proteases. Mitochondrial matrix harbors two major 
proteases, namely LON and CLPXP. LON protease is shown to preferentially 
degrade oxidized proteins (e.g. aconitase) and to regulate mtDNA copy number 
and transcription by selective degradation of mitochondrial transcription factor A 
(TFAM) (Ngo and Davies, 2007; Matsushima and Kaguni, 2012). CLPXP seems 
to be the main matrix protease that is dealing with unfolded and/or misfolded 
proteins (Zhao et al., 2002).  
 
The UPRmt has extensively been studied in C. elegans, where it acts by 
upregulating the expression of hsp-60 and hsp-6 (Hsp60 and mtHsp70, 
respectively). There are different hypothesis (and some proof) on how UPRmt 
signals are sensed and transported into the nucleus (Figure 1.3). CLPXP 
recognizes and degrades misfolded proteins into peptides of 8-20 residues (Choi 
and Licht, 2005). Those peptides accumulating in the mitochondrial matrix are 
extruded via an ABC (ATP Binding Cassette) transporter called HAF-1. This 
efflux of peptides is believed to activate bZIP transcription factor ATFS-1 in C. 
elegans, which further activates downstream UPRmt signaling targets (Haynes et 
al., 2010). ATFS-1 harbors both a nuclear localization sequence and a 
mitochondrial targeting sequence. Under physiological conditions, ATFS-1 is 
imported into mitochondria and degraded by Lon protease. However, during 
mitochondrial stress, import efficiency is reduced and ATFS-1 accumulates in the 
cytosol and nucleus where it activates genes coding for mitochondrial chaperones 
(Nargund et al., 2012). It has also been proposed ATFS-1 import to mitochondria 
can be slowed by peptide efflux via HAF-1, which occurs when the mitochondrial 
chaperone capacity is exceeded by unfolded proteins. But the mechanism of this 
attenuation in protein import is not fully understood and it is being hypothesized 
to be evolved independently of the UPRmt (Haynes et al., 2013).  
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Figure 1.3 The mitochondrial unfolded protein response (UPRmt) in Caenorhabditis 
elegans. 
Mitochondrial unfolded protein response is activated during mitochondrial stress and it 
upregulates the transcription of mitochondrial chaperones, proteases, genes necessary for 
ROS metabolism, glycolysis and mitochondrial protein import machinery (Haynes et al., 
2013). In normal conditions, Activating Transcription Factor associated with Stress-1 
(ATFS-1) is imported into mitochondria and degraded by LON protease. However, 
during mitochondrial stress, import efficiency was reduced and ATFS-1 accumulates in 
the cytosol and nucleus where it activates genes coding for mitochondrial chaperones. 
Moreover, ATFS-1 import to mitochondria can be slowed by peptide efflux via HAF-1. 
TIM: Translocase of the Inner Membrane; TOM: Translocase of the Outer Membrane. 
 
In mammals, UPRmt is less understood. Still, the upregulation of Hsp60 and 
mtHsp70 is observed, similar to UPRmt response in C. elegans. The activation of 
the nuclear genes as a result of UPRmt seems through the heterodimerization of 
the transcription factors C/EPBβ (CCAAT enhancer-binding protein β) and CHOP 
(C/EBP homology protein). These transcription factors are activated via JUN 
transcription factor that binds to an AP-1 (activator protein-1) element in the 
promoter of both genes. There is evidence that JNK2 (c-Jun N-terminal kinase 2) 
can be also involved in this signalling pathway (Aldridge et al., 2007). Several 
genes encoding mitochondrial protein quality control proteins that are responsive 
to mitochondrial unfolded protein stress, as well as 15 nuclear genes encoding 
other mitochondrial proteins, also contain a CHOP-binding element in their 
promoter region (Horibe and Hoogenraad, 2007). Interestingly, CHOP gene itself 
Coordination of mitochondrial stress with UPRmt
induction
Recent work from our laboratory has indicated the require-
ment for Activating Transcription Factor associated with
Stress-1 (ATFS-1) in UPRmt induction [27,29]. In addition
to a nuclear localization sequence (NLS) in the leucine-
zipper domain, ATFS-1 has an N-terminal MTS. The
unique ability to localize to both compartments potentially
enables ATFS-1 to function as a sensor of mitochondrial
import efficiency. In the absence of mitochondrial stress or
UPRmt induction, ATFS-1 is imported into mitochondria
and degraded by the Lon protease (Figure 1), presumably
as a negative regulatory mechanism [27].
During mitochondrial dysfunction, when UPRmt signal-
ing occurs, a small percentage of ATFS-1 fails to be
imported into mitochondria and accumulates in the cyto-
sol, suggesting that mitochondrial import is impaired
[27,29]. Additional mitochondrial proteins were also found
in the cytosol, suggesting a general impairment of mito-
chondrial import during stress, but because ATFS-1 also
has a NLS it is able to traffic to the nucleus to induce the
UPRmt (Figure 1). Consistent with the cell monitoring
mitochondrial import efficiency via ATFS-1, any condition
that perturbs import, including inhibition of the TOM and
TIM complexes, ETC perturbation, paraquat treatment,
and mitochondrial chaperone inhibition, caused ATFS-1-
dependent UPRmt induction. Furthermore, preventing mi-
tochondrial import of ATFS-1 by simply deleting the MTS
was sufficient to cause ATFS-1 nuclear accumulation and
UPRmt induction, even in the absence of mitochondrial
dysfunction [27].
Dual localization of a protein to the cytosol and mito-
chondrial matrix has been documented for several pro-
teins, including the enzyme fumarase [38]. Interestingly,
the MTS from both the mitochondria- and cytosol-localized
forms of fumarase is cleaved in the matrix. If the C-termi-
nal domain remains unfolded during mitochondrial im-
port, the MTS is cleaved and the entire protein enters
the matrix, where it folds and functions in the tricarboxylic
acid cycle. However, if the C-terminal domain folds before
being completely imported, the MTS is cleaved but the
remainder of the polypeptide diffuses back into the cytosol
[39]. In this respect, fumarase localization depends on
import efficiency, although the process is thought to be
stochastic because fumarase accumulates in both compart-
ments under normal physiological conditions.
Additionally, it is not unprecedented that the regulation
of a stress-associated transcription factor be tightly linked
to its degradation. Both p53 and Hif1 are constitutively
translated, recognized by a regulatory ubiquitin ligase, and
ultimately degraded by the cytosolic or nuclear pool of
proteasomes [40,41]. Only in the presence of stress such
as DNA damage or hypoxia do these transcription factors
avoid degradation and activate their respective transcrip-
tional responses. However, coupling of degradation with
mitochondrial import as a means to control transcription
factor activity appears to be a novel means of mitochon-
dria-to-nucleus communication dependent on ATFS-1 hav-
ing dual organelle-localization signals.
Once in the nucleus, ATFS-1 activates a relatively broad
transcriptional response to alleviate the effects of mito-
chondrial stress. The transcriptional response mediated by
ATFS-1 during mitochondrial stress is consistent with
what might be expected of a mitochondrial stress response
or an UPRmt. As expected, ATFS-1 induced the expression
of the known mitochondrial chaperone genes as well as
several mitochondrial proteases that re-establish protein
homeostasis as well as restore import efficiency. Addition-
ally, the UPRmt induced several ROS-scavenging compo-
nents that are localized to both the mitochondria and the
cytosol, consistent with increased ROS production during
mitochondrial stress. Interestingly, numerous genes in the
glycolysis pathway were also upregulated, suggesting that
ATFS-1 may shift metabolism from mitochondrial-depen-
dent respiration to glycolysis as an alternative means of
ATP production in the presence of mitochondrial dysfunc-
tion.
Lastly, ATFS-1 mediates the upregulation of two core
components of the TIM23 complex, tim-17 and tim-23,
which are required for the import of N-terminal MTS-
containing proteins to the mitochondrial matrix [30], such
as ATFS-1 and the mitochondria-targeted molecular cha-
perones that ATFS-1 transcriptionally upregulates. The
increase in mitochondrial protein-import machinery high-
lights the link between ATFS-1 and mitochondrial import
efficiency and suggests a possible means to increase import
of protective proteins such as chaperones as well as to
downregulate the UPRmt once stress has been alleviated by
improving mitochondrial import and thus preventing
ATFS-1 from reaching the nucleus.
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Figure 1. The mitochondrial unfolded-protein response (UPRmt). An illustration of
the sign ling mechanism that regulates the induction of the UPRmt as elucidated i
Caenorhabditis elegans. The UPRmt is activated during mitochondrial dysfunction
or stress resulting in the transcriptional upregulation of protective genes including
mitochondrial chaperones and proteases, those involved in reactive oxygen
species (ROS) detoxification, the glycolysis pathway, and the mitochondrial
protein-import machinery. The cell determines mitochondrial function and when
it is appropriate to induce the UPRmt by monitoring the mitochondrial protein-
import efficiency of the transcription factor Activating Transcription Factor
associated with Stress-1 (ATFS-1). In the absence of mitochondrial stress, ATFS-
1 is translated and efficiently imported into mitochondria via a mitochondrial
targeting sequence (MTS), where ATFS-1 is degraded by the Lon protease.
However, during mitochondrial dysfunction, general protein-import efficiency
is reduced, allowing a percentage of ATFS-1 to accumulate in the cytosol. Because
ATFS-1 also has a nuclear localization sequence (NLS), it then traffics to the
leus where it induces the mt. Mitochondrial import efficiency can be
impaired or reduced by numerous conditions, including mitochondrial chaperone
depletion and respiratory chain dysfunction. Additionally, import can be slowed by
peptide efflux via the ATP-binding cassette (ABC) transporter HAF-1, which occurs
when the mitochondrial chaperone (green) capacity is exceeded by unfolded
proteins (dashed lines). All of these result in inducti n of the UPRmt to maintain
organelle homeostasis. Abbreviations: TIM, Translocase of the Inner Membrane;
TOM, Translocas  of the Outer Membran .
Review Trends in Cell Biology July 2013, Vol. 23, No. 7
313
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seems to be upregulated by the accumulation of unfolded proteins in mitochondria 
(Zhao et al., 2002). It has been proposed that UPRmt can be a two-stage regulatory 
process (Ryan and Hoogenraad, 2007). First, the unfolded proteins in 
mitochondria are sensed and via the retrograde signaling to the nucleus, they 
activate CHOP (and possibly other) genes. Second, CHOP, in cooperation with 
C/EBPβ, then binds to target promoters and activates the transcription of 
mitochondrial-responsive genes. CHOP, also a part of induction of UPRER, have a 
promoter with separate mitochondrial and ER UPR elements and that is the way it 
can differentially upregulate responsive genes for either UPRmt or UPRER (Horibe 
and Hoogenraad, 2007). 
 
1.4.3.1 ‘Mitokines’ and Fibroblast growth factor 21 (FGF21) 
 
In the movie Scream, in the dawn of one-year anniversary of Sidney Prescott’s 
mother's murder, new killings start to take place in Woodsboro. At first, not-so-
bright Deputy sheriff Dewey Riley tries to provide shelter and protection for 
Sidney, which turns out not to be so effective. Local authorities cannot always 
protect you from the vicious serial killers. At that point, signaling to the national 
forces, such as FBI, becomes more crucial.  
 
Mitochondria adopted a similar signaling pathway, which became apparent very 
recently, to send mayday signals to the remote tissues/organs. It has been 
proposed that neuronal cells experiencing mitochondrial dysfunction could 
produce a mitochondrial signal for the upregulation of UPRmt (Durieux et al., 
2011). The interesting thing is those cells can generate an exracellular signal, a 
‘mitokine’, which can be transmitted to the distal cells, in their case intestinal 
cells of C. elegans. This cell-nonautonomous signal can induce UPRmt in those 
distal, far away tissues.  
  
 
27  
In 2010, a report identified the first mammalian mitokine known-to-date, FGF21. 
It has been experimentally proven that mitochondrial dysfunction activates Fgf21 
transcription in skeletal muscle in a dose-dependent manner (Tyynismaa et al., 
2010). FGF21 is produced mainly from liver and circulating FGF21 in the 
bloodstream comes from this organ. However, adipocytes and skeletal muscle 
have also been shown to be able to secrete FGF21, which then acts through 
autocrine or paracrine signaling (Potthoff et al., 2012). Fibroblast growth factor 
(FGF) 21 is a well-known hormone/cytokine, often described as “starvation-
hormone”, which has regulatory roles in glucose, lipid, phosphate and bile acid 
metabolism (Kharitonenkov et al., 2005). Sometimes it is also seen as a potential 
‘miracle hormone/cytokine’ due to the fact that its systemic administration causes 
reductions in body weight, fat mass, and the levels of blood glucose and insulin 
(Xu et al., 2009).  
 
In the beginning of 2013, another report strengthened the role of FGF21 as a 
mitokine (Kim et al., 2013). The authors showed that autophagy deficiency in 
skeletal muscle induced expression of Fgf21 through activating transcription 
factor 4 (Atf4), which leads to increased β-oxidation and browning of WAT, and 
finally to protection from high fat diet (HFD)-induced insulin resistance (Kim et 
al., 2013). Thus it seems that we laid our hands on the first-ever-identified 
mammalian mitokine. 
 
1.4.4 (Macro)Autophagy and Mitophagy 
 
What if your normal FBI agents also fail in protecting you from our everyday 
serial killer? The logical next step is to employ better FBI agents, not the normal, 
just-out-of-Quantico ones, but agents like experienced Fox Mulder and Dana 
Scully. They will search ‘the truth out there’ by invoking every possible help 
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source they can lay their hands on, even from the evil ‘Cancer Man’. But, do not 
be fooled: this could also lead to your demise!  
 
The lysosome and the proteasome are the two major degradation systems in 
eukaryotes (Mizushima and Komatsu, 2011). Proteasomal degradation has high 
selectivity and recognizes only ubiquitinated substrates. On the other hand, 
lysosomal degradation does not necessarily has this selectivity and uses 
autophagy for delivery of to-be-recycled products. (Macro)Autophagy (the other 
kinds of autophagy, namely microautophagy, and chaperone-mediated autophagy, 
are not in the scope of this thesis), ‘self-eating’ in Greek, is an evolutionary 
conserved mechanism in which the cytoplasmic constituents, which also includes 
organelles, are destined to the lysosomes inside double-membrane vesicles (Yang 
and Klionsky, 2010). Autophagy exists in order to (i) get rid of misfolded 
proteins, damaged organelles and/or microorganisms, (ii) during starvation, to 
provide building blocks for biosynthesis, (iii) remodel the cell to cellular stress. 
Autophagy deploys ‘autophagosomes’, basically a small part of the cytoplasm in 
an isolation membrane, which fuses with the lysosome to give rise to 
autolysosome and degrade the materials contained (Mizushima et al., 2010). 
Molecules that were subjected to autophagic degredation are sent back to the 
cytoplasm and used for recycling or production of energy. Autophagy is a 
dynamic process that is up- or downregulated as a response to cellular stress. The 
best example of induced autophagy is as a result of nutrient starvation. Autophagy 
suppression, is on the other hand, is a phenomenon seen in various diseases and 
aging (Mizushima et al., 2010). 
 
In yeast, multiple autophagy-related (ATG) proteins govern autophagosome 
formation (Yang and Klionsky, 2010). In mammalian cells, most of the Atg 
proteins are observed on isolation membranes (i.e., ULK1/2, Atg13, FIP200, 
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Atg101, Beclin 1, Atg14, LC3, Atg12, Atg16L1) (Longatti and Tooze, 2009); the 
only exception being LC3 (microtubule-associated protein light chain 3), which is 
also available on autophagosomes (Mizushima et al., 2004). That is the reason it 
is the most commonly used marker for autophagy.  
 
Basal autophagy acts as the quality-control machinery for cytoplasmic 
components. There is also increasing evidence indicating selective autophagy for 
specific proteins, organelles, and invading bacteria. Recent studies have described 
a specialized form of autophagy that acts solely on damaged mitochondria, 
mitophagy. It utilizes the same machinery as autophagy; however, the process 
becomes selective through the participation of Atg32, which tags mitochondria for 
elimination (Okamoto et al., 2009). Much of our knowledge about mitophagy 
comes from in vitro studies and currently there is very little, if any, support for the 
role of mitophagy as a quality control mechanism in vivo. Actually, a recent in 
vivo study showed that depolarized mitochondria do not recruit Parkin in 
dopamine neurons (Sterky et al., 2011). Thus, many questions remain as a secret 
about mitophagy and its role as a quality control mechanism and we need more in 
vivo studies to fully understand this process.  
 
1.5. Objectives 
 
Mitochondrial disorders are very heterogeneous from a clinical, genetical, 
biochemical and molecular point of view (Schaefer et al., 2004). Certain tissues 
such as heart, brain, and skeletal muscle are very dependent on the OXPHOS for 
energy production; therefore, these tissues are more involved in mitochondrial 
diseases (Dogan and Trifunovic, 2011). However, this cannot explain the diverse 
manifestations of mutations that would be predicted to have similar effects. The 
mechanisms that regulate the tissue-specific consequence of mitochondrial disease 
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are still largely unknown. In fact, the different patterns of energy crisis are 
perhaps the most puzzling dilemma in the field.  
 
Mutations in nuclear encoded proteins that obey the laws of Mendelian genetics 
and therefore have the same type of defect in all different cell types, often have 
tissue or organ specific presentation. One class of enzymes that fall into that 
category is mitochondrial aminoacyl-tRNA synthetases. The first described 
pathological mitochondrial synthetase mutation was in the DARS2 gene, which 
encodes for the mitochondrial aspartyl-tRNA synthetase (Scheper et al., 2007). 
Eased by advantages in whole genome sequencing, large number of mutation in 
other synthetase genes quickly followed. Strikingly, the mutations in different 
mitochondrial synthetase genes often gave rise to clinically diverse diseases and 
organ involvement. However, we cannot really observe a general aspect that is 
common in all of those diseases that can explain this phenomenon. To investigate 
those diseases in detail, mouse models may be useful tools but to date none have 
been reported.  
 
For this PhD thesis, we wanted to generate a novel mouse model that does not 
mimic the clinical presentations of a disease but having a strong respiratory chain 
deficiency as observed in majority of mitochondrial diseases. As no such model 
was available so far, we generated one by deleting Dars2 gene encoding for 
mitochondrial aspartyl-tRNA synthetase, thus directly disrupting mitochondrial 
protein synthesis. With this model, we aimed to analyze tissue specific 
consequences of defective mitochondrial translation. We specifically wanted to 
compare effects of DARS2 depletion on heart and skeletal muscle -tissues of 
common origin that are often affected in mitochondrial diseases-, and with 
another mouse model in forebrain neurons: three of the high energy demanding 
tissues.  
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Cells have developed various kinds of compensatory mechanisms in response to 
mitochondrial respiratory chain deficiency that could play a central role in 
determining the extent of tissue-specific defects. We wanted to study those 
mechanisms, as well as mitochondrial stress signaling pathways, in order to find a 
mechanism for tissue-specific activation of adaptive responses during the 
development of mitochondrial diseases. 
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2. Materials and Methods 
 
2.1 Mouse Experiments 
 
2.1.1 Animal Care 
 
Care of all animals was within institutional animal care committee guidelines. All 
animal procedures were conducted in compliance with protocols and approved by 
local government authorities (Bezirksregierung Köln, Cologne, Germany) and 
were in accordance with NIH guidelines. Animals were housed in groups of 3 - 5 
mice per cage at an ambient temperature of 22 – 24 oC and kept at a 12-hour light 
/ 12-hour dark cycle. Mice were sacrificed by cervical dislocation; the only 
exceptions were the brain-specific knockout and wild type animals, for which 
lethal CO2 anesthesia was used.  
 
2.1.2 Mouse handling and breeding 
 
General handling and breeding of mice was performed according to Silver (Silver, 
1995). 
 
2.1.3 Mice 
 
Mitochondrial aspartyl-tRNA synthetase (Dars2) gene targeting was carried out as 
part of the International Knockout Mouse Consortium (KOMP), in the JM8.N4 
embryonic stem cell line on a C57BL/6N genetic background. The targeted 
Dars2tm1a(KOMP)WTSI allele carried a gene-trap DNA cassette, inserted into the second 
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intron of the gene, consisting of a splice acceptor site, an internal ribosome entry site, 
and a β-galactosidase reporter, followed by a neomycin resistance marker expressed 
from an independent β-actin promoter (further information available at 
http://www.knockoutmouse.org, Project ID: 41773). Full body knockout mice were 
generated by mating the Dars2+/tm1a(KOMP)WTSI animals with transgenic mice 
ubiquitously expressing the Cre recombinase. Heart and skeletal muscle specific 
knockout mice were generated by mating Dars2loxP/loxP animals with transgenic mice 
expressing cre recombinase under the control of muscle creatine kinase promoter 
(Ckmm-cre) (Larsson et al., 1998). Forebrain specific knockout mice were generated 
by mating Dars2loxP/loxP animals with transgenic mice expressing cre recombinase 
under the control of CaMKIIα promoter (CaMKII-cre) (Xu et al., 2000). 
 
The animals were maintained in the pathogen-free animal facility of the CECAD/Max 
Planck Institute for Biology of Aging.  
 
2.1.4 Blood collection and determination of blood glucose, non-esterified 
fatty acids and FGF21 levels 
 
Tail bleeding of mice was performed as described (Silver, 1995). Venous blood 
samples were stored on ice for 15 minutes and subsequently centrifuged at 13.000 
rpm for 20 minutes. Resulting serum was stored at -80 oC. Determination of 
metabolite levels and collection of blood samples from control and knockout mice 
were performed side-by-side in the morning to avoid intra-group deviations due to 
circadian variations. 
 
Fed blood glucose concentrations were measured after tail-vein incision using 
glucose strips, which were read for absorbance in a reflectance meter (ACCU-
CHEK AVIVA, Roche, Mannheim, Germany). 
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Serum Non-esterified fatty acids (NEFA) levels were determined using an acyl-
CoA oxidase based colorimetric kit (WAKO NEFA-C; WAKO Life Sciences, 
Inc., Richmond, USA). NEFA standard solutions were used for the linear 
regression plot and absorbency measured at 550 nm in a Paradigm plate reader 
(Molecular Devices, Sunnyvale, USA). 
 
Serum FGF21 concentrations were measured with a Mouse/Rat FGF-21 
Quantikine ELISA Kit (R&D Systems, Minneapolis, USA) according to 
according to the manufacturer's instructions. 
 
2.1.5 Analysis of body composition (NMR) 
 
Nuclear magnetic resonance (NMR) was employed to determine the body fat 
content of live animals using the NMR Analyzer Minispec mq7.5 (Bruker Optik, 
Ettlingen, Germany). 
 
2.1.6 Perfusion 
 
Mice were anesthetized with 20 µl/g body weight of Avertin (2,2,2-tribromoethyl 
alcohol with tert-amyl alcohol), given subcutaneously intraperitonal. Afterwards, 
perfusion is performed intracardially with phosphate buffered saline (PBS) 
followed by 4% paraformaldehyde (PFA) in 0.1M PBS (pH 7.4). Isolated brains 
were post-fixed in 4% PFA at 4 oC (for Transmission Electron Microscopy 
analysis, post-fixed in 2% Glutaraldehyde at 4 oC) overnight and then stored at 4 
oC in 0.05% Sodium azide-PBS (NaN3-PBS) until further analysis. 
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2.2 Molecular biology 
 
2.2.1 Isolation of genomic DNA from mice tails 
 
Mice tail biopsies were incubated overnight in lysis buffer (100 mM Tris-HCl pH 
8.5, 5 mM EDTA, 0.2% (w/v) SDS, 0.2 M NaCl, 500 mg/ml Proteinase K) in a 
thermoshaker (Eppendorf, Hamburg, Germany) at 55 oC. DNA was precipitated 
by adding an equivalent volume of 2-Propanol (100%) and centrifuging at 
maximum speed for 20 minutes in a benchtop centrifuge. After removing the 
supernatant, the pellet was washed with 70% (v/v) ice-cold ethanol and 
centrifuged at maximum speed for 15 minutes. Then, the samples were pulsed 
down and DNA pellets were resuspended in 100 µl dH2O by shaking at 37 °C for 
1 h.  
 
2.2.2 Isolation of genomic DNA from mice tissues 
 
Shock-frozen mice tissues (about 3 mm3) were incubated overnight in lysis buffer 
(50 mM Tris-HCl pH 8.0, 2.5 mM EDTA, 0.5% (w/v) SDS, 0.1 M NaCl, 500 
mg/ml Proteinase K) in a thermoshaker (Eppendorf, Hamburg, Germany) at 55 
oC. DNA was precipitated by adding 75 µl of 8 M potassium acetate and 0.5 ml 
chloroform, and centrifuging at maximum speed for 10 minutes in a benchtop 
centrifuge. The upper, aqueous phase (not the lower chloroform phase) was 
transferred to a new 1.5 ml eppendorf tube. 1 ml of 95% ethanol was added to the 
samples, which were further inverted several times. The samples were centrifuged 
at maximum speed for 10 minutes. The pellet is, then, rinsed with 70% (v/v) ice-
cold ethanol and centrifuged for an additional 5 minutes. Afterwards, the samples 
were pulsed down and DNA pellets were resuspended in 100 µl ddH2O.  
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2.2.3 Isolation of total RNA from mice tissues 
 
Total RNA was isolated either using the ToTALLY RNA Total RNA isolation kit 
(Ambion, Life Technologies GmbH, Darmstadt, Germany) or TRIzol reagent 
(Life Technologies GmbH, Darmstadt, Germany). To start with, 50-100 mg 
tissues were dissected and placed into Precellys (Bertin Technologies, Versailles, 
France) 1.5 ml tubes with beads (500 µl of denaturing buffer (ToTALLY RNA 
kit) or 500 µl of TRIzol reagent). The tissues were homogenized by a Precellys 24 
(Bertin Technologies, Versailles, France) fast-prep machine at 5500 rpm for 2x30 
seconds. Afterwards, manufacturer's instructions’ were followed. 
 
2.2.4 Quantification of nucleic acids 
 
DNA and RNA concentrations were quantified by measuring the sample 
absorption at 260 nm and 280 nm with a NanoDrop ND-1000 UV-Vis 
spectrophotometer (Peqlab, Erlangen, Germany). A ratio greater than 2 of 
absorptions at 260 nm (DNA/RNA) divided by the absorption at 280 nm (protein) 
was used as an index of purity of DNA/RNA. 
 
2.2.5 Polymerase chain reaction (PCR) 
 
PCR reactions were used to detect whether the mouse genome contains floxed 
(LoxP flanked) exons (wt) –for full body knockout mice giving only wt band and 
for tissue-specific mice two bands corresponding to LoxP regions and wt band-, 
full body knockout (ko) –for full body knockout mice-, and cre-recombinase gene 
(cre) with primers described in Table 2.1.  
 
Reactions were performed in a Veriti Thermal Cycler (Applied Biosystems, Life 
Technologies GmbH, Darmstadt, Germany). All amplifications were performed in 
a total reaction volume of 20 µl. For wt and ko PCR, 12.35 µl of dH2O, 4 µl of 5x 
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GoTaqBuffer (Promega), 1 µl of dNTPs (1.25 mM each), 0.8 µl of each primer 
(10 µM), and 0.05 µl of GoTaq (5 U/µl, Promega) were added to 1 µl of sample 
DNA. For cre PCR, 10.5 µl of dH2O, 4 µl of 5x GoTaqBuffer, 3.2 µl of dNTPs 
(1.25 mM each), 0.6 µl of each primer (10 µM) and 0.1 µl of GoTaq (5 U/µl) 
were added to 1 µl of sample DNA. Bands were determined by visualization of 
PCR products using 1% agarose gel with ethidium bromide. 
 
Table 2.1 Genotyping PCR primer sequences 
 
Primer Sequence 
Forwardwt ATGAATTCTAGGCCAGCCAC 
Reversewt TGGCAATCTCTTAGGACTAAG 
Forwardko CGCTACCATTACCAGTTGGT 
Reverseko TGACTGGCTATAATGCTGAAG 
Forwardcre CACGACCAAGTGACAGCAAT 
Reversecre AGAGACGGAAATCCATCGCT 
 
 
PCR programs for wt and ko PCR started with 5 minutes of denaturation at 95 oC, 
followed by 30 cycles consisting of denaturation at 95 oC for 30 seconds, 
annealing at 60 oC for 30 seconds and elongation at 72 oC for 45 seconds, and a 
final elongation step at 72 oC for 7 min. 
 
PCR programs for cre PCR started with 5 minutes of denaturation at 95 oC, 
followed by 35 cycles consisting of denaturation at 95 oC for 30 seconds, 
annealing at 53 oC for 30 sec and elongation at 72 oC for 30 sec, and a final 
elongation step at 72 oC for 5 min. 
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2.2.6 Southern blot analysis for mitochondrial DNA (mtDNA) 
quantification 
 
After DNA isolation from mice tissues (as mentioned before), 10 µg DNA was 
digested by SacI restriction enzyme (New England Biolabs, Ipswich, USA) 
overnight at 37 oC. DNA was precipitated by addition of 20 µl 5M NaCl and 500 
µl 99.5% EtOH to the digestions. After mixing, the samples were left at -80 oC for 
30 minutes. Further, the samples were centrifuged at maximum speed for 20 
minutes in a benchtop centrifuge, washed with 1 ml 70% EtOH, airdried and 
resuspended in 20 µl dH2O and 6 µl 6X DNA loading dye (Fermentas, St. Leon-
Rot, Germany). Samples were run on a 0.7% agarose gel at 1V/cm for 16-20 
hours. Next day, the gel is denatured by shaking twice for 15 minutes in 
denaturation solution (1,5 M NaCl and 0.5 M NaOH). After rinsing shortly with 
dH2O, the gel was neutralized by shaking twice for 20 minutes in neutralization 
solution (1.5 M NaCl and 1 M Tris-HCl pH 7.5). The gel was blotted overnight by 
sandwiching two long, bridging Whatman papers -presoaked in 20X saline-
sodium citrate (SSC) (3M NaCl and 300 mM sodium citrate)-, two short 
Whatman papers, gel (surrounded tightly with plastic wrap to circumvent 
shortcuts), Hybond N+ nylon membrane (GE Healthcare, Munich, Germany), two 
short Whatman papers, about 10-15 cm of paper staple and a weight of 600 g on 
top. After disassembling of the blot, the membrane was UV-crosslinked with 
Stratalinker UV Crosslinker (Agilent Technologies, Waldbronn, Germany) twice 
at 200000 Joule/cm2. Afterwards, the membrane was placed in a glass 
hybridization bottle and prehybridized for 60 minutes at 65 oC in 10 ml rapid-hyb 
buffer (GE Healthcare, Munich, Germany). In the meantime, the probe, PAM1 – 
for the whole mouse mitochondrial genome- was labelled with Prime-It II 
Random Primer Labeling Kit (Agilent Technologies, Waldbronn, Germany) and 
α-32P-dCTP for 15 minutes. After denaturation of the probe, it was added to the 
glass hybridization bottle and hybridized for 2 hours at 65 oC. The membrane is 
washed in 2X SSC/0.1% SDS for 20 minutes at room temperature, in 1X 
  
 
39  
SSC/0.1% SDS for 20 minutes at 65 °C and finally in 0.1X SSC/0.1% SDS for for 
20 minutes at 65 °C. The membrane, wrapped in a plastic bag, exposed to 
Amersham Hyperfilm (GE Healthcare, Munich, Germany) overnight.  
 
2.2.7 Northern blot analysis for mRNA and tRNA levels 
 
After RNA isolation (as mentioned above), 2 µg total RNA was taken and topped 
up to 10 µl with nuclease-free H2O. 10 µl Ambion RNA Loading dye (Life 
Technologies GmbH, Darmstadt, Germany) was added to the samples, which 
were heated to 70 oC for 10 minutes. The agarose gel was prepared by addition of 
72 ml DEPC H2O, 1.2 g Agarose (Agarose-LE from Ambion, Life Technologies 
GmbH, Darmstadt, Germany). After heating up this mixture in the microwave, 
10X MOPS Running Buffer (Ambion, Life Technologies GmbH, Darmstadt, 
Germany) and 18 ml farmaldehyde solution (Sigma Aldrich, Seelze, Germany) 
were added with clean pipettes. The gel was run in 1X MOPS Buffer for 2 hours 
at 130 V. The gel was shaken three times for 15 minutes with clean, nuclease-free 
H2O and for 20 minutes in 20X SSC solution. The gel was blotted overnight by 
the same sandwiching technique mentioned in Southern blot analysis. After 
disassembling of the blot, the membrane was UV-crosslinked with Stratalinker 
UV Crosslinker (Agilent Technologies, Waldbronn, Germany) twice at 200000 
Joule/cm2. Afterwards, the membrane was placed in a glass hybridization bottle 
and prehybridized for 60 minutes at 65 oC in 10 ml rapid-hyb buffer (GE 
Healthcare, Munich, Germany). The probes for mitochondrial-encoded protein 
coding genes were prepared with Prime-It II Random Primer Labeling Kit 
(Agilent Technologies, Waldbronn, Germany) and α-32P-dCTP exactly as in 
Southern blot analysis. The probes for tRNAs were prepared by mixing 10 pmol 
of the probe, with 2 µl of 10X T4 Polynucleotide Kinase Reaction Buffer (New 
England Biolabs, Ipswich, USA), 1 µl T4 Polynucleotide Kinase (New England 
Biolabs, Ipswich, USA), 12 µl dH2O and 40 µCi γ-32P-dATP. After denaturation 
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of the probe, it was added to the glass hybridization bottle and hybridized for 2 
hours at 65 oC (for mRNAs) or 42 oC (for tRNAs). The membrane is washed in 
2X SSC/0.1% SDS for 20 minutes at room temperature, in, again, 2X SSC/0.1% 
SDS for 20 minutes at 65/42 °C and finally in 0.2X SSC/0.1% SDS for for 20 
minutes at 65/42 °C. The membrane, wrapped in a plastic bag, exposed to 
Amersham Hyperfilm (GE Healthcare, Munich, Germany) overnight. The probes 
used for Northern blot analysis can be found in Park et al. (2007). 
 
2.2.8 Reverse transcriptase PCR (Gene expression analysis) 
 
Isolated total RNA was treated with DNAse (DNA-free Kit, Ambion, Life 
Technologies GmbH, Darmstadt, Germany) and subsequently reversely 
transcribed with the High capacity reverse transcription kit (Applied Biosystems, 
Life Technologies GmbH, Darmstadt, Germany). Probes for target genes were 
from TaqMan Assay-on-Demand kits (Applied Biosystems, Life Technologies 
GmbH, Darmstadt, Germany). The only exceptions are Nppa and Nppb 
(Natriuretic peptide precursor type A and B) (Riehle et al., 2011), and 
mitochondrial and nuclear encoded MRC subunits (Karamanlidis et al., 2013) , 
where Brilliant III Ultra-Fast SYBR Green QPCR Master Mix (Agilent 
Technologies, Waldbronn, Germany) was used. Real-time PCR analysis was 
performed on an ABIPRISM 7700 Sequence detector (Applied Biosystems, Life 
Technologies GmbH, Darmstadt, Germany). Samples were adjusted for total 
RNA content by Hypoxanthine-guanine phosphoribosyltransferase (HPRT). 
Relative expression of mRNAs was determined using a comparative method 
(2−δδCT) according to the ABI Relative Quantification Method. The TaqMan 
probes used and their accession numbers are: Trim63 - Muscle RING-finger 
protein 1 (MuRF1 - Mm01185221_m1), Atrogin 1/Fbxo32 - Fbxo32 – F-box 
protein 32 (Mm00499523_m1), Myod1 - Myogenic differentiation 1  
(Mm00440387_m1), Myf5 - Myogenic factor 5 (Mm00435125_m1), Ddit3/chop 
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(Mm00492097_m1), Fgf21 (Mm00840165_g1), Atf4 (Mm00515324_m1), ATF5 
(Mm00459515_m1), Pdk4 (Mm00443325_m1), Cpt1b (Mm00487200_m1), Ppar-
α (Mm00440939_m1), Ppar-δ (Mm01305434_m1), Ppar-Υ (Mm00440945_m1), 
Pgc-1α (Mm00447180_m1).  
 
2.3 Biochemistry 
 
2.3.1 Protein isolation from tissues 
 
Proteins from brain were isolated by RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 
mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 
dH2O and one tablet of protease inhibitor (Roche, Mannheim, Germany). Proteins 
from other mice tissues were isolated by organ lysis buffer (50 mM HEPES, pH 
7.4, 50 mM NaCl, 10 mM EDTA, 1% Triton X-100, 10 mM sodium 
orthovanadat, 100 mM NaF, 0.1% SDS, dH2O and one tablet of protease inhibitor 
(Roche, Mannheim, Germany).  
 
To start with, 3 mm3 tissues were dissected and placed into Precellys (Bertin 
Technologies, Versailles, France) 1.5 ml tubes with beads (300 µl of RIPA buffer 
or 500 µl of organ lysis buffer). The tissues were homogenized by a Precellys 24 
(Bertin Technologies, Versailles, France) fast-prep machine at 6500 rpm for 2x20 
seconds. After incubation on ice for 10 minutes, the samples were centrifuged at 
13000 rpm for 45 minutes at 4 °C. The supernatant was transferred to a new tube 
and the protein concentrations were measured by Bradford reagent (Sigma 
Aldrich, Seelze, Germany) according to the manufacturer's instructions. Later on, 
proteins were stored at -80 °C until used. 
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2.3.2 Mitochondria isolation from tissues other than skeletal muscle 
 
After the mice were sacrificed, the tissues were transferred into a 50 ml falcon 
tube which includes 20 ml of mitochondria isolation buffer (MIB: 100 mM 
sucrose, 50 mM KCl, 1 mM EDTA, 20 mM TES, 0,2% BSA free from fatty acids, 
pH 7.2). After the blood was removed, the tissues were transferred onto a petri 
dish and cut into small pieces with razor. The pieces were transferred into a glass 
homogenizer tube (at this step, 1 mg/ml of Subtilisin A was added only for heart). 
The pieces were homogenized by hand until the solution became homogeneous. 
Later, the homogenate was transferred into 50 ml Falcon tube and centrifuged at 
8500 g for 5 minutes at 4 °C. The supernatant, with floating fat, was discarded 
and the pellet was resuspended by shaking in 30 ml MIB. Another centrifugation 
step (at 800 g for 5 minutes at 4 °C) was performed and this time the supernatant, 
comprising of mitochondria, was transferred into a new 50 ml tube. The 
supernatant was then centrifuged at 8500 g for 5 minutes at 4 °C to pellet 
mitochondria. The supernatant was decanted and the remaining pellet in 
resuspended in 50 µl MIB without BSA. The concentrations were measured by 
Bradford reagent (Sigma Aldrich, Seelze, Germany) according to the 
manufacturer's instructions.  
 
2.3.3 Mitochondria isolation from skeletal muscle 
 
After the mice were sacrificed, the tissues were transferred into a 50 ml falcon 
tube that includes 10 ml of ice-cold PBS supplemented with 10 mM EDTA. After 
the hairs/blood were removed, the tissues were transferred onto a petri dish and 
cut into small pieces with razor. The pieces were transferred into a 50 ml Falcon 
tube including ice-cold PBS/10 mM EDTA and 0.05% trypsin was added. After 
30 minutes of incubation on ice, the samples were centrifuged at 200 g for 5 min 
at 4 °C. The supernatant was discarded and the pellet was resuspended in IMB1 
(67 mM Sucrose, 50 mM KCl, 50 mM Tris-HCl pH 8, 10 mM EDTA, 0,2% BSA 
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free from fatty acids, pH 7.4). The pieces were transferred into a glass 
homogenizer tube and were homogenized by hand until the solution became 
homogeneous. Later, the homogenate was transferred into 50 ml Falcon tube and 
centrifuged at 700 g for 10 minutes at 4 °C. The supernatant, comprising of 
mitochondria, was transferred into a new 50 ml tube and was centrifuged at 8000 
g for 10 minutes at 4 °C to pellet mitochondria. The supernatant was decanted and 
the remaining pellet in resuspended in 5 µl of MIB2 (250 mM sucrose, 0.3 mM 
EGTA-Tris, 10  mM Tris-HCl, pH 7.4). After decanting of the supernatant, the 
pellet was resuspended in 100 µl of MIB2. The concentrations were measured by 
Bradford reagent (Sigma Aldrich, Seelze, Germany) according to the 
manufacturer's instructions.  
 
2.3.4 Blue Native polyacrylamide gel electrophoresis (BN-PAGE) and in-
gel activity of respiratory chain complexes I and IV 
 
BN-PAGE was carried out using the Novex Bis-Tris system (Life Technologies 
GmbH, Darmstadt, Germany) according to the manufacturer’s specifications. CO 
I in-gel activity was measured by incubating BN-PAGE gel in NADH 0.1 mg/ml 
nitrotetrazolium blue (NTB) 2.5 mg/ml in 5mM Tris (pH 7.4) for 1 hour. CO IV 
in-gel activity was measured by incubating BN-PAGE gel at 37 °C in 0.24 unit/ml 
catalase, 10% Cytochrome C and 0.1% Diaminobenzidine tetrahydrochloride 
(DAB) in 50 mM Tris (pH 7.4) for 1 hour. One set of samples was transferred to 
PVDF membrane using iBlot™ system (Life Technologies GmbH, Darmstadt, 
Germany) and immunodetection of mitochondrial protein complexes was 
performed. 
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2.3.5 Western blot analysis 
 
Frozen protein extracts were thawed and 50 µg of proteins were separated by 
NuPAGE Bis-Tris Gel 4-12% system (Life Technologies GmbH, Darmstadt, 
Germany) according to the manufacturer's instructions. The proteins were blotted 
to nitrocellulose membranes in a dry-transfer manner by iBlot™ system (Life 
Technologies GmbH, Darmstadt, Germany). Membranes were incubated with 5% 
Milk-PBST for 1 hour for blocking purposes. Subsequently, primary antibodies 
(Table 2.2), diluted in 5% Milk-PBST were applied for overnight at 4 °C. 
Afterwards, the membrane was washed 3 x 5 minutes with PBST. The secondary 
antibody (all secondary antibodies were purchased from Sigma Aldrich, Seelze, 
Germany and the dilution used was 1:2000) was diluted in 5% Milk-PBST and 
applied for 1 hour at room temperature. The membrane was again washed 3 x 5 
minutes with PBST and ECL solution (GE Healthcare, Munich, Germany) was 
applied. The membranes were developed by using ImageQuant LAS4000 (GE 
Healthcare, Munich, Germany). Western blot quantification was performed with 
ImageJ software as intensity per mm2. Average protein expression of control mice 
was set to 100% and compared to protein expression of knockout animals unless 
stated otherwise. 
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Table 2.2 Primary antibodies used for Western blot analysis 
 
Antigen Distributor Dilution 
AFG3L2 Polyclonal antisera made by Prof. Elena I. Rugarli 1:1000 
MRPL-13 Polyclonal antisera made by Prof. Nils-Göran Larsson 1:200 
MRPS-27 Polyclonal antisera made by Prof. Nils-Göran Larsson 1:200 
COXII Polyclonal antisera made by Prof. Nils-Göran Larsson 1:200 
TFAM Polyclonal antisera made by Prof. Nils-Göran Larsson 1:1000 
Porin Calbiochem (Merck, Darmstadt, Germany) 1:2000 
ATP5a1 Mitosciences (Abcam, Cambridge, UK) 1:1000 
COXIV Invitrogen (Karlsruhe, Germany) 1:1000 
UQCRC2 Invitrogen (Karlsruhe, Germany) 1:1000 
SDHA Invitrogen (Karlsruhe, Germany) 1:10000 
NDUFA9 Invitrogen (Karlsruhe, Germany) 1:1000 
COX5B Invitrogen (Karlsruhe, Germany) 1:1000 
COXIII Invitrogen (Karlsruhe, Germany) 1:1000 
HSP60 StressMarq (Victoria, Canada) 1:1000 
DNP Millipore (Merck, Darmstadt, Germany) 1:150 
MnSOD Millipore (Merck, Darmstadt, Germany) 1:500 
MRPS-35 Proteintech (Chicago, USA) 1:1000 
DARS2 Proteintech (Chicago, USA) 1:1200 
Actin Santa Cruz (Dallas, USA) 1:5000 
HSC70 Santa Cruz (Dallas, USA) 1:10000 
PGC-1α Santa Cruz (Dallas, USA) 1:1000 
CLPP Sigma Aldrich, Seelze, Germany 1:1000 
mtHSP70 Abcam (Cambridge, UK) 1:1000 
ND5 Abcam (Cambridge, UK) 1:1000 
MRPL-12 Abcam (Cambridge, UK) 1:500 
LON Abcam (Cambridge, UK) 1:1000 
LC3B Cell Signaling, Danvers, USA 1:1000 
Ubiquitin Cell Signaling, Danvers, USA 1:1000 
Beclin Cell Signaling, Danvers, USA 1:1000 
ATG7 Cell Signaling, Danvers, USA 1:1000 
ATG12 Cell Signaling, Danvers, USA 1:1000 
p62/SQSTM1 Abnova (Taipei, Taiwan) 1:1000 
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2.3.6 Citrate synthase activity and respiratory chain complex activity assays 
 
The measurements of respiratory chain enzyme complex activities and citrate 
synthase activity were performed as previously described (Wibom et al., 2002).  
 
2.3.7 Oxygen consumption rates 
 
Oxygen consumption rates were measured with OROBOROS Oxygraph-2k for 
high-resolution respirometry (Oroboros Insturments, Vienna, Austria). In short, 
mitochondrial CO I activity was measured with 0.1 mg of heart mitochondria, 
with addition of 1 mM ADP, 5 mM pyruvate, 2 mM malate, 10 mM glutamate. 
Mitochondrial coupling was then evaluated by inhibition of ATP synthase by 
adding 1.5 µg/ml oligomycin, and uncoupling by a multiple-step FCCP titration. 
After inhibition of CO I by 0.5 µM rotenone, respiratory capacity with substrates 
for CO II alone were measured with 10 mM succinate as a substrate. 
Mitochondrial respiration was also measured in saponin-permeabilized fibers 
isolated from skeletal muscle as described (Kuznetsov et al., 2008).  
 
2.3.8 Analyses of de novo transcription and translation in isolated 
mitochondria 
 
In organello transcription assay was performed as previously described (Park et 
al., 2007). In brief, after mitochondria isolation, 1 mg mitochondria was 
resuspended in transcription incubation buffer (25 mM sucrose, 75 mM sorbitol, 
100 mM KCl, 10 mM K2HPO4, 50 µM EDTA, 5 mM MgCl2, 1 mM ADP, 10 mM 
glutamate, 2.5 mM malate, 10 mM Tris-HCl pH 7.4 and 1 mg/ml BSA), 
supplemented with 50 µCi of α-32P-UTP. The samples were incubated for 1 hour 
at 37 °C with gentle rotation for pulse or without radioactivity for 3 and 6 hours of 
‘cold chase’. After incubation, mitochondria were washed twice with 1 ml of 
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washing buffer (10% glycerol, 10 mM Tris-HCl pH 6.8 and 0.15 mM MgCl2) and 
resuspended in 1 ml of TRIzol reagent (Life Technologies GmbH, Darmstadt, 
Germany) for RNA isolation. Isolated RNA was analyzed by Northern blotting 
and radiolabeled transcripts were visualized by autoradiography.  
 
In organello translation was performed as previously described in mitochondria 
from heart and liver (Edgar et al., 2009). Skeletal muscle mitochondria were 
incubated in translation buffer containing 25 mM sucrose; 75 mM sorbitol; 100 
mM KCl; 1 mM MgCl2; 0.05 mM EDTA; 10 mM Tris–HCl; and 10 mM 
K2HPO4, pH 7.4 with addition of 10 mM glutamate, 2.5 mM malate, 1 mM ADP, 
and 1 mg/ml fatty acid‐free bovine serum albumin (BSA). In organello proteins 
synthesis was performed for 1 hour in presence of 35S-met at 37°C. After this 
period, one-third of mitochondria was isolated by incubation in the SDS-PAGE 
loading buffer, while the other two-thirds were washed and incubated for 
additional 3 or 6 hours for the “cold-chase” experiment in a translation buffer 
containing all amino acids, including methionine. Translation products were 
separated by SDS-PAGE, the gel was stained with Coomassie Brilliant Blue R-
250 incubated in Amplify solution (GE Healthcare, Munich, Germany), dried and 
newly synthesized polypeptides were detected by autoradiography.  
 
2.3.9 tRNA aminoacylation assay 
 
For analysis of the tRNA aminoacylation, total RNA was isolated with TRIzol 
reagent as described before. Total RNA was resuspended in 0.3 M NaOAc (pH 
5.0) and 1 mM EDTA. Aminoacylation status was determined by acid-urea 
PAGE, using 6.5% (19:1) polyacrylamide, 8 M urea gels in 0.1 M NaOAc (pH 
5.0) buffer. Gels were run for 48 hours at 4°C with regular buffer changes. tRNAs 
were detected using specific γ-32P-dATP labeled oligonucleotide probes (Park et 
al., 2007).   
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2.4 Histological Analyses 
 
2.4.1 Vibratome and cryostat sections 
 
After perfusion, coronal sections were cut on a Leica VT1200S with a thickness 
of 30 - 40 µm. Free floating sections were kept at 4 °C in 0.05% NaN3-PBS.  
 
For cryostat sections, brains were directly isolated after sacrificing the animals, 
directly embedded in Tissue-Tek (Sakura, Alphen aan den Rijn, The Netherlands) 
and placed onto dry ice until the Tissue-Tek froze. Afterwards, brains were stored 
at -80 °C. Coronal sections were cut on a Leica CM1850 cryostat with a thickness 
of 7 µm. Sections were directly mounted onto microscope slides and stored at -20 
°C. 
 
2.4.2 Transmission electron microscopy 
 
Semithin and ultrathin sections, as well as transmission electron microscopy were 
prepared and visualized by Shuaiyu Wang as described previously (Almajan et al., 
2012).  
 
2.4.3 Nissl Staining 
 
Vibratome sections were mounted on a microscope slide with cromalin solution 
(5% gelatine w/v, 2mM KCr(SO4)2 · 12 H2O in water) and dried at 37 °C for 30 
minutes. Sections were incubated 45 seconds with Nissl solution (0.04 N NaOH, 
0.2 Acetic acid, 8.7 mM thionin acetate), washed shortly in dH2O, dehydrated 
with increasing ethanol concentration (50%, 70%, 80%, 90 %, 95%, 100%, each 
step 30 seconds) and incubated in Xylene for 4 minutes.  
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2.4.4 COX-SDH staining 
 
COX-SDH staining was performed on cryosections. The sections were air-dried 
for 1 h, surrounded with a PAP pen, incubated in a humid chamber for 40 minutes 
at 37 °C in COX solution (0.8 ml 3,3 diaminobenzidine tetrahydrochloride, 0.2 ml 
500 µM cytochrome c, a few grains of catalase), and then washed in PBS. Later 
on, sections were incubated in SDH solution (0.8 ml 1.875 mM Nitroblue 
tetrazolium, 0.1 ml 1.3 M sodium succinate, 0.1 ml 2 mM Phenazine 
methosulphate, 0.01 ml 100 mM Sodium azide) for 90 minutes at 37 °C in a 
humid chamber. Sections were washed in PBS, dehydrated with increasing 
ethanol concentration (75% for 2 minutes, 95% for 2 minutes, 100% for 10 
minutes), air dried, and mounted in D.P.X. (VWR, Darmstadt, Germany). 
 
2.4.5 Hemotoxylin and Eosin staining (H&E Staining) 
 
H&E staining was applied to cryosections. The sections were incubated for 1 
minute in tap water, 6 minutes in Mayer's Hematoxylin solution (Sigma Aldrich, 
Seelze, Germany), and again with tap water, this time for 15 minutes. Afterwards, 
the samples were further incubated in 1 minute in dH2O and 1 minute in Eosin. 
Following, the sections were washed several times with tap water, and then 
dehydrated with ethanol (75% for 1 min, 96% for 1 min, 100% for 1 min) and 
Xylene for 1 min. The final mounting was done with Entellan (Millipore, Merck, 
Darmstadt, Germany). 
 
2.4.6 Masson’s trichrome staining 
 
Masson’s trichrome staining was performed on cryosections using a staining kit 
(Sigma Aldrich, Seelze, Germany), according to the manufacturer's instructions. 
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2.4.7 TUNEL assay 
 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay 
was performed on 30 mm vibratome sections with ApopTag Plus Peroxidase In 
Situ Apoptosis Detection Kit (Millipore, Merck, Darmstadt, Germany) according 
to the manufacturer’s protocol. Briefly, sections were fixed in PFA 4% in PBS for 
10 minutes at room temperature. After post-fixation and permeabilization steps, 
sections were washed, incubated in proteinase K (20 mg/ml in PBS) for 15 
minutes, washed in PBS and then quenched in 3% H2O2 in PBS for 5 minutes. 
Sections were then pre-incubated for 15 seconds in equilibration buffer and then 
in working strength TdT enzyme for 1 hour at 37°C. After the reaction was 
stopped, sections were washed in water, dehydrated with increasing ethanol 
concentration and Xylene. 
2.4.8 Immunohistochemical and immunofluorescence analyses 
 
Free-floating sections were washed extensively and pretreated for 30 minutes in 
2% Triton X-100/PBS to remove cryoprotectant. Subsequently, the sections were 
treated with 0.3% H2O2 in PBS for 20 minutes to quench endogenous peroxidase 
activity. Sections were permeabilized and blocked in 0.4% Triton X-100, 10% 
goat serum in PBS for 1 hour at room temperature. Primary antibodies [GFAP 
(1:2000, NeoMarkers, Fremont, USA), IBA1 (1:3000, WAKO Life Sciences, Inc., 
Richmond, USA), p62 (SQSTM -Sequestosome 1 – for heart sections only) 
(1:200, Abnova, Taipei, Taiwan)] were incubated overnight in 0.4% Triton X-
100, 5% goat serum in PBS at 4 °C. After 3x 5 minutes washing with PBS, 
secondary antibodies [anti-mouse Alexa Fluor 488 (1:2000, Invitrogen, Karlsruhe, 
Germany), anti-rabbit Alexa Fluor 546 (1:2000, Invitrogen, Karlsruhe, Germany) 
were applied in 5% goat serum in PBS for 2 hours. Finally, the sections were 
washed in PBS and mounted using FluorSave Reagent (Calbiochem, Merck, 
Darmstadt, Germany). 
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Light microscopy images were acquired by a Leica SCN400 slide scanner (Leica 
Microsystems, Wetzlar, Germany). Evaluation and processing was done with 
SlidePath Gateway Client software (version 2.0). Fluorescent images were 
acquired by an Axio-Imager M2 microscope equipped with Apotome 2 (Zeiss, 
Jena, Germany). Images were processed with AxioVision software (version 
4.8.2). 
 
2.5 Statistical analyses 
 
A two-tailed unpaired student’s t-test was used to determine statistical 
significance. All p values below 0.05 were considered significant. Error bars 
represent standard error of the mean (S.E.M.). *p<0.05 ; **p<0.01 ; ***p<0.001; 
****p<0.0001. 
 
2.6 Chemicals and biological material 
 
Size markers for agarose gel electrophoresis (Gene Ruler DNA Ladder Mix) and 
for SDS-PAGE (Page Ruler Prestained Protein Ladder Mix) were obtained from 
Fermentas, St. Leon-Rot, Germany. GoTaq® Green Master Mix and DNA 
Polymerase were purchased from Promega, Mannheim, Germany. Chemicals used 
in this work are listed in table 2.3. Solutions were prepared with double distilled 
water. 
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Table 2.3 Chemicals used and suppliers 
 
Chemical Supplier 
β-mercaptoethanol Applichem, Darmstadt, Germany 
2,2,2-Tribromoethanol (Avertin) Sigma-Aldrich, Seelze, Germany 
2-Methyl-2-Butanol Sigma-Aldrich, Seelze, Germany 
Acetic Acid Merck, Darmstadt, Germany 
Acetone KMF Laborchemie, Lohmar, Germany 
Acrylamide Roth, Karlsruhe, Germany 
Agarose Sigma-Aldrich, Seelze, Germany 
Agarose (Ultra Pure) Life Technologies, Darmstadt, Germany 
Ammonium Acetate Merck, Darmstadt, Germany 
Ammoniumpersulfat (APS) Sigma-Aldrich, Seelze, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Seelze, Germany 
Bromophenol Merck, Darmstadt, Germany 
Calcium Chloride Merck, Darmstadt, Germany 
Chloroform Merck, Darmstadt, Germany 
Deoxynucleotides (dNTPs) Sigma-Aldrich, Seelze, Germany 
Dimethylsulfoxide (DMSO) Merck, Darmstadt, Germany 
di-Natriumhydrogenphosphate Merck, Darmstadt, Germany 
Enhanced chemiluminescence (ECL) GE Healthcare, Munich, Germany 
Ethanol, absolute Applichem, Darmstadt, Germany 
Ethidium bromide Sigma-Aldrich, Seelze, Germany 
Ethylendiamine tetraacetate (EDTA) Applichem, Darmstadt, Germany 
Glycine Applichem, Darmstadt, Germany 
HEPES Applichem, Darmstadt, Germany 
Hydrochloric acid (37%) Applichem, Darmstadt, Germany 
Hydrogen peroxide Sigma-Aldrich, Seelze, Germany 
Isopropanol (2-propanol) Roth, Karlsruhe, Germany 
Magnesium chloride Merck, Darmstadt, Germany 
Methanol Roth, Karlsruhe, Germany 
Nitrogen (liquid) Linde, Pullach, Germany 
Paraformaldehyde (PFA) Sigma-Aldrich, Seelze, Germany 
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, Seelze, Germany 
Phosphate buffered saline (PBS) Gibco BRL, Eggenstein, Germany 
Potassium chloride Merck, Darmstadt, Germany 
Potassium hydroxide Merck, Darmstadt, Germany 
Protease Inhibitor Cocktail Tablets Roche, Basel, Switzerland 
Sodium acetate Applichem, Darmstadt, Germany 
Sodium azide Sigma-Aldrich, Seelze, Germany 
Sodium chloride Applichem, Darmstadt, Germany 
Sodium citrate Merck, Darmstadt, Germany 
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Sodium dodecyl sulfate Applichem, Darmstadt, Germany 
Sodium fluoride Merck, Darmstadt, Germany 
Sodium hydroxide Applichem, Darmstadt, Germany 
Sodium orthovanadate Sigma-Aldrich, Seelze, Germany 
Sucrose Applichem, Darmstadt, Germany 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Seelze, Germany 
Trishydroxymethylaminomethane(Tris) Applichem, Darmstadt, Germany 
Triton X-100 Applichem, Darmstadt, Germany 
Tween 20 Applichem, Darmstadt, Germany 
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3. Results 
 
 
3.1. Mitochondrial aspartyl-tRNA synthetase (DARS2) is essential 
for embryonic development in the mouse 
 
To determine the in vivo function of mitochondrial aspartyl-tRNA synthetase 
(DARS2) in mammals and to unravel the consequences of DARS2 deficiency, we 
have generated a novel mouse model whose part of 2nd intron and 3rd exon of the 
DARS2 gene is floxed, allowing Cre-recombinase mediated excision and 
conditional disruption of DARS2 gene (Figure 3.1A). The targeting vector, which 
is obtained as sperm from the Knockout Mouse Project (KOMP) Repository, 
presents itself as 'Knockout-first allele' (Testa et al., 2004), having the ability to 
cause frame-shift to create a null allele without the need for Flp- or Cre-mediated 
excision. Nevertheless, we first mated the mice heterozygous for the targeting 
allele with mice carrying Flp recombinase under the control of the human beta-
actin promoter, thus excising the neomycin selection cassette (Figure 3.1A). 
Afterwards, Dars2+/loxp mice were mated with mice expressing cre recombinase 
under the control of the β-actin promoter (ACTB-cre) to generate heterozygous 
DARS2 knockout mice (Dars2+/−) (Figure 3.1A and 3.1B). Following the removal 
of the floxed region, transcript is predicted to produce a truncated protein product, 
which can be subjected to non-sense, mediated decay (NMD). Intercrossing of 
Dars2+/− mice produced no viable homozygous knockouts (Dars2−/−), whereas 
the other two genotypes were recovered at expected Mendelian proportion (total 
pups n=79; Dars2+/+ n=25, Dars2+/− n=54). We then analyzed embryos derived 
from intercrossing of Dars2+/− mice at embryonic day (E) 8.5 and found that 
~25% embryos had a mutant appearance (Figure 3.1C). Genotyping confirmed 
that all mutant embryos were homozygous knockouts (Dars2−/−) (Figure 3.1B). 
These results show that loss of DARS2 causes embryonic lethality at ~E8.5.  
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Figure 3.1 Disruption of Dars2 in the germline.  
(A) Targeting strategy for the conditional disruption of Dars2 gene. EN2-SA - Splice 
acceptor of mouse homeobox protein engrailed-2 exon 2; IRES - Internal ribosome entry 
site from encephalomyocarditis virus; lacZ - lacZ gene; pA - SV40 polyadenylation site; 
hBactP - Human beta actin promoter; neo - Neomycin selection cassette. Depicted by 
arrows are the PCR primers used for genotyping of the alleles. (B) Genotyping PCR for 
one wild-type (+/+), two heterozygous (+/-), or one homozygous knockout (-/-) Dars2 
animals. DNA fragments corresponding to the wild type (wt – 475 bp), and knockout (ko 
– 1100 bp) Dars2 loci are indicated. Marker (M) used is Generuler 100 bp (Fermentas). 
(C) Morphology of a wild-type (DARS2+/+) and two homozygous knockout (DARS2-/-) 
embryos at day ~E8.5. Scale bar, 100 µm. 
 
3.2. DARS2 +/- mice are haplosufficient 
 
We next analyzed heterozygous Dars2+/- mice to determine if one copy of the 
gene is sufficient to maintain proficient mitochondrial protein synthesis. 
Heterozygous Dars2+/- mice were born in expected Mendelian proportions, 
developed normally, and displayed no obvious phenotype even at 24 months of 
age. In order to assess the effect of loss of one Dars2 allele, we analyzed steady-
state levels of the mitochondrial respiratory chain (MRC) complexes in Dars2+/- 
mice. Mitochondrial proteins isolated from liver, heart and skeletal muscle were 
separated on n-dodecyl-β-D-maltoside-based blue native polyacrylamide 
electrophoresis (BN-PAGE) (Figure 3.2A), followed by Western blot analysis 
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with antibodies raised against different subunits of each of the five respiratory 
complexes (Figure 3.2B). We did not observe any reduction in steady-state levels 
of different OXPHOS complexes in mitochondrial extracts from Dars2+/- mice 
(Figure 3.2A and 3.2B), suggesting that one copy of the gene is sufficient to 
sustain proficient mitochondrial protein synthesis. Consequently, in gel activities 
of complex I (NADH:ubiquinone oxidoreductase, COI, EC 1.6.5.3) and complex 
IV (cytochrome c oxidase, COX – COIV, EC 1.9.3.1) were also not changed in 
Dars2+/- mitochondria (Figure 3.2C and 3.2D, respectively).  
 
 
 
Figure 3.2 Respiratory Chain Complexes in Heart, Skeletal Muscle (SkM) and Liver 
Mitochondria of 104-Week-Old wild type (+/+) and heterozygous (+/-) Dars2 mice. 
(A) Coomassie brilliant blue stained BN-PAGE, (B) Western blots, (C) In gel activity of 
CO I and (D) In gel activity of CO IV performed after BN-PAGE. 
 
 
 
 
 
  
 
57  
3.3. Tissue-specific disruption of Dars2  
 
In order to shed more light on the consequences of DARS2 deficiency in different 
tissues and to unravel their coping mechanisms against this deficiency, we 
decided to generate two different tissue specific mice models:  
(i) by disrupting the gene by breeding Dars2loxP/loxP (from now on denoted 
as L/L) mice with transgenic mice expressing cre-recombinase from 
the muscle creatine kinase promoter (Ckmm-cre), and 
(ii) by mating L/L mice with mice expressing the cre-recombinase under 
the control of the Ca2+/calmodulin-dependent kinase II alpha promoter 
(CaMKIIα-Cre). 
By creating different models, we wanted to see how these different tissues (heart, 
skeletal muscle and brain), the most commonly affected ones in various 
mitochondrial diseases, react to defective mitochondrial protein synthesis and 
whether they activate mitochondrial stress signals. 
 
3.4. DARS2 deficiency leads to early pathological changes in heart 
and skeletal muscle 
 
DARS2 deletion in heart and skeletal muscle was mediated by cre-recombinase 
under the muscle creatine kinase promoter to produce Dars2 L/L, +/Ckmm-cre 
(hereafter denoted as L/L, cre) mice. The muscle creatine kinase promoter is fully 
active in heart and skeletal muscle after embryonic day 15.5 (E15.5) (Lyons et al., 
1991). We first confirmed the complete loss of DARS2 in both targeted tissues at 
6 weeks of age (Figure 3.3A). Liver extracts were used as a negative control 
throughout the experiments. 
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Figure 3.3 Phenotypic characterization of tissue-specific DARS2-deficiency in heart 
and skeletal muscle. 
(A) Western blot analysis of DARS2 protein levels in heart, skeletal muscle (SkM) and 
liver of control (L/L) and Dars2 tissue-specific knockout mice (L/L, cre). * Unspecific 
protein. (B) Heart-weight to body-weight ratio in mice at 3, 4 and 6 (n=5-9) weeks of age. 
(C) Heart and SkM morphology of 6-week-old mice. 
Bars represent mean ± S.E.M. Asterisks indicate level of statistical significance (Student's 
t-test, **p<0.01; ***p<0.001).  
 
 
The maximal lifespan of the DARS2-deficient mice was shortened only to 6-7 
weeks. Out of 210 mice, only nine were observed to live until they are 8-week-
old. The knockout mice had hypertrophied hearts and atrophied skeletal muscles. 
Moreover, we detected a decrease of body weight from 4 weeks of age 
accompanied by progressive cardiomyopathy characterized by a strong increase in 
heart size with increasing age (Figures 3.3B and 3.3C).  
Does the observed phenotypes also coincide with the molecular clues? To answer 
that question, we checked hypertrophy, atrophy and myogeny markers. We 
detected clear signs of degeneration in both tissues at 6 weeks of age, as measured 
by the increased expression of hypertrophy markers Nppa and Nppb in heart, and 
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atrophy markers MuRF1 and Atrogin1 in skeletal muscle (Figure 3.4A). Although 
we found no change in expression of myogenic markers Myod1 and Myf5, 
increased number of cells with centrally positioned nuclei suggests a possible 
upregulation of skeletal muscle regeneration in DARS2-deficient mice (Figure 
3.4B).  
 
 
Figure 3.4 Molecular characterization of tissue-specific DARS2-deficiency in heart 
and skeletal muscle. 
(A) Relative expression levels of cardiac hypertrophy markers (Nppa and Nppb), muscle 
atrophy markers (MuRF1 and Atrogin-1) and myogenic factors (Myod1 and Myf5) in 3- 
and 6-week-old mice. (n=6) (B) Hematoxylin & Eosin (H&E) staining of muscle sections 
from 6-week-old mice. Arrowheads indicate fibers with centrally located nuclei. (Scale 
bar: 100µm). 
Bars represent mean ± S.E.M. Asterisks indicate level of statistical significance (Student's 
t-test, *p<0.05, **p<0.01; ***p<0.001).  
 
The ultrastructural analysis showed disruption of myocardial organization with 
accumulation of mitochondrial mass in 6-week-old DARS2-deficient hearts 
(Figure 3.5). Abnormally shaped mitochondria were also available in hearts. 
Surprisingly, we only seldom observed long, fused mitochondria, with no increase 
in mitochondrial mass, or major changes in fiber organization. COX-SDH 
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staining revealed a very strong and comparable respiratory chain deficiency in 
both tissues. Formation of excess fibrous connective tissue (fibrosis) was 
exemplified in both tissues via Masson’s Trichrome staining. Ragged-red fibers 
were not apparent (data not shown).  
 
 
Figure 3.5 Immunohistochemical characterization of heart and skeletal muscle. 
TEM – Transmission Electron Micrographs (Scale bar: 1µm), COX-SDH - Enzyme 
histochemical double staining for COX and SDH activities and Masson’s Trichrome 
staining (Scale bars: 100µm) (n=4). 
 
As mentioned above, we observed increased mitochondrial mass in Transmission 
Electron Micrographs (TEM) of heart only. Moreover, COX-deficient 
cardiomyocytes showed also high succinate dehydrogenase (SDH) activity (blue 
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staining), consistent with this observed mitochondrial mass increase (Figure 3.5). 
Even if TEM did not reveal any mitochondrial biogenesis in skeletal muscle, we 
wanted to employ other additional experimental methods to search for signs of 
increased mitochondrial mass. We measured citrate synthase activity, as this is 
one of the most commonly used markers of mitochondrial biogenesis. This 
enzymatic assay proved that mitochondrial mass was only increased in DARS2-
deficient hearts (Figure 3.6A).  
 
 
Figure 3.6 Increased mitochondrial mass was observed only in DARS2-deficient 
cardiomyocytes.  
(A) Citrate synthase enzyme activity in heart, skeletal muscle (SkM) and liver of control 
(L/L) and DARS2-deficient mice (L/L, cre). (B-C) Western blot analysis (B) and 
corresponding quantification (C) of PGC-1α and TFAM levels in total protein extracts 
from heart and SkM. (D) Relative mtDNA levels presented as percentage of control. 
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Moreover, PGC-1α and TFAM levels were only up in cardiomyocytes (Figure 
3.6B-C). As a last proof, we performed Southern blotting to detect mitochondrial 
DNA (mtDNA) levels and found out that mtDNA was also significantly 
upregulated in heart but not in skeletal muscle (Figure 3.6D). These data suggest 
that mitochondrial biogenesis is occurring only in cardiomyocytes, and other 
pathways could be involved in adaptive responses in DARS2-deficient skeletal 
muscle. 
 
3.5. Defective mitochondrial translation gives rise to strong 
respiratory chain deficiency 
To analyze biochemical consequences of DARS2 deficiency in heart and skeletal 
muscle, we first measured the levels of MRC enzyme activities (Figure 3.7A). A 
dramatic decrease in all complexes (except nuclear DNA-encoded CO II) was 
apparent in heart and skeletal muscle. Further, oxygen consumption 
measurements were performed in isolated heart mitochondria (Figure 3.7B) and 
skeletal muscle fibers (Figure 3.7C) and a general reduction in all inducible 
respiratory states was observed. 
BN-PAGE analysis revealed reduction in the amount of fully assembled CO I, CO 
III and CO IV in both heart and skeletal muscle (Figure 3.7D), the latter being the 
most affected. The Western blots to detect the MRC subunits from the 
corresponding BN-PAGE analysis also showed a similar pattern (i.e. CO IV is 
nearly absent in knockout mice) (Figure 3.7E). Reduction of CO I and CO IV 
levels was mirrored by the decrease in in-gel activity in both tissues (Figure 3.7F 
and 3.7G, respectively). Furthermore, the Western blots from the total protein 
extracts revealed a strong decrease in the steady-state levels of CO IV subunits 
and a moderate reduction in the levels of CO I and CO III subunits in both tissues 
(Figure 3.7H). 
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Figure 3.7 Characterization of mitochondrial dysfunction in 6-week-old DARS2-
deficient heart and skeletal muscle. 
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(A) Relative MRC complex activities in isolated heart and SkM mitochondria of DARS2-
deficient mice (L/L, cre) presented as a percentage of control (L/L) (n=5). (B-C) 
Measurement of substrate-dependent oxygen consumption of (B) isolated heart 
mitochondria and (C) permeabilized skeletal muscle fibers from L/L and L/L, cre mice. 
CO I-specific substrates (pyruvate, malate, glutamate); CO II-specific substrate 
(succinate). State III - ADP-stimulated oxygen consumption rate; State IV – respiration 
rate after addition of oligomycin; UC – oxygen consumption rate in the presence of an 
uncoupler. Bars represent mean ± S.E.M. Asterisks indicate level of statistical 
significance (*p ≤ 0.05; **p ≤ 0.01; ****p < 0.0001; Student's t-test; n=5). (D) 
Coomassie Brilliant Blue staining of BN-PAGE with indicated position of specific 
complexes. (E) Western blots for MRC complexes. Antibodies against individual MRC 
subunits (indicated on the left) and used to detect MRC complexes (indicated on the 
right).  (F) In-gel activity of CO I and (G) CO IV, performed after BN-PAGE (n=4). (G) 
Western blots for the steady-state levels of individual MRC subunits from total protein 
extracts of heart, SkM and liver. 
 
We detected a strong deregulation of de novo protein synthesis in DARS2-
deficient mitochondria from heart and skeletal muscle (Figure 3.8A). Figure 3.8B 
corresponds to the loading control for in organello gel. While the turnover rates 
seem to be rather slow compared to liver mitochondria and unchanged between 
the two tissues after 3 hours of cold-chase (Figures 3.8C-D). This analysis also 
revealed two interesting points: (1) ND2 subunit does not contain a single 
aspartate residue in its sequence, thus we see and upregulation; (2) ATP6 (ATP 
synthase F0 subunit 6) contains only one aspartate residue which is in its 244th 
amino acid – and it is a 246 amino acid long polypeptide. In our in organello gel, 
ATP6 presents an additional polypeptide with a slightly lower molecular mass 
than, which is likely a truncated form of this protein lacking the last two residues, 
(Fig 3.8A – highlighted box). The number, percentage and positions of aspartate 
residues mitochondrial-encoded MRC subunits contain can be reviewed in Table 
3.1.  
The observed strong upregulation of ND2 subunit (NADH dehydrogenase subunit 
2) is likely a consequence of increased number of ribosomes inside DARS2-
deficient mitochondria (Figure 3.8D). Remarkably, the upregulation of 
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mitochondrial ribosomal subunits is observed in isolated mitochondria from both 
tissues, although the upregulation was less severe in skeletal muscle.  
 
 
Figure 3.8 Deregulated protein synthesis and steady-state levels of mitochondrial 
ribosomal subunits. 
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(A) Representative gel of in organello translation in heart, SkM and liver mitochondria 
(n=4). De novo synthetized proteins are isolated immediately after labeling with 35S-met 
(1h pulse). Positions of individual mitochondrial-encoded proteins are indicated. (B) 
Commassie Brilliant Blue stained gel used as loading control. (C) Turnover of the newly 
synthesized proteins after 3 hours of ‘cold chase’ in isolated heart, SkM and liver 
mitochondria. (F) Western blots of mitochondrial ribosomal subunits MRPS-35, MRPS-
27, MRPL-13, MRPL-12 in heart and SkM. HSC70 (Ctr) and Ponceau S used as loading 
controls. 
 
 
 
Table 3.1 Length of mitochondrial-encoded MRC subunits and the number, 
percentage and positions of aspartate residues 
Subunit Length 
(amino 
acid) 
Aspartate 
number 
Aspartate 
percentage 
Aspartate positions 
Complex I     
ND1 318 3 0.94 51, 199, 283 
ND2 345 0 0 0 
ND3 115 2 1.74 42, 66 
ND4 459 6 1.31 46, 59, 87, 187, 251, 281 
ND4L 97 1 1.03 87 
ND5 607 12 1.98 83, 111, 163, 179, 208, 297, 
352, 355, 393, 447, 449, 554 
ND6 172 6 3.49 110, 118, 122, 129, 130, 172 
     
Complex III     
cytb 381 11 2.89 20, 58, 72, 171, 214, 216, 228, 
248, 252, 254, 374 
Complex IV     
COXI 514 16 3.11 14, 50, 51, 91, 144, 212, 221, 
227, 298, 300, 364, 369, 406, 
407, 442, 445 
COXII 227 11 4.85 11, 25, 57, 88, 112, 115, 119, 
127, 139, 158, 173 
COXIII 261 4 1.53 60, 111, 190, 246 
     
Complex V     
ATP6 226 1 0.44 224 
ATP8 67 1 1.49 5 
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As we showed that mitochondrial protein synthesis is strongly affected with 
DARS2 deficiency, we next analyzed mitochondrial transcripts. We detected a 
general upregulation of mitochondrial transcript levels (mt-mRNAs) primarily in 
DARS2-deficient hearts, while Cyt b levels were increased also in skeletal muscle 
mitochondria (Figure 3.9A-B). This upregulation might purely reflect the 
increased mitochondrial mass in cardiomyocytes.  
Although pathogenic mutations in some aminoacyl-tRNA synthetases lead to a 
decrease in the level of cognate tRNAs (Belostotsky et al., 2011; Edvardson et al., 
2007), we found no changes in the steady-state levels of mitochondrial tRNAs, 
including tRNAAsp (Figure 3.9A-B).  
 
 
Figure 3.9 RNA-related assays (Northern blot, aminoacylation and in organello 
transcription). 
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(A) Northern blot analysis of mitochondrial mRNA and tRNA levels in heart. 18S rRNA 
and 5S rRNA are used as loading controls. (B) Quantification of mitochondrial mRNA 
and tRNA levels in heart and SkM presented as a percentage of control (n=5). (C) 
Aminoacylation assay for mitochondrial tRNAAsp and tRNALys in heart and SkM. 
Positions of charged (AA-tRNAAA) and uncharged tRNAs (tRNAAA) are indicated. (D) In 
organello transcription assay in heart and SkM mitochondria (n=5). Steady-state CoxII 
transcript levels are used as a loading control (Ctr).  
Bars represent mean ± S.E.M. Asterisks indicate level of statistical significance (Student's 
t-test, *p<0.05) 
 
We also analyzed the level of tRNA aminoacylation by separation of charged and 
uncharged forms of tRNAAsp under acidic conditions. While a full separation of 
the two forms, as shown for tRNALys, cannot be achieved for tRNAAsp (Enriquez 
and Attardi, 1996), we could observe minute, yet detectable shift in wild type 
samples compared to DARS2-deficient mitochondria (Figure 3.8C). This suggests 
that majority of tRNAAsp in DARS2-deficient tissues is present in uncharged 
form, consistent with the predicted role of DARS2.   
 
The question asked next was whether the rate of de novo transcription was 
affected. The analysis revealed similar in organello transcription rates but a 
slower turnover rate of skeletal muscle mitochondrial transcripts were observed 
(Figure 3.9D).  
 
3.6. Mitochondrial stress responses are activated exclusively in 
DARS2-deficient heart 
 
DARS2-deficient cardiomyocytes exhibited higher level of mitochondrial 
biogenesis. We were very intrigued by this observation and wanted to have an 
insight whether other mitochondrial stress responses were at work.  
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One of the hallmarks of mitochondrial dysfunction is the increased reactive 
oxygen species (ROS) production that leads to accumulation of oxidized proteins 
and upregulation of antioxidant responses in the cell. We performed oxyblot assay 
for protein carbonylation and Western blot for MnSOD (SOD2), the major 
mitochondrial ROS scavenging enzyme (Figure 3.10A). Quantified oxyblot assay 
can be found in Figure 3.10B. We found no differences between control and 
knockout mice for the parameters checked. This is in agreement with previous 
findings that general MRC deficiency does not affect ROS production (Trifunovic 
et al., 2005). 
 
 
Figure 3.10 Antioxidant responses in DARS2-deficient heart and skeletal muscle. 
(A) Oxidative stress levels via Western blot analysis of DNP (protein carbonylation) and 
MnSOD in heart and SkM. (B) Quantification of DNP levels presented as percentage of 
control. 
Bars represent mean ± S.E.M. (Student's t-test) 
 
We have shown that DARS2-deficiency directly interferes with mitochondrial 
translation, and therefore, one would hypothesize that affected mitochondrial 
proteostasis might lead to the activation of mitochondrial unfolded protein 
response (UPRmt). Indeed, in heart mitochondria, we detected increased levels of 
LON and AFG3L2, proteases involved in the turnover of misfolded proteins 
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(Figure 3.11A-B). Furthermore, two main mitochondrial chaperones mtHSP70 
and HSP60 were upregulated, confirming the UPRmt activation in 6-week-old 
hearts; however we did not observe any upregulation of CLPP, which is also one 
of the main players in UPRmt (Figure 3.11A-B).  
 
Figure 3.11 Mitochondrial unfolded protein response and autophagy in 6-week-old 
DARS2-deficient heart and skeletal muscle. 
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(A) Western blot analysis of CLPP, mtHSP70, LON, HSP60 and AFG3L2 levels in heart 
and SkM of control (L/L) and DARS2-deficient mice (L/L, cre). (B) Relative 
quantification of proteins involved in UPRmt (CLPP, HSP60, LON, mtHSP70 and 
AFG3L2) in 6-week-old DARS2-deficient hearts and skeletal muscle normalized to 
respective controls. (C) Western blot analysis of LC3 and p62 levels in heart and SkM. 
(D) p62 (green) immunostaining of heart sections. DAPI (blue), (Scale bar: 100µm). (E) 
Western blot analysis of BECLIN-1, ATG7 and ATG12. (D-E) Western blot analysis (D) 
and quantification (E) of poly-UQ proteins in total protein extracts of heart and SkM. 
HSC70 (Ctr) is used as loading control. Bars represent mean ± S.E.M. Asterisks indicate 
level of statistical significance (Student's t-test, one p value is indicated over the error bar 
*p<0.05, **p<0.01, ***p<0.001) (n=5-8). 
 
Another striking observation was the reduction in (macro)autophagy. In DARS2-
deficient hearts, we observed the suppression of LC3B-I to LC3B-II conversion 
(Figure 3.11C) and accumulation of p62 (Figure 3.11C-D), suggesting a reduction 
in autophagy. This was further supported by the lack of autophagosomes on 
multiple heart section analyzed by TEM. Other components of the autophagy 
pathway, such as ATG7, ATG12 and BECLIN-1, were not affected (Figure 
3.11E). In agreement with a reduction in autophagy and perturbations in protein 
folding environment, we detected somewhat higher levels of polyubiquitinated 
(poly-UQ) proteins (p value 0.0794) exclusively in DARS2-deficient hearts 
(Figure 3.11F-G).  
Our observations so far proved the existence of MRC deficiency in both heart and 
skeletal muscle and upregulation of mitochondrial stress responses, such as 
UPRmt, exclusively in heart. These posed the question whether MRC deficiency in 
DARS2-deficient skeletal muscle reached the threshold for the activation of stress 
responses observed in heart mitochondria. To test this, we analyzed DARS2-
deficient heart mitochondria at 3 weeks of age that showed no obvious signs of 
mitochondrial cardiomyopathy (Figure 3.3B).  
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3.7. Early disturbance in mitochondrial proteostasis triggers stress 
responses in heart independent of MRC deficiency 
 
Contrary to their 6-week-old counterparts, 3-week-old DARS2-deficient heart 
mitochondria only showed minor downregulation in MRC enzyme activities, CO 
IV being the only significantly affected one (Figure 3.12A).  
 
Figure 3.12 Characterization of mitochondrial dysfunction and stress responses in 3-
week-old DARS2-deficient heart and skeletal muscle. 
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(A) Relative MRC complex activities in heart and SkM mitochondria of DARS2-
deficient mice (L/L, cre) presented as a percentage of control (L/L) (n=5). (B-E) BN-
PAGE analysis of respiratory chain complexes for 3- and 6-week-old mice. (B) 
Coomassie Brilliant Blue staining of BN-PAGE with indicated position of specific 
complexes. (C) Western blots for MRC complexes. Antibodies against individual MRC 
subunits (indicated on the left) and used to detect MRC complexes (indicated on the 
right).  (D) In-gel activity of CO I and (E) CO IV, performed after BN-PAGE (n=4). (F) 
Western blot analysis with corresponding quantification of PGC-1α, p62 and LC3 levels. 
HSC70 is used as loading control (Ctr). (n=5) (G) Western blots and corresponding 
quantification (n=4) of poly-UQ proteins from mitochondrial (Mito P) or total protein 
(Tot P) extracts in 3- and 6-week-old hearts. Results presented as fold-increase compared 
to the control (n=4). (H) Western blot analysis and quantification of CLPP, HSP60, LON, 
mtHSP70 and AFG3L2 levels in 3-week-old control (L/L) and DARS2-deficient (L/L, 
cre) hearts.  
Bars represent mean ± S.E.M. Asterisks indicate level of statistical significance (Student's 
t-test, *p<0.05, **p<0.01, ***p<0.001). 
 
BN-PAGE and Western blots for subunits of MRC complexes also revealed a 
mild-to-moderate change in knockout hearts, as well as no obvious change in the 
in-gel activities of CO I and CO IV (Figure 3.12B-E). Were the stress signals that 
were observed previously still persistent in 3-week-old DARS2-deficient hearts 
even if their mitochondrial function is barely changed? We found evidence for 
mitochondrial retrograde signaling via an increase in PGC1α level (Figure 3.12F). 
Downregulated autophagy was still observed, illustrated by increased p62 levels 
and LC3B-I levels (Figure 3.12F). In agreement with a reduction in autophagy, 
we detected significantly higher levels of polyubiquitinated proteins in total tissue 
protein extracts and a tendency to increase in isolated mitochondrial extracts 
(Figure 3.12G). This suggests that mechanisms other than respiratory chain 
deficiency are the primary activators of adaptive changes in DARS2-deficient 
hearts.  
We also checked the levels of mitochondrial proteases in 3-week-old animals as 
we performed for their 6-week-old counterparts. The levels of major 
mitochondrial proteases were up; this time including CLPP, which was not 
changed in 6-week-old hearts (Figure 3.12H). Interesting enough, those changes 
in proteases were not reflected in the levels of the two main mitochondrial 
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chaperones mtHSP70 and HSP60. None of these changes were observed in 3-
week-old skeletal muscle from the same animals (data not shown).  
These observations gave us hints that mitochondrial proteostasis could be the 
initial signal for the activation of different stress responses observed in DARS2-
deficient heart mitochondria. We wanted further proof regarding the perturbed 
proteostasis.  
In organello translation assay in 3-week-old heart mitochondria revealed higher 
de novo protein synthesis in knockouts, contrary to previous results (Figure 
3.13A).  
 
Figure 3.13 Proof on perturbed mitochondrial proteostasis in DARS2-deficient 
hearts. 
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(A) Representative gel of in organello translation in 3-week-old heart mitochondria and 
corresponding Commassie Brilliant Blue stained gel used as loading control. (B) Relative 
expression levels of MRC subunits from 3-week-old hearts (n=5). (C) Western blot 
analysis and relative quantification of steady-state levels of MRC subunits in 3-week-old 
hearts (n=4). 
Bars represent mean ± S.E.M. Asterisks indicate level of statistical significance (Student's 
t-test, *p<0.05, **p<0.01). 
 
Moreover, analysis of mRNA levels for MRC subunits revealed upregulation of 
transcripts for some nuclear- and mtDNA-encoded subunits (Figure 3.13B). 
Contrary to this, steady-state levels of different MRC subunits revealed a clear 
decrease in the level of CO IV subunits, both nuclear- and mtDNA-encoded 
(Figure 3.13C), in agreement with our previous results showing mild-to-moderate 
decrease in the level of fully assembled CO IV. Notably, the mRNA levels of CO 
IV were upregulated even if the protein levels were down. These findings identify 
an increased protein turnover of mtDNA- and nucleus-encoded MRC subunits, 
adding evidence for the disrupted protein-folding environment in DARS2-
deficient hearts.  
Recently, FGF21 was suggested as a novel marker of mitochondrial dysfunction. 
In skeletal muscle, MRC deficiency induced Fgf21 transcription levels leading to 
a mitochondrial stress response with global changes (Tyynismaa et al., 2010). We 
wanted to check whether we would see a similar activation in Fgf21 levels. What 
we found was an astonishing upregulation in the mRNA levels of Fgf21 (250-
fold) in both 3- and 6-week-old DARS2-deficient cardiomyocytes (Figure 3.14A).  
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Figure 3.14 Fibroblast growth factor 21 (FGF21) levels and related adaptive 
systemic changes in DARS2 knockout mice. 
(A) Fgf21 expression levels in heart, SkM, white adipose tissue (WAT), brown adipose 
tissue (BAT) and liver of 3- and 6-week-old mice control (L/L) and DARS2-deficient 
mice (L/L, cre) (n=6). (B) Relative expression levels Atf4, Atf5 and Chop in heart and 
SkM of 1-, 3- and 6-week-old mice, including Fgf21 levels in 1-week-old mice (n=5). 
Results represent fold-increase compared to control. (C) FGF21 levels in serum from at 
3- and 6-week-old age. (D) Circulating free fatty acid levels in 3- (n=3) and 6-week-old 
(n=12) control and knockout mice. (E) Blood glucose concentrations in 6-week-old 
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animals (n=6). (F) Percentage of body fat and (G) absolute lean mass in 6-week-old 
animals measured by NMR (n=10-12). (H) Relative expression levels of members of 
Ppar family (α, σ and γ) and Pgc-1α in heart and SkM of 6-week-old animals (n=6). 
Results presented as fold-increase compared to the control.  
Bars represent mean ± S.E.M. Asterisks indicate level of statistical significance (*p ≤ 
0.05; **p ≤ 0.01; ***p < 0.001; Student's t-test). 
 
This increase in mRNA levels was also reflected in circulating levels of FGF21 in 
the serum of 6-week-old knockout mice (Figure 3.14C). Liver, skeletal muscle, 
white adipose tissue (WAT) and brown adipose tissue (BAT) are the main sources 
of FGF21 (Potthoff et al., 2012). Thus, all those tissues were checked for any 
signs of Fgf21 upregulation. RT-PCR analysis confirmed that the increase in 
circulating FGF21 levels comes exclusively from the Fgf21 upregulation in heart 
(Figure 3.14A). In animal models of diabetes, administration or overexpression of 
FGF21 caused reductions in body weight, blood glucose and lipid concentrations 
and liver fat content, as well as insulin resistance enhancement (Kharitonenkov et 
al., 2005). In agreement with those observations, we detected higher circulating 
free fatty acid levels, lower blood glucose and decreased fat mass in 6-week-old 
DARS2-deficient animals (Figures 3.14D-G). Therefore, mitochondrial 
dysfunction in heart, through increased cardiac Fgf21 expression, seems to be 
acting as a global signal that changes the metabolism of the animal. Fgf21 
expression is shown to be regulated by two transcription factors: PPARα and 
ATF4 (Potthoff et al., 2012; Kim et al., 2013). PPARα, by directly binding to the 
Fgf21 promoter, is responsible for fatty acid catabolism in the liver (Inagaki et al. 
2007). We detected downregulation of Pparα but high uprgulation of Atf4 (Figure 
3.14H). Moreover, the levels of additional bZIP transcription factors that mediate 
protein homeostasis, Chop and Atf5 (Wek and Cavener, 2007), were increased 
(Figure 3.14H). 
These interesting results prompted us to look for additional support for our theory 
for the fact that impaired mitochondrial proteostasis is acting as an initial signal 
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for different mitochondrial stress responses, not MRC dysfunction per se. Thus, 
we wanted to check some of the parameters also in 1-week-old mice. The very 
first changes observed in 1-week-old DARS2-deficient hearts are mild 
upregulation of UPRmt transcription activators ATF5 and CHOP, and a 6-fold 
increase in Fgf21 levels (Figure 3.14B). On the contrary, Western blots for 
different proteases, autophagy markers, and the steady-state levels of MRC 
subunits did not reveal any changes between control and knockout mice (Figure 
3.15). These results indicate that loss of proteostasis is a very early event that 
upregulates the UPRmt transcription regulator(s). 
 
 
Figure 3.15 Western blots analysis of 1-week-old hearts. 
Western blots analysis of 1-week-old hearts for the levels of individual MRC subunits 
(NDUFA9, COXI and COXIV); LON, CLPP and AFG3L2 protease; and markers of 
autophagy – p62 and LC3B. HSC70 (Ctr) was used as loading control (n=3). 
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Moreover, the upregulation of FGF21 expression coincides with the increase in 
the UPRmt transcription activators. Our results indicate that, FGF21 can be one of 
the early markers of mitochondrial dysfunction and it might be a direct target of 
UPRmt. 
Together, our data show that accumulation of unfolded/unassembled proteins acts 
as the primary signal that leads the activation of mitochondrial stress responses. 
Those responses arise independently of respiratory chain deficiency and give rise 
to adaptive cell-intrinsic changes, and systemic shifts in metabolism.       
 
3.8. DARS2 deficiency in forebrain neurons, hippocampus and 
striatum 
Disclaimer: Some parts and figures of the remaining sections were published as 
part of Master of Science thesis of Stephan Lotter, who is supervised by Prof. Dr. 
Aleksandra Trifunovic and the author, Sukru Anil Dogan (Lotter, 2013). 
 
The second mouse model generated was Dars2 L/L, +/CaMKIIα-Cre, in which Dars2 
gene was disrupted in forebrain neurons, hippocampus and striatum by mating 
floxed (L/L) mice with mice expressing the cre-recombinase under the control of 
the Ca2+/calmodulin-dependent kinase II alpha promoter (CaMKIIα-Cre). As in 
the previous model, the control mice are denoted as L/L and tissue-specific 
knockout mice as L/L, cre in the figures. The Ca2+/calmodulin-dependent kinase II 
alpha promoter is active from postnatal day 14 (P14), and maximal recombination 
occurs at P29 (Xu et al., 2000). Cerebellum is not affected, which is used as a 
negative control throughout the experiments. 
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Knockout mice were born in Mendelian proportions. They appeared normal, 
however, after weaning, they started to lose weight, which became more apparent 
when they become 12-16 weeks of age (Figure 3.16A-B). 
 
 
 
Figure 3.16 Phenotypic characterization of tissue-specific DARS2-deficiency in 
forebrain neurons, hippocampus and striatum. 
(A-B) Body weight vs. age graph for (A) male, and (B) female control (L/L; black) and 
Dars2 L/L, +/CaMKIIα-Cre mice (L/L, cre; red). (C) Self-inflicted injuries as a result of 
excessive scratching in Dars2 L/L, +/CaMKIIα-Cre mice. (D) Representative brain pictures 
and (E) brain weight graph of control and Dars2 L/L, +/CaMKIIα-Cre mice. Ages are 
indicated on the left of the panel D. n=16. 
Bars represent mean ± S.E.M. Asterisks indicate level of statistical significance (Student's 
t-test, *p<0.05; **p<0.01; ***p<0.001).  
 
The mice showed no behavioral abnormalities until 28 weeks of age, when they 
started scratching their necks and face, leading to occurrence of self-inflicted 
wounds (Figure 3.16C). They had to be sacrificed when their wounds become 
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severe. For example, some knockout mice did not show any scratching behavior 
until they were in their early 30-weeks. Therefore, due to increased morbidity, 
majority of Dars2 L/L, +/CaMKIIα-Cre mice had average lifespans of 32 weeks. 
The first thing we analyzed was the brain size and morphology. When the 
knockout mice were 20-week-old, the gross morphology of their brains was 
indistinguishable from the control mice. However, in a short span of 2 months, the 
forebrain atrophied, which was even more severe in older mice, such as 32-week-
old mice (Figure 3.16D-E). Taking these data into consideration, we have decided 
to group the mice in three different time points for the experiments: (i) 20-week-
old, (ii) 28-30-week-old, and (iii) >30-week-old.  
 
3.9. DARS2 deficiency in forebrain cause respiratory chain 
deficiency 
 
After gross morphological analysis, we wanted to analyze biochemical 
consequences of DARS2 deficiency in forebrain neurons, as we did for the heart 
and skeletal muscle specific mice. First, we measured the levels of MRC enzyme 
activities (Figure 3.17A).  
 82 
 
Figure 3.17 Characterization of mitochondrial dysfunction in 28- (and 23-) week-old 
DARS2-deficient cortex and unaffected cerebellum. 
(A) Relative MRC complex activities in isolated cortex mitochondria of Dars2 L/L, 
+/CaMKIIα-Cre mice (L/L, cre) presented as a percentage of control (L/L). Bars represent 
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mean ± S.E.M. Number on the error bar and asterisks indicate level of statistical 
significance (*p ≤ 0.05; **p ≤ 0.01; Student's t-test; n=3).  (B) Representative Coomassie 
Brilliant Blue stained BN-PAGE gel (with indicated position of specific complexes), 
Western blots for MRC complexes and in-gel activity of CO I and CO IV, performed 
after BN-PAGE for 23- and 28-week-old control (L/L) and Dars2 L/L, +/CaMKIIα-Cre (L/L, 
cre) mice. Cerebellum is used as negative control. (C) Representative gel of in organello 
translation of 28-week-old mice cortex and cerebellum mitochondria (n=3). De novo 
synthetized proteins are isolated immediately after labeling with 35S-met (1h pulse). 
Positions of individual mitochondrial-encoded proteins are indicated. Commassie 
Brilliant Blue stained gel used as loading control. Turnover of the newly synthesized 
proteins are assessed after 3 hours of ‘cold chase’. 
 
Significant decreases in CO III and IV was apparent, as well as a decline in CO I 
activity. Interestingly, we observed a decreased activity of CO II, in which all 
subunits of which are nuclear DNA encoded. This suggests that defective 
mitochondrial translation is exerting an adverse effect on CO II activity, which 
needs further experimental addressing.  
BN-PAGE analysis did not reveal any abnormalities in the amount of fully 
assembled MRC complexes in both cortex and cerebellum when Dars2 L/L, 
+/CaMKIIα-Cre mice were 28-week-old (Figure 3.17B). The Western blots to detect the 
MRC subunits from the corresponding BN-PAGE analysis also showed a similar 
pattern, as well as the in in-gel activities (Figure 3.17B). However, the F1 
subcomplex of CO V was visible in Western blots, indicating a translational 
problem. On the contrary, 23-week-old Dars2 L/L, +/CaMKIIα-Cre mice showed 
decreased CO IV levels when BN-PAGE and the Western blots were performed 
(Figure 3.17B). However, this change was not reflected in CO IV in gel activity.  
We did not detect a strong deregulation of de novo protein synthesis in DARS2-
deficient mitochondria from cortex and cerebellum of 28-week-old Dars2 L/L, 
+/CaMKIIα-Cre mice (Figure 3.17C). The turnover rate of mtDNA-encoded proteins, 
after 3 hours of cold-chase, was also not significantly different in Dars2 L/L, 
+/CaMKIIα-Cre mice. As observed in heart and skeletal muscle specific DARS2 
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knockout mice, ND2 subunit, which does not contain a single aspartate residue, 
was still upregulated. Moreover, ATP6 showed an additional polypeptide with a 
slightly lower molecular mass, which is likely a truncated form of this protein 
(Fig 3.17C).  
For these experiments, we were using cortex mitochondria and this mixed tissue 
contains not only neurons but also other cell types, i.e. glial cells. The lack of 
severe effects in BN-PAGE, in organello translation assay and in-gel activities 
can be attributed to the existence of cell types that are not affected by cre 
recombination and thus still contains DARS2. Another explanation could be the 
neurons that had DARS2 deficiency might had been lost as a result of cell death 
and the analyzed ones were the remaining, healthy ones.  
 
To further investigate the respiratory chain dysfunction in Dars2 L/L, +/CaMKIIα-Cre 
mice, we have performed COX-SDH staining on the group of 28-30 weeks of age 
mice (Figure 3.18A).  
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Figure 3.18 Further characterization of mitochondrial dysfunction by COX-SDH 
staining and TEM in 28/30-week-old mice. 
(A) COX-SDH - Enzyme histochemical double staining for COX and SDH activities 
(Scale bars: 20 µm). Arrows indicate COX deficiency. (B) Transmission Electron 
Micrographs (Scale bar: 0.5 µm) of control (L/L) and Dars2 L/L, +/CaMKIIα-Cre (L/L, cre) 
mice hippocampus and cortex (n=3). 
 
 
Observed blue staining, indicating COX-deficiency, was apparent in cortex and to 
a higher extent in the stratum pyramidale of the cornu ammonis 1 (CA1) and the 
stratum granulosum of the dentate gyrus (DG) regions of hippocampus (Figure 
3.18A, arrows).  
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Figure 10: Mitochondrial dysfunction. (A) COX/SDH staining of cortex and
hippocampus of 29-week-old control and knockout mice. COX-deficient cells appear blue
(arrows) whereas cells with normal COX activity appear brown. (B) Representative
transmission electron micrographs of mitochondria derived from the hippocampus of
control and knockout mice at an age of 29 weeks. The images on the right side are
close-ups of the indicated area (white boxes). Scale bars: (A) 20 m, (B) 0.5 m.
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Furthermore, we performed ultrastructural analysis of hippocampus in Dars2 L/L, 
+/CaMKIIα-Cre mice (Figure 3.18B). Loss of cristae structure, which we did not 
observe in heart and skeletal muscle of the previous model, was apparent in 
hippocampal region, as well as accumulation of swollen and degenerating 
mitochondria, suggesting different tissue-specific responses might be responsible 
for the observed differences in TEM (Figure 3.18B).  
 
Taken together, these results indicate that even if some techniques might not be 
sensitive enough to observe the extent of mitochondrial dysfunction in DARS2-
deficient brains; enzymatic activities, histochemical and ultrastructural analyses 
provide enough evidence for the MRC deficiency.  
 
3.10. DARS2 deficiency causes progressive neuronal 
degeneration 
 
Intrigued by our observations so far, we wanted to assess the degree and reasons 
of atrophy in our mouse model. H&E staining for the microanatomical features of 
cell bodies and Nissl staining for the details in the perikaryon, cytoplasm of 
neurons, were the first stainings we performed.  
 
20-week-old Dars2 L/L, +/CaMKIIα-Cre mice, which also did not show any differences 
in brain size compared to controls, revealed no apparent differences upon Nissl 
staining (Figure 3.19A).  
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Figure 3.19 Neuronal degeneration in DARS2-deficient cortex and hippocampus.  
(A) Representative Nissl staining (Scale bars: 500 µm) of hippocampal regions of 20-, 
29- and 32-week-old control (L/L) and Dars2 L/L, +/CaMKIIα-Cre (L/L, cre) mice. Close-ups 
are for the indicated areas. (B) H&E staining of 29-week-old control and Dars2 L/L, 
+/CaMKIIα-Cre mice for cortex, DG ad CA1 regions (Scale bars: 500 µm). Arrows indicate 
pyknosis, whereas arrowheads show vacuolar abnormalities. (C) Semithin sections for 
DG and CA regions of hippocampus for 29-week-old mice (Scale bars: 25 µm). 
 
On the other hand, with increasing age, considerable degeneration in cortex and 
severe disruption of cortical organization were observed (Figure 3.19A). We 
observed reduced cortical and hippocampal thickness, especially in the DG 
regions of 29- and 32-week-old Dars2 L/L, +/CaMKIIα-Cre mice. Progressive cellular 
infiltration within the hippocampus (Figure 3.19A – close-ups) was seen in 29 and 
32-week-old mice, which we hypothesized to be the result of an immune 
response. We concluded that the atrophy observed in knockout brains is due to the 
degeneration of neuronal cells in cortex and hippocampus.  
 
H&E staining comprises of a blue color staining the nuclear chromatin, and thus 
nucleus, and shades of pink for the rest. When our mid-time point, 28-30-week-
old mice, were analyzed, a decrease in neuron numbers were observed, most 
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prominently in CA1, CA2 and DG regions of hippocampus (Figure 3.19B). The 
cortical and hippocampal organization of the cells were disrupted, with occasional 
pyknotic nuclei, an indicator of apoptosis (Figure 3.19B – arrows). Another 
observation that was revealed by H&E staining was the abnormal vacuolar 
structures, which are signs of neuronal degeneration (Figure 3.19B – arrowheads).  
 
Next, we wanted to confirm these results with semithin sections of the 
hippocampal DG and CA regions of 29-week-old mice. Both vacuolar lesions 
(Figure 3.19C - arrowheads) and signs of pyknosis, condensations of chromatin as 
a result of apoptosis/necrosis, (Figure 3.19C – arrows) were also observed. 
Semithin sections showed a substantial loss of pyramidal neurons, mostly in the 
DG and CA1 fields (Fig. 20 D), whereas neurons in the CA2 and CA3 regions 
were present more or less in normal numbers, although some pyknotic nuclei were 
observed.  
 
Our results show that the atrophy of the brain size coincides with the decreased 
number of neurons and disorganized neuronal structure. We concluded that 
neurodegeneration observed in Dars2 L/L, +/CaMKIIα-Cre mouse is progressive and 
affecting the specific regions of hippocampus more than the other neurons. 
 
3.11. Corticohippocampal nerve cell loss was highly likely to be 
caused by apoptosis 
 
The presence of pyknosis and loss of neurons prompted us to look for types of cell 
death by which neurons in Dars2 L/L, +/CaMKIIα-Cre mice die. To assess apoptosis, 
TUNEL staining was performed on different regions of cortex and hippocampus 
(Figure 3.20A-D).  
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Figure 7: Neuronal apoptosis. Vibratome sections from brains of 20-, 29- and
32-week-old control and knockout mice were stained with TUNEL to detect apoptotic
cells (arrows) in (A) the somatosensory cortex, (B) the retrosplenial cortex, (C) the
hippocampal CA1 region, and (D) the hippocampal DG region. Scale bars: 100 m.
Apart from microglia also astrocytes respond to altered physiological conditions
within the CNS as observed during infection, trauma, ischemia, and disease. This
process is commonly referred to as reactive astrogliosis and involves changes in mor-
phology and molecular expression of astrocytes (Sofroniew, 2009). To detect reac-
tive astrocytes, we performed immunostainings of the glial fibrillary acidic protein
(GFAP), which is the most frequently used marker in this context. In the healthy
CNS, not all astrocytes express detectable levels of GFAP (Sofroniew and Vinters,
2010), as observed in the control cortex (Fig. 9A, 9B). During mild or moderate re-
active astrogliosis, there is a marked upregulation of GFAP expression, whereas the
appearance of overlapping and considerably extended cellular processes and newly
proliferated astrocytes occurs only in severe di↵use reactive astrogliosis (Sofroniew
and Vinters, 2010). The cortex of knockout mice showed an interesting occurrence
of reactive astrocytes: at 20 weeks of age only the outer layers of the somatosen-
sory cortex, meaning the 1st/2nd and the 6th layer, showed a marked upregulation
of GFAP expression as compared to control brains, whereas the inner layers re-
33
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Figure 3.20 TUNEL staining in DARS2-deficient cortical and hippocampal regions.  
(A-D) TUNEL staining for apoptosis in (A) the somatosensory cortex, (B) the 
retrosplenial cortex, (C) the hippocampal CA1 region, and (D) the hippocampal DG 
region of 20-, 29-, and 32-week-old control (L/L) and Dars2 L/L, +/CaMKIIα-Cre (L/L, cre) 
mice (Scale bars: 100 µm). Arrows indicate apoptotic neurons. 
 
When Dars2 L/L, +/CaMKIIα-Cre mice were 20-week-old, the somatosensory cortex, 
retrosplenial cortex, CA1 and DG regions of hippocampus showed increased 
numbers of apoptotic cells (brownish dots) when compared to the control mice 
(Figure 3.20A-D). Retrosplenial cortex was the region that affected the most 
(Figure 3.20B). When different regions in our second time point (29-week-old 
mice) were examined, we detected apoptosis in all the regions except retrosplenial 
cortex (Figure 3.20B). Somatosensory cortex (Figure 3.20A) and DG region 
(Figure 3.20 D) showed somewhat similar numbers of TUNEL-positive cells 
when compared to 20-week-old Dars2 L/L, +/CaMKIIα-Cre mice. However, in CA1 
region, the number of apoptotic neurons increased (Figure 3.20C). In our last time 
point (32-week-old mice), retrosplenial cortex also did not show apoptotic cells 
(Figure 3.20B). On the contrary, apoptosis increased progressively in 
somatosensory cortex (Figure 3.20A) and CA1 region of hippocampus (Figure 
3.20C) and to a lesser extent in DG region (Figure 3.20D). These results were 
puzzling. TUNEL-positive cells in 20-week-old mice, seen especially in cortical 
regions, did not coincide with our observations of neuronal cell loss and 
disorganization as evident by Nissl staining of the same-aged mice. Moreover, 
when Dars2 L/L, +/CaMKIIα-Cre mice were 29 weeks of age, brain atrophy indicated 
massive neuronal cell loss, which was not the case when TUNEL-positive nuclei 
were considered. We hypothesized that vast amount of apoptosis might be 
occurring during the 8-9 weeks of time when mice showed no microanatomical 
differences (20 weeks of age) to when they have lost most of their cortex (29 
weeks of age). Thus, at this middle time point (29 weeks of age) we do not 
observe many TUNEL-positive nuclei while they have already been lost. When 
Dars2 L/L, +/CaMKIIα-Cre mice were around 32 weeks of age, we again observed 
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massive apoptotic cells, especially in somatosensory cortex and CA1 region. This 
might be explained by the fact that when we decreased the time interval, we 
managed to observe the death of the previously ‘healthy’ neurons when the mice 
are 29-week-old.   
 
Another interesting point to be mentioned was the differential regional 
involvement of neuronal loss as evidenced by apoptosis. Why some regions are 
more prone to mitochondrial dysfunction is an interesting question that should be 
addressed via further experimental addressing. Apoptosis should be checked at 
different time points and shorter time intervals (i.e before 20 weeks of age, 
between 20 and 29 weeks of age, etc.) to further investigate the differential 
regional loss of neurons. Moreover, cleaved caspase 3 staining, as well as RT-
PCR should be performed to confirm our apoptosis-related results. 
 
To sum up, we observed massive cell loss due to apoptosis in different regions of 
DARS2-deficient brain. It is still possible that other types of cell death pathways, 
such as necrosis, can contribute to the observed cell loss, however this still awaits 
experimental confirmation. 
 
3.12. Increased immune response and gliosis in DARS2-
deficient mice 
 
The cellular infiltration we observed by Nissl staining was a hint for us that, 
maybe, those cells might be the activated microglia. Immunohistochemistry, 
specifically IBA1 staining, showed the presence of an inflammatory response in 
Dars2 L/L, +/CaMKIIα-Cre mice. IBA1 is a calcium binding protein that is upregulated 
during the activation of microglia/macrophages. As the endogenous brain defense 
cells, microglia can be found in ‘resting’ and ‘activated’ forms (Emerit et al., 
2004). ‘Resting’ microglia has smaller cell bodies and a lot of protrusions; 
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whereas ‘activated’ form retract their protrusions and increase the size of their cell 
bodies; this happens when there is some sort of ‘insult’ to the brain.  
 
Both somatosensory and retrosplenial cortical areas, previously analyzed by 
TUNEL staining showed increased IBA1 staining and, thus, activated microglia in 
three different time points (20, 29, and 32 weeks of age) (Figure 3.21A-D). An 
age-dependent decrease in activated microglia was apparent in the somatosensory 
and retrosplenial cortex (Figure 3.21A-B), in contrast to hippocampal regions, 
where we saw increased number of activated microglia with increasing age 
(Figure 3.21C-D). This temporal decrease was interesting for us. We think that 
when Dars2 L/L, +/CaMKIIα-Cre mice are 20-week-old, number of activated microglia 
are increased as the brain experiences some sort of ‘insult’. However, when the 
other later time points were considered, the inflammatory response in 
somatosensory and retrosplenial cortex were decreased due to the possibility that 
the ‘insult’ was also reduced in these regions. The increased numbers of activated 
microglia in hippocampal regions, on the other hand, might point out the ‘insult’ 
in play was still present and DARS-deficient hippocampus further upregulated the 
defense system against the ‘insult’.  
 
Furthermore, in hippocampal regions and retrosplenial cortex, TUNEL-positive 
nuclei and the activated microglia overlapped, suggesting that increased apoptosis 
was mainly responsible for the activation of microglia and promoting an immune 
response in the affected regions. However, somatosensory cortex of 32-week-old 
Dars2 L/L, +/CaMKIIα-Cre mice showed decreased levels of activated microglia 
compared to its 20-week-old counterpart. 32-week-old was the time point when 
we observed the most increased levels of apoptotic nuclei in somatosensory 
cortex. We concluded that different stress responses might be in play when 
neurons of different regions were taken into consideration. For example, a stress 
response other than the activation of microglia might be more active in the 
somatosensory cortex when neurodegeneration progresses. 
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Figure 8: Activation of microglia cells. Coronal brain sections of 20,- 29- and 32-
week-old control and knockout mice were labeled with an IBA1 antibody to visualize
microglia cells in (A) the somatosensory cortex, (B) the retrosplenial cortex, (C) the
hippocampal CA1 region, and (D) the hippocampal DG region. Scale bars: 100 m.
mained una↵ected (Fig. 9A). The retrosplenial cortex of 20-week-old knockout mice
also showed a large number of GFAP-positive cells (Fig. 9B). At 29 and 32 weeks
of age, knockout mice showed markedly increased numbers of reactive astrocytes
throughout the cortex (Fig. 9A, 9B). The appearance of overlapping, extended cel-
lular processes, as seen in the somatosensory cortex of 20-week-old knockout mice
(Fig. 9A), indicated severe di↵use reactive astrogliosis even at 20 weeks of age.
Generally, severe di↵use reactive astrogliosis is found in areas surrounding infec-
tions, severe focal lesions, or areas responding to chronic neurodegenerative triggers
(Sofroniew and Vinters, 2010). At least in the somatosensory cortex of 20-week-
old knockout mice, reactive astrocytes surrounded the “inner” cortical layers which
showed an increased number of apoptotic cells (Fig. 7A, 9A). The hippocampus
of control brains presented by far more GFAP-positive astrocytes than the cortex
(Fig. 9). Nevertheless, the number of GFAP-positive cells was markedly increased
in the hippocampus of knockout mice as compared to control brains. Strikingly, as
35
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Figure 3.21 IBA1 staining in DARS2-deficient cortical and hippocampal regions.  
(A-D) IBA1 staining for resting and activated microglia in (A) the somatosensory cortex, 
(B) the retrosplenial cortex, (C) the hippocampal CA1 region, and (D) the hippocampal 
DG region of 20-, 29-, and 32-week-old control (L/L) and knockout (L/L, cre) mice 
(Scale bars: 100 µm).  
 
 
During times of inflammation, microglia interact with astrocytes, the non-
neuronal macroglial cells of central nervous system. We demonstrated the 
presence of gliosis by using GFAP staining to detect reactive astrocytes (Figure 
3.22A-D).  
 
  
 
95  
 
Stephan Lotter
20 weeks 
L/
L 
29 weeks 32 weeks 
L/
L,
 cr
e 
So
m
at
os
en
so
ry
 co
rt
ex
 
L/
L 
L/
L,
 cr
e Re
tr
os
pl
en
ia
l c
or
te
x 
L/
L 
L/
L,
 cr
e Hi
pp
oc
am
pu
s (
CA
1)
 
A 
B 
C 
36
3. RESULTS
20 weeks 
L/
L 
29 weeks 32 weeks 
L/
L,
 cr
e Hi
pp
oc
am
pu
s (
DG
) 
D 
Figure 9: Reactive astrogliosis. Coronal vibratome sections were stained with a
GFAP antibody to label astrocytes in (A) the somatosensory cortex, (B) the retrosple-
nial cortex, (C) the hippocampal CA1 region, and (D) the hippocampal DG region in
the brains of 20,- 29- and 32-week-old control and knockout mice. Scale bars: 100 m.
observed by IBA1 staining, the s. pyramidale and s. granulosum of the hippocam-
pus were progressively infiltrated by reactive astrocytes (Fig. 9C, 9D). Our results
indicate a progressive, age-dependent severity of reactive astrogliosis in hippocam-
pus and cortex. Furthermore, it was shown that activated microglia and reactive
astrocytes have a similar pattern of appearance within these regions. It is known
that astrocytes extensively interact with microglia cells and are able to exert pro-
and anti-inflammatory e↵ects (Sofroniew and Vinters, 2010). However, it needs
further investigations to elucidate how neuronal cell death and activation of mi-
croglia correlate with severe di↵use reactive astrogliosis observed in the forebrains
of conditional Dars2 knockout mice.
37
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Figure 3.22 GFAP staining in DARS2-deficient cortical and hippocampal regions.  
(A-D) GFAP staining for astrocytes in (A) the somatosensory cortex, (B) the retrosplenial 
cortex, (C) the hippocampal CA1 region, and (D) the hippocampal DG region of 20-, 29-, 
and 32-week-old control (L/L) and knockout (L/L, cre) mice (Scale bars: 100 µm).  
 
When Dars2 L/L, +/CaMKIIα-Cre mice were 20-week-old, they had a vast increase of 
GFAP-immunoreactive cells in the outer layers of somatosensory cortex, which 
later diffuses to the other layers with increasing age (Figure 3.22A). These layers 
coincide with the TUNEL-positive nuclei. The retrosplenial cortex of knockout 
mice also exhibited reactive astrocytes in all of the ages examined (Figure 3.22B) 
and their number seemed to be decreased with increasing age of animals, similar 
to activated microglia. So, we concluded that many astrocytes were having 
protrusions directed into the degenerating neocortex. Hippocampal regions also 
showed high number of GFAP-positive astrocytes in knockout mice (Figure 
3.22C-D). The progressive infiltration as observed by activated microglia was 
also observed in activated astrocytes. Reactive astrogliosis increased with 
increasing age in CA1 (Figure 3.22C) and DG (Figure 3.22D) regions of 
hippocampus.  
 
It would be very interesting to repeat these experiments in different age and time 
intervals of Dars2 L/L, +/CaMKIIα-Cre mice, i.e younger mice, to see whether activated 
microglia and/or astrocytes were also available in different regions of DARS2-
deficient brain regions.  
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4. Discussion 
 
You would think that, as Vogons from ‘Hitchhiker’s Guide to the Galaxy’ would 
say, “Resistance is useless!” when you are in a teen slasher movie. However, 
there are some rules that should be mentioned and you would be safe if you follow 
them: 
 
First, you should not sin, not during the movie and not ever! Any sins in the past 
would have the potential to break out and destroy you.  
 
Second, you should not use sentences like ‘Hello?’, ‘Who is there?’, and ‘I’ll be 
right back’ -especially, when wondering around in dark, scary places! They are 
bound to decrease your chance of survival next to zero. 
 
The last and the most important rule is never, ever, under any circumstances 
assume the killer is dead! 
 
Mitochondrial disorders are very heterogeneous from a clinical, genetical, 
biochemical and molecular point of view (Schaefer et al., 2004). This can be 
exemplified by the fact that mitochondrial diseases can be caused by mutations in 
genes either encoded by nuclear DNA or mitochondrial DNA. Moreover, 
mitochondrial diseases can manifest in any organ and the age-onset also varies 
from childhood to adulthood. Eased by the advantages in whole genome 
sequencing, mutations causing mitochondrial diseases were never easier to 
pinpoint as they are today. However, the molecular consequences of 
mitochondrial dysfunction and impaired oxidative phosphorylation in cellular 
and/or organismal level are still far from being completely understood. Especially 
when it comes to the question how similar mutations are presenting themselves as 
different organ/disease manifestations or how different mutations are causing the 
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same mitochondrial diseases, we have no satisfactory answer. Similarly, the 
tissue-specificity of mitochondrial aminoacyl-tRNA synthetase-related diseases 
has been an unforeseen phenomenon. Mutations in nuclear encoded proteins that 
obey the laws of Mendelian genetics and therefore have the same type of defect in 
all different cell types, i.e. aminoacyl-tRNA synthetases, should give rise to 
similar failure in all cells/organs but this is not the case. In determining the extent 
of tissue-specific defects, a pivotal role can be attributed to the different kinds of, 
and largely unknown, compensatory mechanisms that are employed by cells 
against OXPHOS deficiency. Given mitochondrial functions in the cell and 
organism, those mechanisms are bound to be complex.  
  
In this study, we generated the first mouse model that is deficient for 
mitochondrial aspartyl-tRNA synthetase (DARS2). The idea behind was not to 
mimic the clinical presentations of a disease but generating a mouse model with 
strong respiratory chain deficiency as observed in majority of mitochondrial 
diseases. Tissue-specific manifestations and various stress signals/compensatory 
mechanisms activated were examined with different tissue-specific DARS2-
deficient models. We have generated three mouse models: a full body knockout 
(by ACTB-cre mediated recombination), heart and skeletal muscle deficient (by 
Ckmm-cre mediated recombination) and forebrain neurons, striatum and 
hippocampus deficient (by CaMKIIα-cre mediated recombination). These tissues 
are highly dependent on the OXPHOS for energy production; therefore, more 
involved in mitochondrial diseases (Dogan and Trifunovic, 2011). Moreover, 
heart and skeletal muscle are of a common origin.  
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4.1. Mitochondrial aspartyl-tRNA synthetase (DARS2) is essential 
for embryonic development and one copy of the gene is enough 
for survival in mouse 
 
Our results demonstrate that DARS2 is an essential protein needed for early 
mammalian development as complete lack of DARS2 leads to developmental 
arrest around time of organogenesis, which is consistent with results obtained 
from mice deficient in other genes essential for mtDNA maintenance and/or 
expression, such as TFAM (Larsson et al., 1998), POLGA (Hance et al., 2005), 
MTERF3 (Park et al., 2007) and TFB1M (Metodiev et al., 2009). Tfam-/- embryos 
had a mutant appearance with smaller sizes, delayed neuronal development, 
cardiovascular malformations, and lack of mtDNA when examined between E8.5 
and E10.5 (Larsson et al., 1998). TFAM loss caused embryonic arrest after 
implementation. Similarly, disruption of PolgA also resulted in embryonic 
lethality at the time of late gastrulation and before early organogenesis, between 
E7.5 and E8.5 (Hance et al., 2005). After gastrulation, organogenesis starts in 
mouse embryos at E7.5, the time when increased mtDNA replication is needed for 
the activation of aerobic metabolism (John, 2013). Failure to expand mtDNA 
molecules causes embryonic lethality due to the lack of organogenesis. Lessons 
from TFAM, indispensable for mtDNA maintenance, and POLGA, the only DNA 
polymerase in mitochondria, knockout mice emphasized the critical importance of 
mtDNA maintenance and replication during organogenesis.  
 
Some mitochondrial aminoacyl-tRNA synthetases can show misacetylation, i.e. 
mt-tRNAGln can be acetylated by both EARS2 and SARS2 (Nagao et al., 2009). 
We were wondering whether some other mitochondrial synthetases can also 
compensate for the lack of DARS2 but our results suggest that such compensation 
is unlikely due to the embryonic lethality of DARS2-deficient whole body 
knockout mice.  
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Our results clearly show that one working copy of Dars2 gene is sufficient for 
survival of the mouse. This observation is in agreement with data from human 
heterozygous carriers of mutations in DARS2 gene (Isohanni et al., 2010; Scheper 
et al., 2007). Notably, carrier frequency for the common DARS2 mutation is found 
to be relatively high in general Finnish population (1:95) and is thought to be 
quite common in other European derived populations (Isohanni et al., 2010). 
 
4.2. DARS2 deficiency in heart and skeletal muscle causes 
comparable mitochondrial dysfunction in both tissues but 
activates mitochondrial stress responses exclusively in heart 
DARS2 deficiency in heart and skeletal muscle gave rise to strong mitochondrial 
respiratory chain dysfunction in both tissues when the mice are 6-week-old. 
Further, we observed activation of various kinds of mitochondrial stress 
responses, only in DARS2-deficient cardiomyocytes. 
 
Mitochondrial dysfunction in LBSL patients carrying DARS2 mutations is also 
somewhat a matter of controversy (Scheper et al., 2007). Lactate elevation 
commonly detected in white matter of LBSL patients is a hallmark of 
mitochondrial dysfunction, thus suggesting a role of mitochondria in disease 
onset; however, a defect in MRC activities or levels of individual complexes 
could not be confirmed in patient fibroblasts and lymphoblasts (Scheper et al., 
2007). This most probably reflects the tissue-specificity of the observed defect. 
Recently, it was shown that the splicing of DARS2 exon 3, giving rise to the 
common mutation in LBSL patients, is regulated in a cell-type-specific manner 
and is less efficient in neuronal cells (van Berge et al., 2012). Furthermore, efforts 
to correlate missense mutations in LBSL patients with the severity of the disease 
progression did not reveal any connection. For example, the mild disease 
manifestation of one of the LBSL missense mutations do not coincide with the 
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substantial effects the mutation exerts on the catalytic activity when cell culture 
studies were performed (van Berge et al., 2013).  
 
Mitochondrial aminoacyl-tRNA synthetases seem to be involved in tRNA 
maintenance. For example, mutations in both RARS2 and SARS2 cause 
remarkable reduction in the amounts of the corresponding tRNAs (Edvardson et 
al., 2007; Belostotsky et al., 2011). However, this is not a general observation. 
When MARS2 is depleted in Drosophila, no effect was observed on the steady-
state levels of mitochondrial tRNAMet (Bayat et al., 2012). Moreover, the common 
mutation in LBSL patients does not affect the stability of tRNAAsp (van Berge et 
al., 2012). Similarly, our results show that tRNAAsp levels do not change upon 
DARS2 depletion, which further suggests that, the level of aminoacylation or 
binding to DARS2 does not determine stability of tRNAAsp.  
 
Expression of Cre-recombinase from the muscle creatine kinase (Ckmm) 
promoter is a commonly used method to disrupt genes in vivo. Ckmm-Cre 
mediated deletion of mitochondrial maintenance/transcription genes were proven 
to be useful tools to unravel the functions and consequences of defective mtDNA 
replication or transcription. Two different TFAM tissue-specific knockouts have 
been generated so far. Tfam L/L, +/Ckmm-cre mouse shows dilated cardiomyopathy, 
atrioventricular heart conduction blocks, and death at 2–4 weeks of age (Wang et 
al., 1999). Weight loss and increased mitochondrial dysfunction due to mtDNA 
loss are some of the hallmarks of this animal, which are consistent with our 
results. Even if a moderate reduction is observed in mtDNA levels, skeletal 
muscle does not show any signs of respiratory chain dysfunction and myopathic 
symptoms (Wang et al., 1999). The second model for TFAM depletion in heart 
and skeletal muscle has been generated again using Ckmm-Cre but this time with 
nuclear localization signal (NLS) (Hansson et al., 2004). The usefulness of Tfam 
L/L, +/Ckmm-cre was limited due to their short lifespan. Tfam L/L, +/Ckmm/NLS-cre mice, on 
the other hand, had a longer life span of 10–12 weeks and showed similar 
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symptoms, such as progressive increasing heart size, depletion of mtDNA, and 
severe respiratory chain dysfunction in heart (Hansson et al., 2004). This mouse 
model also did not develop any skeletal muscle phenotypes. The Ckmm-Cre that 
was used in our study is also Ckmm/NLS-Cre. Another heart and skeletal muscle 
specific mouse model, MTERF3 knockout animals, had a life span of 18 weeks, 
increased heart sizes, abnormal mitochondria in heart consistent with severe 
respiratory chain deficiency (Park et al., 2007). Yet again, in this model, skeletal 
muscle had normal morphology and mitochondrial function, even in the final 
stages of their lives. Hence, even if depletion of TFAM and DARS2 leads to 
similar phenotypes, i.e. cardiac hypertrophy, severe respiratory chain dysfunction, 
etc., the strong mitochondrial respiratory chain dysfunction observed in DARS2-
deficient skeletal muscle, makes our case intriguing. Moreover, the maximal 
lifespan of our mice is either half (Hansson et al., 2004) or 1/3rd (Park et al., 2007) 
of the mice models discussed. So, the age alone cannot account for the normal 
mitochondrial function in TFAM or MTERF3 knockout skeletal muscle. Our 
results suggest that skeletal muscle has an intrinsic protective mechanism relying 
primarily on the slow turnover of mitochondrial transcripts that is coupled with 
possible upregulation of muscle regeneration. This is very effective when mtDNA 
replication or transcription defects were considered (Hansson et al., 2004; Park et 
al., 2007). Although other factors, including complementation between nuclei due 
to the syncytial nature of skeletal muscle organization and post-transcriptional 
regulation were also proposed to play role in skeletal muscle ability to 
compensate for the mitochondrial deficiency (Wang et al., 1999), our results 
argue that low level turnover rate of mitochondrial transcripts is primary 
mechanism. It has been shown that both nuclear and mitochondrial mRNAs for 
MRC subunits are much more stable in skeletal muscle than in heart (Connor et 
al., 1996). Half-life of COXVIc (nuclear-encoded) and COXIII (mtDNA-
encoded) mRNA in heart were 3.3h and 2.1h, respectively, compared to 16h and 
23h in skeletal muscle (Connor et al., 1996). Similar differences have been 
observed for proteins that directly or indirectly regulate the stability of 
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mitochondrial protein synthesis like TFAM, PGC-1α and NRF-2α (D'souza et al., 
2012). The observed difference seems to be specific for the MRC subunits, as the 
rates of decline for δ-aminolevulinate synthase (ALAs) mRNA did not differ in 
two tissues (Connor et al., 1996) arguing that this indeed is a very specific 
response.  
In our DARS2-deficient heart and skeletal muscle mouse model, the signs of 
mitochondrial retrograde signaling in the form of mitochondrial biogenesis were 
observed only in heart. Increased mitochondrial mass is a common feature of 
mitochondrial dysfunction. For example, Tfam L/L, +/Ckmm/NLS-cre mice had increased 
mitochondrial mass (25%) when they were 8-week-old (Hansson et al., 2004) and 
a similar mitochondrial biogenesis was observed in 12- and 16-week-old Mterf3 
L/L, +/Ckmm-cre mice (Park et. al., 2007). ‘Myopathy mouse’ with skeletal muscle-
specific disruption of Tfam showed accumulation of abnormal mitochondria, 
decline of respiratory chain function and a maximal lifespan of 16-20 weeks 
(Wredenberg et al., 2002). Increased mitochondrial mass and ‘ragged-red fibers’ 
(RRF), indicative of abnormal mitochondria accumulation were observed when 
the mice are 15-week-old (Wredenberg et al., 2002). RRFs with COX deficiency 
are one of the important signs observed in human patients with mitochondrial 
myopathy. RRFs are seen in patients, who have impaired mitochondrial 
translation and ETC defects (Zeviani et al., 1993). In ‘myopathy mouse’, 
increased mitochondrial mass is thought to be beneficial by improving the energy 
homeostasis in skeletal muscle (Wredenberg et al., 2002). As opposed to 
‘myopathy mouse’, in our mouse model, we did not detect any RRFs. Another 
mouse model with increased mitochondrial mass in skeletal muscle is the ‘deletor 
mouse’, expressing mutant mouse mitochondrial helicase Twinkle, which mimics 
late-onset mitochondrial myopathy (Tyynismaa et al., 2005). No signs of 
mitochondrial dysfunction were noted during the first year of the deletor mouse. 
At that age, respiratory chain dysfunction was observed without mitochondrial 
proliferation. However, when deletor mice were 18-month-old, mitochondrial 
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mass was also increase, suggesting mitochondrial dysfunction, as evident by COX 
deficient cells, preceded mitochondrial proliferation (Tyynismaa et al., 2005). 
Skeletal muscle is intrinsically much more equipped to cope with increased levels 
of unassembled proteins and mitochondrial dysfunction. This could be the reason 
that we do not observe increased mitochondrial mass in DARS2-deficient skeletal 
muscle. It is plausible to argue that, as in deletor mice, after a certain age, we 
would also see upregulation of mitochondrial biogenesis also in skeletal muscle. 
Unluckily, the short lifespan of DARS2-deficient mice makes it impossible to test 
this hypothesis. 
Recently, FGF21 was suggested as a novel marker of mitochondrial dysfunction 
(Tyynismaa et al., 2010). FGF21 is a “starvation-hormone”, which has regulatory 
roles in glucose, lipid, phosphate and bile acid metabolism (Kharitonenkov et al., 
2005). In ‘deletor mouse’, the expression of skeletal muscle Fgf21 was increased 
2.5 fold when the mice are 14-month-old and 3.5 fold when they are 20-24-
month-old, which were also reflected in the mouse plasma FGF21 levels 
(Tyynismaa et al., 2010). Surprisingly, the levels of Pparα and Pgc-1α levels 
were not changed. Upon starvation, it is known that the levels of Fgf21 goes up 
~200-fold (Kharitonenkov et al., 2005). In DARS2-deficient cardiomyocytes, 
however, we observed an astonishing upregulation of ~250-fold in Fgf21 levels. 
This increase was evident also in 3-week-old mice. Circulating levels of FGF21 in 
the serum of 6-week-old knockout mice was 70% upregulated. Our results clearly 
show that the upregulation of FGF21 levels in mouse serum comes exclusively 
from DARS2-deficient cardiomyocytes, while we did not observe any 
upregulation of Fgf21 levels in other tissues that are known to secrete this 
cytokine. In ‘deletor mouse’, upregulation of Chop was also observed (Tyynismaa 
et al., 2010). Not only Chop, but also other transcription factors, Atf4 and Atf5, 
was highly upregulated in DARS2-deficient hearts. Those three transcription 
factors regulate the protein homeostasis in the cell (Wek and Cavener, 2007). As 
well, recently it was shown that skeletal muscle–specific deletion of Atg7 
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(autophagy-related 7) increased Fgf21 expression through the induction of Atf4 
(Kim et al., 2013). Autophagy deficiency in the skeletal muscle of these mice 
caused mitochondrial dysfunction, which through Atf4, a master regulator of 
stress response, induced Fgf21, as well as the circulating FGF21 levels (Kim et 
al., 2013). This is in agreement with our results. Moreover, we can argue that not 
only ATF4 but also ATF5 and CHOP can be involved in the regulation of Fgf21 
levels. In accordance with ‘deletor mouse’, in our case, Fgf21 levels were not 
induced by Pparα that is normally responsible for increased Fgf21 expression in 
liver upon fasting, as we detected downregulation of Pparα. As the proposed role 
of FGF21 suggests, we observed systemic changes in DARS2-deficient animals. 
We detected changes in metabolism by rising lipolysis in fat tissues and 
increasing NEFA levels in blood (60%), as well as lower blood glucose levels in 
6-week-old DARS2-deficient animals. Notably, when 1-week-old DARS2-
deficient hearts were examined, we still observed a 6-fold increase in Fgf21 
levels, as well as mild upregulation of ATF5 and CHOP.  
We also have implications that FGF21 might activate mitochondrial biogenesis by 
stabilising PGC1-α levels. It has been shown that FGF21 has a role to increase 
PGC1-α protein levels rather than Pgc1-α expression levels (Fisher et al., 2012). 
Additionally, absence of FGF21 caused decreased PGC1-α levels. In DARS2-
deficient hearts, we also detected higher levels of PGC1-α protein levels both in 
3- and 6-week old mice but not any changes in mRNA levels.  
 
Moreover, the master regulator of mitochondrial biogenesis, PGC1-α, is known to 
be a negative regulator of autophagy (Sandri et al., 2006; Wenz et al., 2009). 
Cardiomyocytes further revealed another remarkable response, in the form of 
reduced (macro)autophagy. One of the best characterized substrates of selective 
autophagy is p62 (sequestosome 1/SQSTM1). p62 directly interacts with LC3 
(microtubule-associated protein light chain 3) on the isolation membrane 
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(Weidberg et al., 2011). Decrease or impairment in autophagy is accompanied by 
accumulation of p62 and accumulation of polyubiquitinated proteins (Mizushima 
et al., 2010). In DARS2-deficient hearts, p62 and LC3B-I levels were upregulated 
as well as polyubiquitinated proteins. Furthermore, we did not observe any 
autophagosomes on TEM sections, strengthening our observation of decreased 
autophagy. As shown before (Kim et al., 2013), autophagy deficiency is enough 
to increase the expression of Fgf21, however it is still unclear whether FGF21 can 
perform the reverse and increased levels of FGF21 can also contribute to the 
observed decreased autophagy phenotype in DARS2-deficient hearts. 
 
A specialized form of autophagy, mitophagy, acts on damaged mitochondria to 
eliminate damage at the organelle level. Much of our knowledge about mitophagy 
comes from in vitro studies. A very recent study pointed out that accumulation of 
misfolded proteins in the mitochondrial matrix could initiate mitophagy mediated 
by PINK1 and the E3 ubiquitin ligase PARK2/parkin by a mechanism 
independent of mitochondrial depolarization (Jin and Youle, 2013). They 
suggested that this leads to mitophagy, which is triggered by the accumulation of 
unfolded proteins in mitochondria. Even if this study is providing evidence that 
unfolded protein load is the main cause of mitophagy and suggesting the role of 
mitophagy as a quality control mechanism, they also used cell culture studies. We 
are in need of more in vivo studies to unravel the role of mitophagy as a quality 
control mechanism in vivo. For example, an in vivo study showed that depolarized 
mitochondria do not recruit Parkin in dopaminergic neurons (Sterky et al., 2011).  
Due to deregulated mitochondrial translation, we saw activation of UPRmt again 
exclusively in heart. Our results from 3- and 6-week-old DARS2-deficient hearts 
indicate that the activation of UPRmt occurs very early and precedes any other 
changes. Moreover, in this study, we present strong evidence regarding the role of 
disturbed protein homeostasis in triggering the mitochondrial stress responses 
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activated in DARS2-deficient hearts, not respiratory chain dysfunction per se. The 
partial loss of MARS2 protein seems to lead to the accumulation of misfolded 
proteins in mitochondria, triggering UPRmt in Drosophila (Bayat et al., 2012). 
Similarly, in Drosophila and human post-mortem samples, it is implied that 
higher levels of misfolded components of respiratory complexes lead to an 
increase in markers of the UPRmt (Pimenta de Castro et al., 2012). Strikingly, a 
recent study found out in C. elegans that when mitochondrial translation is 
inhibited by RNAi knockdown of mitochondrial ribosomal protein S5 (mrps-5), 
worms live longer, even if their respiration rate is decreased (Houtkooper et al., 
2013). The researchers found out that stoichiometric imbalance between nuclear 
DNA- and mtDNA-encoded oxidative phosphorylation proteins, or mitonuclear 
protein imbalance, activates UPRmt that can account for the longevity of the 
worms. We also observed mitonuclear protein imbalance in 3- and 6-week old 
DARS2-deficient hearts. Moreover, the expression levels of nuclear DNA- and 
mtDNA-encoded CO IV subunits were slightly increased, even if the protein 
levels were decreased, which suggest an increased protein turnover. Furthermore, 
a higher de novo protein synthesis in 3-week-old DARS2-deficient hearts was 
observed. These results are the indicators of increased amount of unfolded and/or 
unassembled proteins accumulating in DARS2-deficient heart mitochondria.  
It is generally believed that mitochondrial respiratory deficiency is the primary 
activator of compensatory responses. Our results show that adaptive responses 
activated in heart are independent from respiratory chain deficiency, but rather 
stemming from impaired mitochondrial proteostasis. A recent study indicated that 
mitochondrial translational stress causes defective cell proliferation and this 
occurs before any real OXPHOS defect (Richter et al., 2013). Therefore, 
mitochondrial protein synthesis appears to be an important checkpoint for the 
monitoring of mitochondrial homeostasis and seems to be independent of energy 
metabolism.  
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All those stress signals were only evident in DARS2-deficient cardiomyocytes, 
but not in skeletal muscle. Skeletal muscle, comprising of different cell and even 
mitochondrial subpopulations, has better capacity for folding and turnover of 
mitochondrial proteins. If you add mRNA and protein stability skeletal muscle 
possesses –as discussed before-, intrinsically it is much more equipped to cope 
with increased levels of unassembled proteins. When DARS2-deficient skeletal 
muscles were examined, increased stability of mitochondrial transcripts, moderate 
upregulation of ribosomes and a likely increase in regeneration were observed. 
Inactivated stress responses in skeletal muscle further strengthen the fact that 
these responses arise independently of respiratory deficiency, while the deficiency 
is as strong as in DARS2-deficient heart.  
 
Notably, increased ribosomal subunits were observed in both tissues, even if it 
was less in skeletal muscle. We think that this is due to the increased number of 
stalled ribosomes due to lack of charged tRNAAsp and therefore creation of 
“hungry codons” (Temperley et al., 2010). 
 
Let’s remember the last rule of teen slashers: “Never, ever, under any 
circumstances assume the killer is dead!” Is it possible that the serial killer is not 
dead and hiding for a second and cleverer killing-spree?  
 
Heart is employing different stress responses in order to counteract respiratory 
chain deficiency. It is thought-provoking to argue that these responses might be 
adding to the progression of cardiomyopathy instead of ameliorating it. For 
example, increased expression of PGC-1α in the neonatal heart is beneficial and 
increases mitochondrial biogenesis, while increased expression of PGC-1α in the 
adult heart leads to cardiomyopathy (Lehman et al., 2000; Russell et al., 2004). It 
seems that those stress responses might cause a possible demise of the cells 
instead of improving the disease manifestations.  
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To sum up, our results clearly demonstrate that direct disruption of mitochondrial 
protein synthesis by deletion of Dars2 gene leads to activation of cellular stress 
responses in a tissue-specific manner. DARS2-deficient heart reacts to defective 
translation at a very early stage by enacting a repertoire of mitochondrial and 
extramitochondrial responses, including increased production of FGF21, 
activation of the UPRmt, inhibition of autophagy and increased mitochondrial 
biogenesis. Strikingly, these specific responses arise before any real insult in 
respiratory chain. The triggering signal for these responses appears to be the 
accumulation of unfolded and/or unassembled respiratory chain subunits, 
resulting in mitonuclear imbalance.  
 
On the other hand, we showed that skeletal muscle has increased stability of 
mitochondrial transcripts, moderate upregulation of ribosomes and a likely 
increase in regeneration. We think that if the lifespan of our animals were longer, 
we would have seen, at least some, of the stress responses not only in heart but 
also in skeletal muscle. 
 
We propose that disrupted mitochondrial proteostasis upregulates stress-related 
transcriptional factors/activators like ATF4, ATF5 and CHOP, which further 
contribute to the upregulation of ‘mitokine’ FGF21 and UPRmt (Figure 4.1). By 
increasing PGC1-α stability, FGF21 seems to be of great importance for increased 
mitochondrial biogenesis and decreased autophagy. Moreover, FGF21 mediates 
general metabolic changes in DARS2-deficient mice. Our results are of great 
importance while it is generally believed that mitochondrial respiratory deficiency 
is the primary activator of compensatory responses. However, we emphasize the 
importance of disrupted protein homeostasis that precedes respiratory chain 
deficiency as the driving force behind the activated stress responses. Changing 
this current view could present new therapeutic possibilities for mitochondrial 
diseases.  
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Figure 4.1 Proposed model for the heart-mediated stress responses to perturbed 
protein homeostasis caused by DARS2 deficiency. 
Impaired proteostasis in mitochondria directs preferential upregulation of stress-related 
transcriptional activators like ATF4, ATF5 and CHOP, which in turn regulate FGF21 
levels. The cascade activated leads to the upregulation of mitochondrial biogenesis and 
UPRmt while downregulating autophagy and provide a systemic change in metabolism. 
 
4.3. DARS2 deficiency in forebrain neurons, hippocampus and 
striatum causes progressive neuronal degeneration 
accompanied by an activation of inflammatory responses and 
reactive astrogliosis in an age- and region-dependent manner 
 
In this study, we further wanted to examine forebrain neurons with respect to their 
responses to mitochondrial translation defect caused by DARS2 deficiency.  
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Mitochondrial dysfunction in Dars2 L/L, +/CaMKIIα-Cre mice were not that apparent 
when some techniques were employed. This can be due to the fact that DARS2 
deficiency was induced in forebrain neurons, and the tissue used for the 
experiments, cortex, included other cell types, i.e. different neuronal cell types 
and glial cells. Those cells were not affected by cre recombination and thus still 
contained DARS2. Moreover, severe DARS2-deficient neurons would have 
already been lost as a result of increased apoptosis and we were analyzing 
comparably ‘healthier’ neurons. To be able to conduct those experiments, a whole 
brain knockout, i.e. using Nestin-cre, would have been more useful. However, the 
fact that full body knockout of DARS2 was embryonic lethal and Nestin promoter 
was also active before birth, could also indicate that Dars2 L/L, +/Nestin-Cre mice 
might be embryonic lethal. 
Progressively atrophied brain, abnormal behaviour exemplified via excessive 
scratching, mitochondrial dysfunction were the hallmarks of Dars2 L/L, +/CaMKIIα-Cre 
mice. COX deficiency was more apparent in CA1 and DG regions of 
hippocampus. One interesting fact that should be mentioned is our observation for 
decreased activity for CO II in MRC enzyme activities. This suggests that 
defective mitochondrial translation is exerting an adverse effect on CO II activity, 
which needs further experimental addressing. TEM analysis revealed loss of 
cristae structure in DARS-2 deficient hippocampal regions, which we did not 
observe in heart and skeletal muscle of the previous model.  
Those observations were also in accordance with the literature. Knockout mouse 
models using the CaMKIIα promoter, such as TFAM (Sorensen et al., 2001), 
COX10 (Fukui et al., 2007), PHB2 (Merkwirth et al., 2012), Rieske iron–sulfur 
protein (RISP) (Diaz et al., 2012) and NDUFA5 (Peralta et al., 2013) revealed 
similar findings. For example, mitochondrial late-onset neurodegeneration 
(MILON) mice were generated after postnatal deletion of Tfam gene in forebrain 
neurons (Sorensen et al., 2001). MILON mice appeared perfectly normal and 
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showed no abnormalities until the age of 5-6 months, as in our mouse model. 
Following this time period, their physical condition deteriorated pretty rapidly and 
death occurred within 1-2 weeks. This was a very interesting observation 
indicating that after a threshold had been passed, the mice could no longer carry 
the burdens of TFAM depletion. In our case, however, animals do not die but 
have to be sacrificed due to the excessive scratching. The onset of abnormalities 
seem to be similar, even though mitochondrial translation defect due to DARS2-
depletion appear to be handled better compared to mitochondrial 
maintenance/transcription defect. As Dars2 L/L, +/CaMKIIα-Cre mice, MILON mice 
displayed a progressive, marked neuronal cell loss, degeneration, severe 
disruption of cortical organization and axonal degeneration in neocortex and 
hippocampus, which successfully mimics the late-onset and progressive nature of 
human neurodegenerative diseases (Dogan and Trifunovic, 2011). In Phb2NKO 
mice, however, aging-related phenotypes, such as weight loss and kyphosis, were 
observed around 12-14 weeks of age (Merkwirth et al., 2012). Scratching 
behavior was detected around this time, and the mice died between the ages of 14 
and 22 weeks. Similarly to our study, progressive forebrain atrophy and neuronal 
loss accompanied with increased astrogliosis and mitochondria with almost 
complete absence of cristae. In a recent study, NDUFA5 subunit of CO I was 
selectively ablated in neurons (Peralta et al., 2013). The mice showed mild 
chronic encephalopathy at the age of 11 months, but neuronal death or gliosis 
were not detected. As can be seen from these examples and current study, the age 
onset of mitochondrial dysfunction/behavioral abnormalities varies between these 
mouse models. This could be due to the different roles of different proteins 
knocked out in each mouse model but also as a result of the CaMKIIα-cre mice 
used. For example, Merkwirth et al. used a different CaMKIIα-cre mice 
(Dragatsis and Zeitlin, 2000) but in our and Sorensen et al.’s study another cre 
mice was used (Xu et al., 2000). Even if it is not clear why, the onset of symptoms 
are earlier in Dragatsis and Zeitlin’s CaMKIIα-cre mice. This could be the result 
of different strategies used when these cre lines were generated. Both lines 
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included a nuclear localization signal but the CaMKIIα gene promoter fragments 
were coming from different labs. Finally Dragatsis and Zeitlin’s CaMKIIα-cre 
transgene expression vector was shorter compared to Xu et al.’s. It would be very 
useful to mate these two different CaMKIIα-cre mice to a reporter strain to see 
whether the expression patterns and onset of effects differ from each other.  
 
Our results revealed considerable degeneration in cortex and severe disruption of 
cortical and hippocampal organization in an age-dependent progressive manner. 
The interesting fact was the occurrence of apoptosis in different brain regions in 
different ages. When mice are 20-week-old, retrosplenial cortex showed signs of 
apoptosis but as the age increased, no TUNEL-positive nuclei were found. CA1 
region displayed high occurrence of progressive apoptotic cells with increased age 
whereas DG region of hippocampus, showing the highest signs of COX 
deficiency, displayed very minute amounts of apoptosis. It seems that vast amount 
of apoptosis might be occurring between 20 and 29 weeks of age. Thus, at 29 
weeks of age we do not observe many TUNEL-positive nuclei while they have 
already been lost. Apoptosis should be checked at different time points and 
shorter time intervals (i.e before 20 weeks of age, between 20 and 29 weeks of 
age, etc.) to further investigate the differential regional loss of neurons. 
 
Our results indicate that different regions of brain seem to react differently to 
defective mitochondrial translation, which can be a result of their ability to cope 
with mitochondrial dysfunction. Why some regions are more prone to 
mitochondrial dysfunction is an exciting question that should be further 
experimentally addressed. Neurons are extraordinary in being able to survive even 
with dysfunctional mitochondria. Neurons were found to survive for at least 1 
month after shutting off oxidative phosphorylation in Tfam L/L, +/CaMKIIα-Cre mice 
and that neuronal cell death barely activated defense mechanisms against reactive 
oxygen species (Sorensen et al., 2001). Increased glycolysis and support from 
other neuronal cell types have been proposed to account for this fact (Koopman et 
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al., 2012). Brain is known to utilize glucose as fuel. Both neurons and astrocytes 
rely on OXPHOS for ATP generation but it has been experimentally proven that 
astrocytes can also utilize glycogen. It appears that when glycolysis is stimulated, 
the released lactate can be taken up by neurons and can be used, which indicates 
astrocytes and neurons are metabolically linked by lactate shuttling (Koopman et 
al., 2012). 
 
DARS2-deficient knockout mice showed increased levels of activated microglia 
and reactive astrocytes. The progressive infiltration as observed by activated 
microglia was also available in activated astrocytes. Occurrence of 
neuroinflammatory reactions were a common aspect of neurodegenerative 
disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Multiple 
sclerosis (MS), Huntington’s disease (HD) and Amyotrophic Lateral Sclerosis 
(ALS). Normally, in those diseases, microglia and astrocytes are activated in 
response to apoptosis (Vidal-Taboada et al., 2011).  
 
Microglial cells, resident macrophages of central nervous system (CNS), are of 
mesenchymal origin and comprise 10-20% of the adult glia (Ransohoff and Perry, 
2009). Reactive gliosis, or neuroinflammation, is the aggressive response of glia 
to the activating stimuli such as neuronal death, toxins or mechanical injury 
(Block et al., 2007). Microglia transforms and gets activated to form the first line 
of defense against these stimuli, and that is observed nearly in all of the 
neurological disorders. Reactive microglia are necessary for neuronal survival, i.e. 
phagocytosis to clear toxic and cellular debris. They also release anti-
inflammatory factors, to guide the migration of stem cells to the site of 
inflammation and injury. Astrocytes, on the other hand, ectodermal cells and they 
provide support for surrounding neurons and take part in physical structuring of 
the brain, maintaining ion homeostasis and even promotion of myelination 
(Sofroniew and Vinters, 2010). Not being immune cells per se, astrocytes 
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contribute to the immune response by influencing microglial behavior (Farina et 
al., 2007).  
 
In our knockout mouse model, both somatosensory and retrosplenial cortical areas 
showed activated microglia in three different time points (20, 29, and 32 weeks of 
age) but there existed an age-dependent decrease, in contrast to hippocampal 
regions, where we saw increased number of activated microglia with increasing 
age. This temporal decrease is interesting. The somatosensory cortex is an area of 
the brain that processes input from the various systems in the body that are 
sensitive to touch, including pain and temperature, whereas retrosplenial cortex is 
a region that supports a range of cognitive functions, including episodic memory, 
navigation, imagination and planning for the future (Vann et al., 2009). Moreover, 
retrosplenial cortex is consistently compromised in the most common 
neurological disorders that impair memory. The decline of activated microglia 
with advanced age could suggest that at early age, the ‘insult’ to the retrosplenial 
cortex and the somatosensory cortex is greater. It is provoking to argue that this 
‘insult’ could be pain –in case of somatosensory cortex- and decline in memory 
and navigation –in case of retrosplenial cortex-. When later time points were 
considered, the inflammatory response might be decreased due to the possibility 
that the ‘insult’ was also reduced in these regions.  
 
Reactive astrogliosis patterns coincided with the apoptotic neuronal loss. We can 
also conclude that not only apoptosis but also severe diffuse reactive astrogliosis 
and the microglial activation may have contributed further to neuronal 
degeneration. It is known that this innate immune response can also be potentially 
add to the progression of neurodegeneration while microgliosis can provoke 
amyloid-β plaque formation, dystrophic neurite growth, and excessive tau 
phosphorylation (Vidal-Taboada et al., 2011). As the microgliosis and astrogliosis 
become chronic, similar to our case, the initial neuroprotective effect can 
transform into a cytotoxic one.  This would explain the worsening of the 
 116 
phenotype between the ages of 29 weeks and 32 weeks. It would also be very 
interesting to look for those markers in nonsympomatic younger mice brains and 
compare apoptosis with the activation of immune response.  
 
Neurodegenerative diseases cause the activation of microglia when misfolded 
proteins accumulate, i.e. the amyloid-β peptides are known to activate microglia 
in AD and in the case of ALS and HD, the misfolded proteins, this time 
accumulated intracellularly, are also responsible for microgliosis (Perry et al., 
2010). This is of interest due to the fact that in heart and skeletal muscle specific 
DARS2 knockout mouse, unfolded/misfolded proteins are the first signal that 
causes the systemic changes and activation of stress signals. These specific 
responses precede respiratory chain deficiency. This observation might be also 
true in Dars2 L/L, +/CaMKIIα-Cre mice. Buildup of unfolded and/or unassembled 
respiratory chain subunits due to the imbalance between the increased levels of de 
novo protein synthesis and decreased folding capacity could be directing the 
upregulation of stress-related signals. We have also checked the markers for 
UPRmt both in brain and other tissues in Dars2 L/L, +/CaMKIIα-Cre mice, as suggested 
by the ‘cell-nonautonomous’ theory (Durieux et al., 2011), but we could not 
detect any changes in the levels of mtHSP70 and HSP60 (Lotter, 2013). More 
experimental data concentrating on disturbed proteostasis should be gathered as 
had been done for Dars2 L/L, +/Ckmm-Cre mice, i.e. levels of different proteases.  
 
To sum up, defective mitochondrial translation in Dars2 L/L, +/CaMKIIα-Cre mice 
caused weight loss, abnormal behavior, and severe forebrain atrophy, which is 
caused by neuronal cell apoptosis and accompanied by activation of inflammatory 
responses such as microgliosis and reactive astrogliosis. Surprisingly, 
neurodegeneration occurred in an age-dependent manner and affected cortex and 
hippocampal regions differently. The mechanisms and exact pattern of observed 
phenotypes still waits experimental addressing. 
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4.4. Summary and perspectives 
 
The mechanisms leading to the tissue-specific manifestations of mitochondrial 
diseases are still largely unknown. In this study, we compared three different 
highly-energy demanding tissues, heart, skeletal muscle and forebrain neurons, 
which are commonly affected in mitochondrial diseases. Our results indicate the 
existence of different intrinsic and extrinsic coping mechanisms each tissue 
possesses. Heart reacts to defective mitochondrial translation by enacting a 
repertoire of mitochondrial and extramitochondrial responses; skeletal muscle is 
intrinsically much more equipped to cope with increased levels of 
unassembled/unfolded proteins and mitochondrial dysfunction; neurons employ 
defense/inflammatory systems and rely on the fact that they can live up to 1 
month after OXPHOS is turned off. However, all these responses might be adding 
to the progression of observed phenotypes instead of ameliorating them. 
 
To further strengthen the findings of this study, two new mouse models could be 
very useful. First, generating a double knockout mouse by deletion of Dars2 in 
heart and skeletal muscle, as used in this study, in combination with Fgf21 
knockout mouse would be very interesting. By this, we could experimentally 
prove the pivotal role of FGF21 in activation of the stress responses and pinpoint 
which of the observed responses are due to FGF21.  
Second, generation of a Dars2 L/L, +/Plp-Cre mouse could give us further insights 
about the disease LBSL. Plp1 promoter is tamoxifen-inducible (Leone et al., 
2003). It has been shown that injecting the lactating mothers with 1 mg of 
tamoxifen daily during 5 days starting at postnatal day 1 (P1) induces 
recombination only in brain areas that start myelination between P1 and P5, which 
includes the medulla, the pontine fibers, and white matter tracts in the cerebellum. 
This model might, to some extent, mimic the human disease LBSL, while MRIs 
of LBSL patients show signal abnormalities in the cerebral white matter and 
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specific brain stem and spinal cord tracts (van der Knaap et al., 2003). Therefore, 
Dars2 L/L, +/Plp-Cre could have given insight to the observed phenotypes in patients. 
Moreover, we could compare how neurons, by using the Dars2 L/L, +/CaMKIIα-Cre 
mice of this study, and mature oligodendrocytes, two different cell types, react to 
defective mitochondrial protein synthesis.  
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